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Cutaneous porphyrias are metabolic diseases resulting from the partial deficiency of one of the 
enzymes in the haem biosynthetic pathway which leads to overproduction of porphyrins in the liver 
or bone marrow. Because porphyrins are phototoxic compounds, their accumulation in the skin 
causes photosensitivity. This study was aimed to investigate the characteristics of cutaneous 
porphyrias. 
The prevalence (2.1:100 000, in 2006 n=108) of variegate porphyria (VP) was higher in 
Finland than elsewhere in European countries due to a founder effect (R152C) and careful screening 
of the family members. The incidence of VP was estimated at 0.2:1 000 000 based on the number of 
new symptomatic patients yearly. The prevalence of porphyria cutanea tarda (PCT) was 1.2:100 000 
(in 2006 n=63), which is only one fourth of the numbers reported from other European countries. 
The estimated incidence of PCT was 0.5:1 000 000. Based on measurements of the 
uroporphyrinogen decarboxylase activity in erythrocytes, the proportion of type II PCT was 49% of 
the cases. Erythropoietic protoporphyria (EPP) was less common. The prevalence was estimated at 
0.8:100 000 (in 2006 n=39) including asymptomatic carriers of a mutation in the ferrochelatase 
gene. The incidence of EPP was estimated at 0.1:1 000 000.
In VP 37% of the mutation carriers have a manifest disease, and of those 80% have skin 
symptoms. Of the mutation carriers followed after 1980 (n=57), 30% manifested with skin 
symptoms with the varying severity. Frequency of skin symptoms only was stable during the 
follow-up before or after 1980 (22% vs. 21%), but acute attacks only became rare (29% vs. 7%) 
during the last two decades. The number of patients having both acute attacks and skin symptoms 
decreased also substantially (22% vs. 11%) but still 30% of the symptomatic patients have both 
acute attacks and skin symptoms. The most frequent skin symptoms in the patients with VP were 
fragility (95%) and blistering (46%) of the skin in the backs of the hands. Transient correction of 
porphyrin metabolism using eight haem arginate infusions within five weeks had no effect on the 
skin symptoms in three of four patients studied. In one of them skin lesions disappeared transiently.  
The patient with homozygous VP is a different entity with severe chronic skin lesions since 
birth. Sensory polyneuropathy, glaucoma and renal failure developed during the 25-year follow-up 
without the presence of acute attacks. Four subsequent haem arginate infusions corrected partially 
porphyrin metabolism for a few days only. The I12T mutation was detected in both of the patient’s 
alleles in the protoporphyrinogen oxidase gene. Lack of skin symptoms and infrequency of acute 
attacks in the heterozygous patients with I12T mutation indicate a mild phenotype of this mutation 
at the heterozygous state.  
Four mutations (751delGAGAA, 1122delT, C286T, C343T) in the ferochelatase gene were 
characterised in four of 15 families with EPP. Burning pain (96%) and swelling (92%) of the skin 
immediately after the sun exposure were the major skin symptoms. More than a 50-fold rise of the 
protoporphyrin level in erythrocytes predicted severe photosensitivity. Hepatopathy appeared only 
in one patient. 
Clinical manifestations and associated factors of PCT were similar in sporadic and familial 
types of PCT. In contrast to VP, in the patients with PCT blistering (95%) and fragility (93%) of the 
skin in the backs of the hands occurred equally. The majority of the patients had one to three 
precipitating factors, of which alcohol was the most common (78%). Mutations associated with 





infections (25 %) were less common. Fatty liver disease (67%) and siderosis (67%) were commonly 
found in liver biopsies (n=21). 
 The major histopathological change of the sun-exposed skin in VP (n=20), EPP (n=8) and 
PCT (n=5) was thickening of the vessel walls of the upper dermis suggesting that this is the primary 
site of the phototoxic reaction in each type of porphyria. The fine structure of the vessel walls was 
similar in VP, EPP and PCT consisting of the multilayered basement membrane and excess of finely 
granular substance between the layers which were surrounded by the band of homogenous material.
In addition, EPP was characterised by amorphous perivascular deposits extending also to the 
extravascular space. 
The direct immunofluorescence study of the sun-exposed skin revealed constantly homogenous 
IgG deposits in the vessel walls of the upper dermis in each type of porphyria. IgA, IgM and C3 
were present more frequently in EPP than in PCT and VP indicating that the severe vascular damage 
in EPP results from the abundant leakage of immunoreactants from the circulation. In EPP the 
excess material around vessel walls consisted of other proteins such as serum amyloid protein, and 
kappa and lambda light chains in addition to the basement membrane constituents such as collagen 
IV and laminin. These results suggest that the alterations of the vessel walls are a consequence of 
the repeated damage and the repairing process in the vessel wall.  
The microscopic alterations could be demonstrated even in the normal looking but sun-exposed 
skin of the patients with EPP during the symptom-free phase suggesting that vascular change can be 
chronic. The presence of microscopical changes in those patients with VP who had never 
experienced skin symptoms suggests that photodamage at the level of dermal vessels can be a 
subclinical process. The stability of vascular changes in the patients with PCT after treatment 
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Porphyrias are a group of metabolic diseases due to an inherited deficiency of the haem 
biosynthesis. Each of seven porphyrias is related to one of the eight enzymatic steps in the haem 
biosynthetic pathway (Figure 1). The genes which encode the enzymes for haem production have 
been characterised and several mutations in these genes have been identified. A decreased enzyme 
activity results in overproduction of porphyrins and their precursors either in the bone marrow as in
erythropoietic porphyrias or in the liver as in hepatic porphyrias (Anderson et al. 2001). Excess of 
porphyrins or their precursors is responsible for photosensitivity and acute attacks, which are the 
two major clinical manifestations of porphyria. Photosensitivity occurs in all subtypes of porphyrias 
except in delta-aminolaevulinic acid (ALA)-dehydratase deficiency (MIM 125270) and acute 
intermittent porphyria (AIP; MIM 176000). Circulating porphyrins enter the skin where they 
interact with the light energy resulting in a phototoxic reaction. Thus, cutaneous porphyrias are a 
unique group of photosensitivity diseases caused by the endogenous agent. Acute attacks are related 
to an overproduction of porphyrin precursors in the liver induced by several precipitating factors 
and they are manifested by autonomic and peripheral neuropathy and central nervous system injury. 
  The skin symptoms of porphyrias manifest clinically as an immediate or chronic 
photosensitivity depending on the type of porphyrin which accumulates in the skin. In contrast to 
other photodermatoses in which ultraviolet radiation is usually responsible for photosensitivity in 
porphyria visible light induces the skin symptoms due to the distinctive light absorbing spectra of 
porphyrin molecules (Moore et al. 1987). Toxic properties of porphyrins may also entail 
hepatobiliary disorders in cutaneous porphyrias as in porphyria cutanea tarda (PCT; MIM 176100) 
and erythropoietic protoporphyria (EPP; MIM 177000)(Bloomer et al. 2006). 
  Each subtype of porphyria with clinical symptoms has characteristic features of the blood 
porphyrin profiles and the excretion of porphyrin and their precursors. Thus, biochemical analyses 
provide a basic instrument for the diagnostics and are mandatory to confirm the correct diagnosis in 
the symptomatic phase (Moore et al. 1987; Elder et al. 1990). Because the traditional biochemical 
methods are not sensitive or specific enough to find asymptomatic family members with porphyria, 
a mutation screening may be the only way to detect these individuals  (Kauppinen 2005). 
 
1. CLASSIFICATION OF PORPHYRIAS 
 
Porphyrias are classified as erythropoietic or hepatic according to the tissue where the excess of 
porphyrins or their precursors are predominantly synthesized (Table 1) (Anderson et al. 2001). 
Porphyrias are also divided into acute and cutaneous porphyrias depending on the type of 
symptoms. Hepatic porphyrias manifest themselves by the acute attacks except PCT. Hereditary 
coproporphyria (HCP; MIM 121300) and variegate porphyria (VP; MIM 176200) are characterised 













2. INHERITANCE AND MOLECULAR GENETICS OF PORPHYRIAS 
 
Porphyrias are inherited as an autosomal dominant fashion except extremely rare ALA-dehydratase 
deficiency and congenital erythropoietic porphyria (CEP; MIM 263700). The latter is known also as 
Günther’s disease, and it has an autosomal recessive pattern of inheritance (Table 1) (Anderson et 
al. 2001). In each autosomally dominantly inherited porphyria, homozygous or compound 
heterozygous disorders have been identified. They are very rare and manifest usually with more 
severe symptoms in the early childhood (Hift et al. 1993).  
 The inheritance of PCT is more complex. The disorder can present as a sporadic form (type I) or 
familial form (types II and III, Table 1) (Elder et al. 1989). In type I, which is the most common 
form of PCT, no defects in the uroporphyrinogen decarboxylase (UROD; EC 4.1.1.37) gene are 
currently known and the enzyme deficiency is probably limited to the liver (Elder et al. 1978). In the 
familial forms mutations in the UROD gene have been identified in type II which is characterised by 
low enzyme activity measured in erythrocytes or other cell lines (Elder et al. 1989; Bygum et al. 
2003; Poblete-Gutierrez et al. 2004; Mendez et al. 2007). So far, the genetic background is 
ambiguous in the type III, in which the enzyme activity in erythrocytes is normal as in type I PCT 
despite positive family history (Elder et al. 1989; Mendez et al. 2007).
The genes for all enzymes in the haem biosynthesis have been cloned and sequenced and their 
chromosomal localization is known (Table 1). In each type of porphyria, numerous mutations have 
been identified including missense, nonsense, splicing defects as well as deletions and insertions 
(See for more detailed information in Human Gene Mutation database: http://www.hgmd.org). 
Family-specificity and heterogeneity of mutations and an incomplete penetrance are characteristic 
features of all types of porphyria (Anderson et al. 2001). Although a mutation in an allele results in 
the loss of the enzyme activity, a residual 50% or less of the total activity measured in patients is 
usually sufficient for the normal metabolism of haem. 
 The penetrance of different porphyrias varies, but in AIP and VP around 40-60% of the gene 
carriers have clinical manifestations (von und zu Fraunberg et al. 2002; Hift et al. 2004b; von und zu 
Fraunberg et al. 2005). The penetrance in other cutaneous porphyrias based on mutation analyses is 
not known. 
 Since the presence of a mutation does not necessarily result in a porphyric phenotype, 
additional genetic and environmental factors are usually required for clinical or biochemical 
manifestations. Such genetic factors may include polymorphism of the cytochrome P450 genes 
related to a metabolism of drugs or other porphyrinogens influencing the manifestation of acute 
porphyrias (von und zu Fraunberg et al. 2005) and PCT (Christiansen et al. 2000; Gardlo et al. 
2003). Moreover, polymorphism in the ferrochelatase (FECH) gene affects the phenotype of EPP 
(Gouya et al. 2002), and mutations in the hemochromatosis gene (HFE) are associated with PCT 
(Bulaj et al. 2000). Intake of drugs, alcohol and oestrogen preparations in addition to hepatitis virus 
infections are examples of extrinsic precipitating factors in hepatic porphyrias (Anderson et al. 
2001).   
Despite the heterogeneous molecular background of porphyrias, the clinical and biochemical 
manifestations are quite uniform in these patients. To date, genotype-phenotype correlation has been 
reported in CEP, VP, EPP, and AIP (Warner et al. 1992; Minder et al. 2002; von und zu Fraunberg 
et al. 2002; von und zu Fraunberg et al. 2005), but this relationship has not been confirmed in all 
















































































































































































































































































































































































   
   
   
   
   
   
   
   
   
























































   



































































   
   
   






















































   
   
   



















































   
   
   









































































   Development of animal models has provided new tools to study molecular background, 
pathogenesis and treatment of human diseases. Unfortunately, the PBGD deficient mice resemble 
the homozygous type of acute intermittent porphyria with chronic neuropathy but no acute attacks, 
and biochemical changes could be activated only by administration of barbiturates (Lindberg et al. 
1996). Furthermore, the mouse model for VP manifested the biochemical abnormalities but no 
clinical symptoms (Medlock et al. 2002).  Photosensitivity and liver failure were observed (Tutois et 
al. 1991; Meerman et al. 1999) and skin symptoms could be relieved by the gene therapy in the  
mouse model for EPP (Richard et al. 2004). Heterozygous UROD deficient mice were more 




Haem (iron protoporphyrin IX) is a tetrapyrrole containing a central iron ion (Anderson et al. 2001) 
and it is crucial for the life. Even though it is synthesised in all mammalian cells, around 85% of 
haem, which is essential for haemoglobin synthesis, is produced in the maturating erythrocyte 
precursors in the bone marrow (Anderson et al. 2001). Haem also participates in the regulation of 
the globin synthesis to optimize its level (Chen 2007).  The liver is another major source of haem. 
Most of the hepatic haem is utilized in the synthesis of cytochrome P-450 enzymes and for many 
essential cellular haemoproteins which participate in energy supply and respiration.   
The initial and terminal three enzymes of the haem biosynthesis are located inside the 
mitochondrion, while the other four are in the cytosol (Figure 2). During the first step, the 
condensation of eight molecules of glycine and eight molecules of succinyl coenzyme A is catalyzed 
by ALA-synthase (ALAS) to form ALA. Subsequently, two molecules of ALA are condensed to a 
monopyrrole porphobilinogen (PBG) by ALA-dehydratase. Then, four PBG molecules are 
condensed by the cytosolic PBGD to form a tetrapyrrole intermediate - hydroxymethylbilane. 
During the fourth step, the tetrapyrrole is sealed by uroporphyrinogen III synthase to form 
uroporphyrinogen III. Normally less than 1% of hydroxymethybilane is converted non-
enzymatically to uroporphyrinogen I, but this route is activated in the deficiency of 
uroporphyrinogen III synthase associated with congenital erythropoietic porphyria (CEP).
In the fifth step, the four carboxylic groups of the acetic acid chains in uroporphyrinogen are 
removed step by step by UROD (EC 4.1.1.37) resulting in hepta-, hexa- and pentacarboxylic 
intermediates before the formation of coproporphyrinogen III. During the next stage, 
coproporphyrinogen oxidase which is located in the intermembrane space of mitochondria 
decarboxylates two of the four propionic groups in coproporphyrinogen III to two vinyl groups 
yielding protoporphyrinogen IX. 
At the penultimate stage oxidation of protoporphyrinogen IX to protoporphyrin IX is catalyzed 
by protoporphyrinogen oxidase (PPOX; EC 1.3.3.4). Six hydrogen atoms are removed from the 
porphyrinogen nucleus. PPOX is a homodimeric flavoprotein and is located on the outer surface of 
the inner mitochondrial membrane in this reaction  (Dailey et al. 2005). Iron is inserted into 
protoporphyrin to form haem in the terminal step. The reaction is catalysed by FECH (EC 4.99.1.1) 
which is also known as haem synthase. The human FECH has a homodimeric structure and it is 















Haem biosynthesis is regulated by two isoforms of ALAS coded by two separate genes (Bishop et 
al. 1990). The housekeeping isoform (ALAS1) presents in the liver and in the other non-erythroid 
tissues. The synthesis is repressed by haem and its activity is enhanced by various drugs, alcohol 
and other chemicals (Sassa and Nagai 1996). Erythroid-specific isoform (ALAS2) is expressed in 
erythroid cells only. In contrast to ALAS1, the synthesis is upregulated by the increased haem 
concentration and by the availability of iron (Sadlon et al. 1999; Zoller et al. 2002).  
Determination of three-dimensional crystal structures of the recombinant enzymes and 
characterisation of mitochondrial targeting signals of enzymes have allowed studies of structural 
and functional changes in mutants and their intracellular transport mechanisms  (Ajioka et al. 2006). 
Further studies will clarify the pathogenetic mechanisms of these disorders at the cellular and 
molecular level. 
 
4.  PHOTOSENSITIVITY IN PORPHYRIAS 
 
The photosensitizing properties of porphyrins were first demonstrated in 1913 by a physician 
Meyer-Betz, who injected himself intravenously haematoporphyrin (Meyer-Betz 1913). Shortly 
thereafter he had marked erythema and oedema of the skin after the sun exposure resembling skin 
symptoms of EPP and later on chronic photosensitivity similar to PCT.   
 Porphyrins are phototoxic compounds due to their molecular configuration (Figure 3). An 
extensive double-bond structure of tetrapyrrole ring and one of several ions at the centre render 
porphyrin strong absorbers of the light energy (Poh-Fitzpatrick 1986). The most important 
absorption bands of porphyrins lie in the visible region between 400–410 nm (Soret band) and to 
smaller extent between 500-650 nm (Figure 4). The action spectrum studies performed in patients 
with porphyric skin symptoms have shown similarly that a peak response eliciting cutaneous 
photosensitivity lies at around 400 nm and to a lesser extent between 500 and 600 nm (Magnus 
1961; Rimington et al. 1967). 
 






Figure 4. The spectrum of the solar radiation. 
 
Absorption of photon converts stable ground–state porphyrin molecule to the singlet or triplet 
excited state which is unstable of character (Figure 5).  Porphyrin sensitised photoreaction is 
classified into two types. In type I reaction, transfer of a hydrogen atom or electron from the singlet 
excited state porphyrin to molecular oxygen produces free radicals which cause cellular damage. 
The singlet excited state may return to ground status by emission of typical red fluorescence or it 
may be converted to the excited triplet state porphyrin. 
 
Figure 5. Porphyrin-induced phototoxic reaction. 
 
Type II photoreaction arises from the triplet excited state molecule which generates highly 
reactive singlet oxygen. Excited oxygen may react with hydrogen to form peroxides which are 
destructive for cellular structures such as cell membranes (Spikes 1983; Poh-Fitzpatrick 1986). In 
EPP lipid peroxidation of red cell membrane caused by long wave ultraviolet exposure could be 





(Goldstein and Harber 1972; Brun et al. 1990).  Recently, the generation of oxygen radicals has 
been demonstrated in vivo during light irritation in the skin of protoporphyric mouse (Takeshita et 
al. 2004). 
         Photosensitized porphyrins are also capable of inducing other cellular events which may augment 
the tissue damage. Mast cell degranulation (Glover et al. 1990), complement activation (Gigli et al. 
1980) and increase of collagen synthesis by fibroblasts have been demonstrated in vivo and in vitro
experiments (Varigos et al. 1982).  Uroporphyrin I combined with the long wave UVA radiation 
augments the synthesis of matrix metalloproteinases (MMP-1 and MMP-3) in fibroblast culture to a 
greater degree than by UVA radiation alone but has no effect on the synthesis of the major inhibitor 
of metalloproteinases TIMP-1 (Herrmann et al. 1996). These results suggest that the unbalanced 
synthesis of metalloproteinases may contribute to the injury of the connective tissue leading to 
blistering and photoaging of the skin in PCT (Herrmann et al. 1996). Furthermore, an increased 
proteolytic activity of MMP-2 (72-kDa type IV collagenase) and MMP-3 (stromelysin-1) has been 
demonstrated in the blister fluids of the patients with PCT supporting the implication of 
metalloproteinases in the blister formation (Herrmann et al. 1996).  
 Photosensitization via porphyrins produces two different clinical manifestations: acute skin 
reactions characterised by a burning sensation, oedema and erythema immediately after the sun 
exposure, and chronic skin lesions including blisters and erosions aggravated by mechanical trauma 
in continuously sun-exposed areas (Murphy 1999). The first one occurs in EPP and CEP. Hepatic 
cutaneous porphyrias, HCP, PCT and VP are characterised by a chronic type of photosensitivity. 
CEP manifests with the most severe photosensitivity and is characterised by burning reaction with 
vesicles, bullae and erosions resulting in scarring and mutilations especially on the face and hands in 
addition to erythrodontia and severe anaemia (Murphy 2003).  
 The acute or chronic types of skin symptoms have been explained by different intracellular 
localization and solubility of porphyrins in the aqueous and lipid phases (Sandberg et al. 1982). 
Protoporphyrin has high affinity for lipoproteins in cellular membranes and mitochondria because of 
its lipophilic nature. Uroporphyrin is water soluble and accumulates in lysosomes.  Thus, the clinical 
manifestations may be associated with the intracellular site of the primary photodamage.  
Porphyrins vary in their phototoxicity. It has been shown experimentally that protoporphyrin IX 
is the most potent photosensitiser (Menon et al. 1990). Coproporphyrin III is less efficient than 
protoporphyrin IX and uroporphyrin III is the least potent. However, this is in contrast to the clinical 
experience that the most severe photosensitivity occurs in CEP with a drastic increase of 
accumulation of uroporphyrin I (Murphy 2003).   
 Photodynamic therapy used for the treatment of various malignant and premalignant tumors of the 
internal organs and the skin, is a clinical application of phototoxicity of porphyrins  (Wiedmann and 
Caca 2004; Babilas et al. 2005). Lethal cell damage is achieved by a systemic administration of 
haematoporphyrin derivatives or by topical application of porphyrin precursor ALA, which is 
converted intracellulary to protoporphyrin IX, and by subsequent irradiation with an appropriate 
light source.  
Absence of photosensitivity in AIP is related to the fact that porphyrin precursors (ALA, PBG) 
which accumulate in this disorder are not phototoxic. Although acute attacks are accompanied by 
high urinary excretions of uroporphyrin I and III and spectrofluorometric assay of plasma shows 
fluorescence maximum at 619 nm due to uroporphyrins as in PCT, skin symptoms are not present. 





REVIEW OF LITERATURE  
1. VARIEGATE PORPHYRIA 
  
VP was first identified in the 1930s (van der Bergh and Grotepass 1937). It results from the 
mutations in the PPOX gene which encodes the last second enzyme in the haem biosynthesis. As a 
consequence of a mutation the total cellular activity of PPOX is decreased approximately to 50% of 
that of normal which results in overproduction of protoporphyrin and coproporphyrin in the 
circulation. In addition, porphyrin precursors, PBG and ALA, are overproduced in the liver during 
acute attacks (Mustajoki 1978).  
 
1.1. Prevalence of VP 
The highest prevalence of VP has been reported from South Africa among the Afrikaners (1:300) 
(Dean 1971).  According to later calculations 20 000 South Africans may carry the gene defect of 
VP (Kirsch et al. 1998). Genealogical studies have shown that they are descendents from one of the 
first Dutch settlers from the 17th century (Dean 1971). In the earliest study from Finland the 
prevalence of VP has been estimated 1.3:100 000 in population above the age of 15 years 
(Mustajoki 1980). In the more recent study the prevalence of VP was approximately 1.9:100 000 in 
the whole Finnish population (von und zu Fraunberg et al. 2002). VP is less common in other 
countries. The estimated prevalence of VP in the United Kingdom is 0,5:100 000 (Elder et al. 1997), 
in Sweden 1:100 000 (Wiman et al. 2003b) and in Argentina 1:600 000 (Parera et al. 2003). Among 
acute porphyrias, VP is less common than AIP except in South Africa and in Chile (Armas et al. 
1992; Nordmann and Puy 2002). 
 
1.2. Inheritance and molecular genetics of VP 
 
VP is inherited by autosomal dominant trait. The gene coding PPOX has been characterised 
(Nishimura et al. 1995; Taketani and Fujita 1995) and mapped to chromosome 1q22 (Roberts et al. 
1995). The genomic sequence is spread over 13 exons (12 coding and one non-coding) and spans 
5,5 kb (Puy et al. 1996) The first mutations of the PPOX gene were reported in 1996 (Deybach et al. 
1996; Meissner et al. 1996; Warnich et al. 1996). By October 2007 137 different mutations have 
been reported in the PPOX gene in VP patients (Human Gene Mutation 
Database:http://www.hgmd.org). The mutations have usually been family specific. A founder effect 
may affect a local prevalence and for example in South Africa 95% of the patients have inherited the 
same R59W mutation from a common Dutch ancestor (Meissner et al. 1996; Warnich et al. 1996). 
In Chile, where VP is also the most common type of acute porphyria (Armas et al. 1992), the 
founder mutation in the PPOX gene (1239delTACAC) has been identified (Frank et al. 2001). 
Eleven mutations in the PPOX gene have been identified in 22 Finnish VP families to date (von und 
zu Fraunberg et al. 2002; R.Kauppinen, personal communication). One major mutation (R152C) has 






1.3. Clinical features of VP 
Based on different patient series, 20-50% of gene carriers have a clinically overt disease (Kirsch et 
al. 1998; von und zu Fraunberg et al. 2002; Hift et al. 2004b). Many environmental factors and other 
modifying genes play a crucial role in the phenotype of VP.  Sex hormones also affect clinical 
manifestations, since acute porphyrias do not manifest before puberty. The majority of patients are 
20-40 years old at the onset of the disease (Mustajoki 1980). VP manifests by occasional acute 
attacks, which may be life-threatening, if undiagnosed, and by a chronic type of photosensitivity. 
These symptoms occur independently from each other  (Mustajoki and Koskelo 1976; Day 1986).   
 
1.3.1. An acute attack 
 
An acute attack, which is indistinguishable from that of AIP and HCP, is usually precipitated by 
both exogenous and endogenous factors. The most common precipitating factors include drugs, 
infections, alcohol and fasting (Kauppinen and Mustajoki 1992; Anderson et al. 2001). These 
factors induce ALAS and consequently haem biosynthesis resulting in increased excretion of 
porphyrins and their precursors from the liver into the circulation. The recurrent attacks are rare in 
VP and the menstrual cycle precipitates acute attacks less commonly in comparison with AIP 
(Kirsch et al. 1998).  
The characteristic findings during an acute attack are presented in Table 2. The initial symptoms 
include abdominal pain, constipation and vomiting accompanied by tachycardia and hypertension, 
which are signs of autonomic neuropathy. The peripheral neuropathy is another major feature and 
usually manifests as the pain in the extremities and/or the back.  The acute attack may lead to lethal 
respiratory paralysis or cardiac arrest. 
 
Table 2. Frequency (%) of symptoms of an acute attack in VP 
 N=181 N=1002 N=233 
Abdominal pain                              95 98 95 
Tachycardia   90 80 35 
Constipation 80 60 30 
Neuropathy 60 60    <10 
Vomiting        65 70 55 
Hypertension 60 60 50 
Respiratory muscle paralysis          40 25        7 
Epileptic seizures                            25 25        5 
1Mustajoki (1980); 2Eales et al. (1980); 3Kirsch et al. (1998) 
 
The main hypotheses of the pathogenesis of neuropathy during an acute attack are related to 
direct neurotoxicity of ALA, and the local deficiency of haem in neural tissue (Anderson et al. 2001; 
Meyer et al. 1998). The studies in the transgenic PBGD mouse suggest that multiple mechanisms 
are involved including ALA interaction with GABA receptors and changes in tryptophan 
metabolism (Meyer et al. 1998). Liver transplantation in patients with AIP and VP, which has 
resulted in normalization of porphyrin metabolism and clinical symptoms, has demonstrated the 
importance of the liver as a main source of accumulation of porphyrin metabolites (Seth et al. 2007). 





1.3.2. Skin symptoms 
 
In contrast to acute attacks, no specific factors except solar exposition are known to induce skin 
symptoms. The skin manifestations of VP are presented in Table 3. The characteristic skin 
symptoms include blisters, erosions and excessive skin fragility of the sun-exposed areas, usually on 
the backs of the hands and the face, and less commonly on the arms, legs and feet (Mustajoki 1980; 
Muhlbauer et al. 1982; Day 1986). The lesions heal slowly with crusting, scarring and milia 
formation. The development of skin lesions requires repeated sun exposure and the symptoms 
persist without the direct sun exposure. The symptoms are usually present during the summer time 
worsening in the late summer. A half of the 17 Finnish VP patients with skin symptoms reported no 
seasonal variation in the skin fragility (Mustajoki 1980). The patients complained mainly of the mild 
skin fragility. Other chronic skin symptoms of VP include hypertrichosis and hyperpigmentation on 
the face skin (Corey et al. 1980; Muhlbauer et al. 1982; Day 1986). All skin manifestations in VP 
are indistinguishable clinically from those of PCT and HCP.  
 
Table 3. Skin manifestations in VP       
 Skin fragility of the sun-exposed skin (back of the hands and face) 
 Erosions and blisters in the sun-exposed skin (back of the hands and face) 
 Scarring and hypopigmentation on the old skin lesions 
 Milia formation on the old skin lesions 
 Hypertrichosis on the face skin 




Figure 6. Bulla and erosions on the dorsal side of the hand in a patient with  





 The frequency of skin symptoms reported in different patient series is quite constant. In the 
series including 103 patients from France and United Kingdom  80% of symptomatic VP patients 
reported skin symptoms, and 20% of them had also acute attacks (Whatley et al. 1999). Of the 28 
VP patients from one South African family with  R59W mutation, 40% of the cases has experienced 
  photosensitivity (Hift et al. 2004b). In the Finnish series, which included 103 VP patients having 
various mutations, the frequency of photosensitivity was 76% in symptomatic and 40% in all VP 
patients diagnosed either with mutation screening or with biochemical analyses (von und zu 
Fraunberg et al. 2002). In an earlier Finnish study the frequency of photosensitivity was 45% of all 
VP patients (Mustajoki 1980) indicating that proportion of patients with skin symptoms has not 
changed in Finland and is similar to the frequency in other countries. 
  
1.4. Histopathology of the skin in VP 
Of South African patients with VP, six subjects have been reported to have typical skin fragility in 
the sun-exposed areas, and histological examination revealed lipoid proteinosis-like changes in the 
skin (Findlay et al. 1966). It has been shown in the light microscopy (LM) that these areas 
demonstrate periodic acid-Schiff (PAS)-positive hyaline infiltrates around the vessel walls as has 
been demonstrated in patients with EPP. Homogenous PAS-positive thickening could be 
demonstrated in the vessel walls of the upper dermis in the sun-exposed skin in nine symptomatic 
patients with VP from different series (Rimington et al. 1967; Epstein et al. 1973; Corey et al. 1980, 
Maynard and Peters 1992; Grabczynska et al. 1996). Blisters have subepidermal localization like 
those in PCT. 
 A direct immunofluorescence study (DIF) performed in six patients with VP has revealed 
immunoglobulin G (IgG) and/or immunoglobulin M (IgM) depositions in the vessel walls of the 
upper dermis in the sun-exposed skin (Epstein et al. 1973; Corey et al. 1980; Maynard and Peters 
1992; Grabczynska et al. 1996). In two of them faint complement and fibrinogen deposits have been 
demonstrated in the vessel walls and IgG fluorescence has been present in the epidermal basement 
membrane (Epstein et al. 1973). EM of the skin changes has previously been done in one patient 
only (Epstein et al. 1973). An extensive reduplication of the basal lamina could be demonstrated in 
the upper dermal vessel walls of the clinically involved skin. Widened perivascular spaces contained 
finely fibrillar material which extended beyond the reduplicated basal laminae. The epidermal 
basement membrane showed a reduplication of basal lamina. 
 
1.5. Diagnostics of VP 
1.5.1. Symptomatic patients 
 
In VP patients who experience clinical symptoms fluorometric assay of plasma porphyrin emission 
spectrum shows maximum at 626 nm which is a specific for VP (Figure 7) (Poh-Fitzpatrick 1980; 
Long et al. 1993). The sensitivity of plasma scanning in symptomatic patients varies from 85% to 
100% depending on the clinical patient data (Poh-Fitzpatrick 1980; Long et al. 1993; von und zu 
Fraunberg and Kauppinen 2000; Hift et al. 2004a). In VP, plasma porphyrins are a mixture of 
porphyrins in which the main component is a covalently bound to dicarboxylic porphyrin-protein 





uroporphyrin and 5-carboxyl porphyrin (Poh-Fitzpatrick 1980; Longas and Poh-Fitzpatrick 1982).  
Interestingly, the level of plasma porphyrins has no correlation with the presence of skin symptoms 
of VP (Day 1986).  
Faecal excretion of porphyrins is increased in patients with symptoms with the content of 
protoporphyrin exceeding that of coproporphyrin (Anderson et al. 2001). Bacterial metabolism 
within the intestine, gastrointestinal bleeding and intake of haem-containing food may cause a 
nonspecific increase of faecal protoporphyrin content and give false positive results (Zaider and 
Bickers 1998). Urinary excretions of coproporphyrin and uroporphyrin may vary widely but 
coproporphyrin predominates usually (Corey et al. 1980). Excretions of porphyrins in the urine and 
faeces show inter- and intra-individual variation and overlap with other porphyrias. It  limits the 
usefulness of biochemical analysis in the diagnostics of VP (von und zu Fraunberg et al. 2002). In 
the Finnish series including 103 VP patients, high urinary coproporphyrin level predicted clinical 
symptoms of VP, and normal faecal protoporphyrin level predicted freedom of these symptoms (von 
und zu Fraunberg et al. 2002). During an acute attack urinary excretions of ALA and PBG are 




Figure 7. Fluorescence emission spectra of plasma porphyrins in different porphyrias 
 
 
1.5.2. Asymptomatic patients 
 
The porphyrin measurements fail to identify mutation carriers before puberty. The assays for plasma 
fluorescence and faecal porphyrins are not sensitive enough to detect all mutation carriers also in 
adults (Long et al. 1993; von und zu Fraunberg and Kauppinen 2000; Hift et al. 2004a). The 
sensitivity of plasma scanning in adult asymptomatic family members varies from 76% to 86%, but 
in individuals younger than 16 years the sensitivity remains at 0-25% (Long et al. 1993; Hift et al. 
2004a). The assessment of the PPOX activity in lymphocytes may detect symptom-free family 
members, but the laborious technique limits its suitability for screening test (Deybach et al. 1981; 
Da Silva et al. 1995). DNA analysis provides the only accurate method to confirm the diagnosis of 













VP and to detect gene carriers in the families, provided that a mutation in the PPOX gene has been 
identified (von und zu Fraunberg and Kauppinen 2000; Hift et al. 2004a).   
1.6. Homozygous variegate porphyria 
To date a total of 15 patients with homozygous VP have been identified world-wide (Kordac et al. 
1984; Murphy et al. 1986; Mustajoki et al. 1987; Coakley et al. 1990; Norris et al. 1990a; 
D'Alessandro Gandolfo et al. 1991; Hift et al. 1993; Roberts et al. 1998; Corrigall et al. 2000; 
Poblete-Gutierrez et al. 2006). The mutation analysis has revealed that eight of the ten patients 
studied have been heteroallelic (Frank et al. 1998a; Roberts et al. 1998; Corrigall et al. 2000; Palmer 
et al. 2001; Poblete-Gutierrez et al. 2006) and only two patients, who are consanguineous, have been 
homoallelic for the PPOX gene mutations (Roberts et al. 1998). Despite the high frequency of the 
R59W mutation in South Africa, no R59W homozygote patient has been diagnosed suggesting that 
homozygosity for the R59W mutation is lethal (Corrigall et al. 2000).  
In contrast to heterozygous VP, the homozygous form manifests usually as early as in infancy 
even within the first days of life (Hift et al. 1993). Of 15 patients, 14 subjects have experienced 
severe photosensitivity with blisters and erosions followed by scars on the sun-exposed areas, 
especially on the back of the hands and face, similarly to that in heterozygote cases (Table 4). 
Scarring of the head skin may lead to alopecia. In two South African cases changes in an unexposed 
skin including thickening of the arm skin have been described as well (Hift et al. 1993; Corrigall et 
al. 2000). All patients with severe photosensitivity have hand deformities ranging from clinodactyly 
to shortening of the fingers (Table 4).  
Patients with homozygous VP experience numerous symptoms which are atypical for heterozygous 
condition including neurological disturbances, mental retardation and short stature (Table 4) (Hift et 
al. 1993; Roberts et al. 1998). Occasionally these symptoms may be present before the 
photosensitivity occurs (Murphy et al. 1986; Hift et al. 1993). One patient with homozygous VP has 
experienced only severe neurological disturbances and acute attacks (Coakley et al. 1990). The 
diagnosis of homozygous VP in this patient has been later queried by other investigators based on 
lack of skin symptoms (Hift et al. 1993). The adult onset of clinical manifestations has recently been 
described as exceptional cases in two South African sisters with the same heteroallelic PPOX 
mutations (Corrigall et al. 2000). In contrast to other homozygous cases, in whom acute attacks 
were absent, one of the sisters has experienced acute attacks in addition to photosensitivity, but her 
sister experienced only mild photosensitivity resembling heterozygous state rather than homozygous 
state.  
Biochemical characteristics of homozygous VP include an extremely low PPOX activity (0-
20% of the normal lower range) measured in lymphocytes or fibroblasts and an increased 
erythrocyte protoporphyrin concentration (7-10-fold compared to the upper normal range), which is 
predominantly zinc-chelated. In addition, plasma porphyrins emission peak appears at 626 nm and 
excretions of faecal and urinary porphyrins are increased variably as seen in  heterozygous VP 
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1.7. Treatment of VP 
 
Administration of haem derivatives including haemin and haem arginate is the most effective 
treatment of acute attacks of VP (Mustajoki et al. 1989). Haem suppresses ALAS, the rate-
limiting enzyme of haem biosynthesis, by a negative feedback control and decreases the 
production of haem precursors in the liver (Watson et al. 1978; Mustajoki et al. 1989). The 
precipitating factors must be eliminated when a patient is treated during an attack and 
symptomatic treatment is often necessary (Kauppinen 2005).   
There is no effective treatment for the skin symptoms in VP. In a small number of patients 
treatment using chloroquine (Fromke et al. 1978; Corey et al. 1980; Cramers and Jepsen 1980), 
canthaxantin (Eales 1978) or betacarotene (Corey et al. 1980) has been attempted with no or 
only a little clinical response. Cholestyramine, which  binds porphyrins in the intestinal lumen, 
has been reported to be beneficial in one patient with VP (Wechsler 1975). In a recent study, 
which  included eight patients with VP, administration of oral charcoal resulted in worsening of 
the skin symptoms and an increase in the levels of plasma and urine porphyrins (Hift et al. 
2003). Avoidance of sun exposure and protection of the exposed skin with appropriate clothes 
are the only way to reduce skin symptoms to date.  
Liver transplantation has been performed in two patients with VP due to non-porphyric 
reasons resulting in a full recovery of abnormal porphyrin metabolism (Seth et al. 2007).  
1.8. Prognosis of VP 
 
The prognosis for VP patients with acute attacks has improved over the last decades (Kauppinen 
and Mustajoki 1992; von und zu Fraunberg et al. 2002). Both the mortality and the frequency of 
severe attacks have decreased probably due to increased knowledge of inducing factors, early 
diagnosis with mutation screening and more specific therapy.  
In the Finnish study consisting of 103 VP patients, 40% of the subjects experienced acute 
attacks (von und zu Fraunberg et al. 2002). Interestingly, acute attacks were present only in 14% 
of the VP patients diagnosed after 1980, which is significantly less than before 1980 (38%). In 
the series including 108 patients from France and United Kingdom, approximately 40% of 
symptomatic patients experienced acute attacks (Whatley et al. 1999). In a recent study from 
South Africa, only 4% of the 28 postpubertal individuals with the R59W mutation have had an 
acute attack (Hift et al. 2004b).  
The prevalence of chronic renal failure and hypertension is increased among VP patients 
suggesting that acute porphyria increases the risk for these diseases (Kauppinen and Mustajoki 
1992).To date, two cases of hepatocellular carcinoma (HCC) in VP patients have been reported 
(Kauppinen and Mustajoki 1988; Tidman et al. 1989) suggesting the lower incidence of HCC in 







2. ERYTHROPOIETIC PROTOPORPHYRIA 
 
EPP is the most common porphyria manifesting in the childhood with characteristic 
photosensitivity. It was clinically described for the first time in 1953 (Kosenow and Treibs 1953)
and biochemically characterised in 1961 (Magnus 1961). EPP results from mutations in the gene 
encoding FECH which is the ultimate enzyme in the haem biosynthesis and catalyzes the 
insertion of ferrous iron to protoporphyrin IX to form haem (Figure 2). The reduced activity of 
FECH causes overproduction of protoporphyrin in erythropoietic cells with accumulation of 
protoporphyrin in erythrocytes and consequently in plasma, skin and liver (Todd 1994).  
 
2.1. Prevalence of EPP 
 
The prevalence of EPP in European countries has been estimated to be 0.5-1.3:100 000 (Todd 
1994; Wiman et al. 2003a). A recent survey from United Kingdom gave a prevalence of EPP 
0.7:100 000 and from Scotland 2.3:100000 respectively (Holme et al. 2006b; Dawe 2006). The 
first Finnish family with EPP has been reported in 1973 (Hopsu-Havu et al. 1973).  
2.2. Inheritance and molecular genetics of EPP 
 
The gene encoding FECH has been mapped to the long arm of chromosome 18 in region q21.3 
(Taketani and Fujita 1995). The gene is 45 kb in size and contains 11 exons. The cDNA for 
FECH gene is 1269 bp in size and only one isoform of the enzyme has been demonstrated 
(Nakahashi et al. 1990). Since the first mutation of FECH gene was reported in 1991 (Lamoril et 
al. 1991) about 100 different mutations have been identified by October 2007 (Human Gene 
Mutation Database :http://www.hgmd.org).  
Inheritance of EPP is considered to be autosomal dominant with  low clinical penetrance 
because less than 10% of the mutation carriers develop clinical symptoms (Schneider-Yin et al. 
2000). In recent studies autosomal dominant inheritance was verified in 95% of  French patients 
with EPP and autosomal recessive inheritance in 3-4% of French and British series (Whatley et 
al. 2004; Gouya et al. 2006). A large pedigree analysis performed in the Netherlands before the 
era of molecular diagnostics has suggested that a clinically manifest disease is a result of the 
coinheritance of deleterious FECH allele and “low-expressed normal” FECH allele from a 
healthy parent (Went and Klasen 1984; Norris et al. 1990b). The different results of the 
lymphocyte FECH analysis in patients, their symptomatic and asymptomatic parents also 
suggested that EPP is not transmitted in a simple dominant fashion (Norris et al. 1990b).  
The DNA studies indicate that the coinheritance of a non-mutant, FECH allele including a 
single nucleotide polymorphism, IVS3-48T>C, in intron 3, and a mutated FECH allele causes 
aberrantly spliced FECH mRNA which leads to the decreased level of normal mRNA and  
additional reduction of FECH activity (Gouya et al. 2002). This is consistent with the 
observations that the level of FECH activities measured from lymphocytes of symptomatic 
patients is 10-40% of that of normal, while that of asymptomatic patients is approximately 50% 
of the normal  (Todd 1994; Schneider-Yin et al. 2000).  In several series the presence of IVS3-
48C polymorphism and FECH mutation has been demonstrated in patients with the clinically 
manifest disease and the absence of polymorphism in symptom-free patients respectively 
(Risheg et al. 2003; Wiman et al. 2003a; Bloomer et al. 2005; Bloomer et al. 2006). Thus, EPP 
acts as a recessive disease even though the deleterious FECH mutation is present in one allele. 





different ethnic populations, which may influence the prevalence of EPP in them (Gouya et al. 
2006). 
In addition to the IVS3-48TC polymorphism other polymorphic sites in the FECH gene 
have been suggested to modulate the clinical penetrance of EPP (Schneider-Yin et al. 2000). In
vitro studies have suggested that FECH mutations affecting the certain sites of dimeric FECH 
protein may also cause clinically overt EPP in the absence of the modifying polymorphic allele 
(Najahi-Missaoui and Dailey 2005). In addition, myelodysplastic process may affect the FECH 
gene in haematopoietic cell line resulting in late-onset EPP without an inherited mutation (Aplin 
et al. 2001). 
Two mouse models of EPP have been developed including a strain with a homozygous 
point mutation (M98K) in the FECH gene and a heterozygous strain with exon 10 deletion in the 
FECH gene (Tutois et al. 1991; Magness and Brenner 1999). In the first case phenotype is 
characterised by severe photosensitivity and grave liver dysfunction, while the other mouse 
model exhibits only a mild disease with no liver disease. The animal models may provide tools 
for studying the molecular basis and pathogenesis of human disease and for the development of a 
better treatment of EPP (Richard et al. 2004; Abitbol et al. 2005).
 




EPP is clinically manifested by acute photosensitivity that usually commences in the early 
infancy or the first years of life. In a recent report from the United Kingdom, the median age at 
the onset of the symptoms was  one year (range 0-12 years) (Holme et al. 2006b). The most 
characteristic skin symptom of EPP is a burning pain within a few minutes to hours after a sun 
exposure (Table 5) (Murphy 2003). The exposure through a window glass or thin clothing may 
provoke symptoms. Cooling of the skin by cold water is typical relief for pain expressed by 
patients with EPP (Todd 1994). Although in the earlier reports itching has been reported in up to 
88% of the patients, painful sensations are currently the leading initial symptom of 
photosensitivity (>90%) (de Leo et al. 1976; Lehmann et al. 1991; Holme et al. 2006a). This 
difference may be related to the interpretation of symptoms rather than to a real change of 
clinical characteristics. The pain and itching may be related to the mast cell activation and the 
release of histamine and cytokines (Lim et al. 1987; Glover et al. 1990) and down-regulation of 
epidermal eicosanoid metabolism as a consequence of phototoxic reaction (He and Lim 1991).  
Painful sensations are followed by swelling of the exposed areas. In the recent survey this 
was present within six hours after solar exposure (Holme et al. 2006a). The swollen skin is 
usually normal in colour, but it may also be pale or erythematous. Sunburn-like reactions after 
short solar exposure have been reported (Meigel et al. 1981). Prolonged exposure may cause 
superficial vesicles followed by crusting on the facial skin. Petechiae and purpura following the 
swelling and bullous lesions after the overexposure to the sun are unusual skin manifestations of 
EPP (Torinuki and Miura 1983; Keller and Hornstein 1983; Lehmann et al. 1991; Patel et al. 
2000). 
Duration of exposure, which provokes skin symptoms, may vary on the subsequent days in 
such a way that the patient tolerates the sun exposure for several hours on the first day, but the 
next day skin symptoms appear just after a few minutes of exposure (Todd 1994). This event, 
called priming phenomenon, has been reported in 85% of patients (Holme et al. 2006a). It could 
be explained by a two-phased phototoxic reaction in the endothelial cells of the skin vessels 





protoporphyrin from erythrocytes to the endothelial cells as demonstrated in cell cultures, and an 
additional exposure evokes promptly the damage in the protoporphyrin-enriched endothelial 
cells (Poh-Fitzpatrick 1989; Brun et al. 1990). 
Chronic skin changes in EPP include linear and pitted scars on the cheeks and chin, furrows 
on the lips, perioral rhagades and thickening of the skin on the knuckles and the interphalangeal 
joints (Murphy 2003).  Indurated plaques with firm papules in the shoulder region have been 
described in only one EPP patient (Meigel et al. 1981).  
Since the painful sensations may be the only manifestation of photosensitivity in EPP or the 
skin signs are mild and transient, the correct diagnosis may be delayed or overlooked (Murphy 
2003). In a recent study the median age at the time of the diagnosis of EPP was 12 years, but in 
one third of the patients the diagnosis was not confirmed until the age of 20 years or later in spite 
of an early onset of symptoms (Holme et al. 2006a). 
 The onset of skin symptoms of EPP in the adulthood is rare. Only 12 adult patients with the 
first clinical manifestations at the age of 33-73 years have been reported (Murphy et al. 1985; 
Fallon et al. 1989; Yamamoto et al. 1994; Henderson et al. 1995; Goodwin et al. 2006). Of those, 
eight patients had associated sideroblastic anaemia or other myelodysplastic syndromes or 
myeloproliferative disorders (Lim et al. 1992; Shirota et al. 2000; Aplin et al. 2001; Goodwin et 
al. 2006; Sarkany et al. 2006). The development of EPP in these patients is associated with an 
acquired somatic mutation in the FECH gene in haematopoietic cells (Aplin et al. 2001; 
Goodwin et al. 2006).  Only one patient with EPP with first clinical manifestation at middle-age 
and a germ line mutation in the FECH gene has been reported (Berroeta et al. 2007).  







    Holme3 
     N=223 
I. Acute photosensitivity    %    %   % 
 Burning sensations      20 100      31  97   187  85 
 Pruritus     n.a.       28  88    n.a. . 
 Swelling      13   65      30  94   179  80 
 Erythema      17   85      22  69     45  20 
 Blisters         3   15        1    3     37  17 
 Crusting lesions        3   15     n.a.      32  14 
 Petechiae or purpura        3   15        1    3     20    9 
II. Chronic lesions       
 Linear and pitted scars        3   15        6  19    149  67 
 Thickening of the skin on the knuckles        6   30     n.a.       78  35  
1Lehmann et al. (1991); 2de Leo et al. (1976); 3Holme et al. (2006a) n.a. not applicable 
 
2.3.2. Liver disease  
 
Hepatobiliary complications have been reported in 20-30% of the EPP patients (Doss and Frank 
1989; Meerman 2000). Usually the liver disease is mild and limited to increased serum 
transaminase level and only mild abnormalities in the liver histology (Cripps and Goldfarb 1978; 
Meerman 2000). Gallstones, which  develop as a result of accumulation of protoporphyrin in bile 
and may occur as early as in childhood, have been reported in 8-10% of the cases (de Leo et al. 
1976; Doss and Frank 1989; Holme et al. 2006a). 





liver failure which is the most severe sequel of EPP occurring even in childhood (Todd 1994; 
Meerman 2000). An extensively high or progressively increasing erythrocyte protoporphyrin 
level and increased urinary coproporphyrin excretion, predominantly isomer I, may precede liver 
dysfunction (Doss and Frank 1989).  Cholestatic injury and dysregulation of mitochondrial 
respiratory chain enzymes leading to oxidative stress have been proposed as etiologic factors of 
liver failure (Meerman 2000; Bloomer et al. 2005). Although liver complications have been 
linked to compound heterozygosity of the defective FECH mutation (Cox et al. 1998), and to 
exon deletion and a C175 stop codon (Schneider-Yin et al. 1994) and “null allele” mutations in 
FECH gene (Minder et al. 2002), it has not been possible so far to assess the genetic risk for 
development of liver failure. Mouse model studies suggest that genetic background modulates at 
least the severity of liver injury in EPP (Abitbol et al. 2005). 
The histopathological examination of the liver may reveal protoporphyrin deposits 
presenting as pigment with a characteristic birefringence on polarizing microscopy and needle-
like crystals in hepatocytes and bile canaliculi (MacDonald et al. 1981; Komatsu et al. 2000). In 
EM crystal-containing vacuoles  in hepatocytes and bile canaliculi have been demonstrated in 
EPP patients without apparent clinical liver disease and with normal histopathology  
(MacDonald et al. 1981; Rademakers et al. 1990). Moreover, portal or periportal fibrosis and 
mononuclear inflammatory cell  infiltrates may be present without any clinical evidence of liver 
dysfunction (Cripps and Goldfarb 1978; MacDonald et al. 1981). In advanced liver disease 
micronodular cirrhosis and cholestasis are present in addition to a massive accumulation of 
protoporphyrin  (Cripps and Goldfarb 1978; MacDonald et al. 1981). 
 
2.3.3. Haematological changes  
Mild anaemia including microcytosis and hypochromia has been reported in 20-60% of EPP 
patients (de Leo et al. 1976; Baart de la Faille et al. 1991; Holme et al. 2007). A downward shift 
in haemoglobin level has been a constant finding also in those patients without anaemia (Holme 
et al. 2007). Serum ferritin level was decreased in the majority of the patients (2/3), but serum 
soluble transferin receptor-1 and iron concentrations were normal suggesting that the bone 
marrow has been adopted to impaired erythropoiesis, and absorption and supply of iron is 
inhibited to avoid storage of toxic iron compounds (Holme et al. 2007). Studies in the FECH 
mouse model demonstrated that microcytic anaemia associated with FECH deficiency was not 
caused by iron deficiency but was accompanied by a redistribution of iron from the liver to the 
spleen (Lyoumi et al. 2007).  Iron deficiency in EPP patients may also be related to mutations of 
iron regulatory protein 2 (Cooperman et al. 2005). There is some evidence that haem-regulated 
inhibitor kinase, which controls balanced globin-haem synthesis, is responsible for the 
hypochromia and microscytosis in EPP related anaemia as well as in iron deficiency (Chen 
2007).  
 
2.4. Histopathology of the skin in EPP 
The major histopathological findings of the skin were identified soon after EPP was 
characterised as a separate entity. Thickening of the vessel walls of the upper dermis and 
amorphous deposits in and around them have been demonstrated in the sun-exposed skin 
(Peterka et al. 1965; Ryan 1966; Epstein et al. 1973; Baart de la Faille 1975). Similar changes 
were discovered in the clinically normal skin of  eight patients with EPP on the dorsum of the 
hand (Rimington et al. 1967). In these studies no abnormalities have been demonstrated in the 





demonstrated (Rimington et al. 1967).
The amorphous material in and around the vessel walls is strongly PAS-positive suggesting 
the presence of glycoprotein (Rimington et al. 1967). In addition lipids and tryptophan have been 
demonstrated in the vessel walls and in the amorphous depositions (Rimington et al. 1967). In 
the immunohistochemical studies, collagen IV and laminin, which are glycoprotein components 
of normal basement membrane matrix, have been identified in the thickened vascular walls 
(Wick et al. 1979). Connective tissue and elastic fibres constituents such as serum amyloid P 
component, fibronectin and vitronectin have been discovered  in the vessel walls (Breathnach et 
al. 1983; Dahlbäck et al. 1988). 
In DIF including samples of 15 patients immunoglobulins, mainly IgG, were demonstrated in 
the vessel walls (Epstein et al. 1973: Baart de la Faille 1975). EM revealed a concentric 
reduplication of the basal lamina and fine granular material at the basement membrane zone 
(Ryan and Madill 1968; Anton-Lambrecht and Bersch 1971; Epstein et al. 1973; Baart de la 
Faille 1975).  
2.5. Diagnostics of EPP 
 
2.5.1. Symptomatic patients  
 
The biochemical diagnosis of EPP is based on the demonstration of elevated level of 
protoporphyrin concentration in erythrocytes (Todd 1994). The fluorescence microscopy of a 
blood smear from patients with EPP have demonstrated that up to 30% of the erythrocytes 
express bright, transient fluorescence (fluorocytes) (Zaider and Bickers 1998). 
Spectrofluorometric scanning of plasma shows a maximum emission at 634 nm for 
protoporphyrin (Figure 7) (Poh-Fitzpatrick and Lamola 1976). The excretion of protoporphyrin 
to faeces may be increased or normal (Todd 1994). Urinary excretion of porphyrins is usually 
normal, but the excretion of coproporphyrin with predominance of isomer I is increased in 
patients with the liver disease (Doss and Frank 1989).  
Increased protoporphyrin concentrations in erythrocytes occur also in iron deficiency, 
sideroblastic anaemia, lead poisoning and in homozygous forms of porphyria, but in these 
conditions protoporphyrin is mostly zinc-chelated and unable to diffuse across the cell 
membrane and bind to plasma proteins (Zaider and Bickers 1998) resulting in negative plasma 
scanning.  
 
 2.5.2. Asymptomatic patients 
 
In the asymptomatic individuals who have inherited a FECH mutation the erythrocyte 
protoporphyrin concentration is commonly normal (Goerz et al. 1996). Red fluorescence of 
peripheral red cells may also be demonstrated in asymptomatic patients (Went and Klasen 1984).  
The erythrocyte and leucocyte FECH activity is usually decreased, approximately 50% of 
normal, but the levels of the enzyme activity may overlap with health controls (Norris et al. 
1990b; Gouya et al. 1999). As in other porphyrias, DNA analysis is the most reliable way to 






2.6. Treatment of EPP 
To date no curative, standard treatment exists for photosensitivity in EPP. The oral 
administration of beta-carotene has been reported to increase tolerance to sunlight in 70-80% of 
EPP patients, and it is the most widespread treatment in EPP (Mathews-Roth et al. 1977; Poh-
Fitzpatrick 1982; Lehmann et al. 1991). The photoprotective effect of beta-carotene in EPP is 
probably due to its ability to quench singlet oxygen or to scavenge reactive free radicals 
generated in phototoxic reaction (Poh-Fitzpatrick 1982). In a single placebo-controlled crossover 
trial with EPP patients, the efficacy of beta-carotene was poor (Corbett et al. 1977). For the 
clinical use the dosage of beta-carotene should be 120-180 mg/day for adults and 30-90 mg/day 
for children (Todd 1994). If serum carotene level is monitored, it should be maintained at 600-
800 ug/dl during the treatment.  
Oral vitamin C because of its antioxidant properties, may improve the tolerance to sunlight in 
EPP (Boffa et al. 1996). Phototherapy using PUVA (Ros 1988) or narrow-band UVB (Warren 
and George 1998) has alleviated photosensitivity in single cases. Administration of cysteine has 
been found to increase the symptom-free period during light exposure (Mathews-Roth and 
Rosner 2002). Pyridoxine with high doses has reliefed the photosensitivity in two child patients 
with EPP (Ross and Moss 1990). Terfenadine inhibits partly the immediate flare reaction to light 
irradiation in patients with EPP (Farr et al. 1990), but its efficacy has not been proved in clinical 
trials. Avoidance of light exposure, use of protective clothing and application of topical UVA 
blocking sunscreen agents containing titanium or zinc oxide may be helpful (Murphy 2003) 
Cholestyramine and ursodeoxycholic acid have been used to control the progression of liver 
disease (Murphy 2003). These compounds may increase hepatic excretion of protoporphyrin into 
the bile and interrupt the enterohepatic circulation of protoporphyrin. The efficacy of these types 
of treatment has not been established in controlled trials. The best management for advanced 
liver disease of EPP is currently liver transplantation although recurrent protoporphyrin-induced 
damage in the allograft has been reported in 65% of transplanted cases (McGuire et al. 2005). 
In animal models the bone marrow transplantation corrects the FECH deficiency in the bone 
marrow resulting in improvement of photosensitivity (Pawliuk et al. 1999; Fontanellas et al. 
2001). Similar results have been obtained in a patient with EPP and myelogenous leukaemia 
after bone marrow transplantation (Poh-Fitzpatrick et al. 2002) and in another patient with EPP 
who developed severe cholestasis (Wahlin et al. 2007). In the latter case the bone marrow 
transplantation was also curative for cholestasis. The bone marrow transplantation may provide 
new treatment option of EPP in the future in combination with liver transplantation which might 
prevent the recurrence of EPP liver disease. Haematopoietic stem cell gene therapy has corrected 
a progressive rise of erythrocyte protoporphyrin level and photosensitivity in mice with EPP 
(Richard et al. 2004).  
 
 
3. PORPHYRIA CUTANEA TARDA  
PCT was first described in 1937 in patients with porphyrinuria and skin symptoms in the sun-
exposed areas manifesting in adulthood (Waldenström 1937). PCT results from the decreased 
activity of UROD in the liver accompanied by overproduction of uroporphyrin and other highly 
carboxylated porphyrins. In the majority of cases the disease is not related to the mutation in the 
UROD gene, but other individual genetic factors probably control susceptibility to the 
environmental factors which precipitate the clinical expression of the disease (Badminton  and 
Elder 2005). Clinically PCT is manifested by photosensitivity of a chronic nature and by the 
liver disease. 
3.1. Prevalence of PCT 
PCT is the most common type of porphyria in Europe and USA, where the prevalence of PCT 
has been estimated at 4-10:100 000 (Elder et al. 1990; Anderson et al. 2001; Rossmann-Ringdahl 
and Olsson 2005). The highest frequency of PCT, 1:1000 (100:100 000) among the adult popula-
tion, has been estimated in former Czechoslovakia and Mongolia based on the porphyrin screen-
ing of urine (Martasek et al. 1987). A high prevalence among South African Bantu people has 
been linked to use of alcohol and cooking in ironware resulting in hepatic siderosis (Elder 1998). 
3.2. Inheritance and molecular genetics of PCT 
PCT has been classified into four subgroups (Table 6) according to the heredity and the extent of 
the UROD defect in the tissues (Elder 1998; Anderson et al. 2001). In all of them the UROD 
activity is decreased in the liver (Elder 1998). In type I, called sporadic or acquired PCT, no 
mutations of UROD locus have been identified (Garey et al. 1993) (Human Gene Mutation 
Database:http://www.hgmd.org), and the UROD activity is normal when measured from 
patients’ erythrocytes and fibroblasts (Elder et al. 1978). Familial PCT includes types II and III 
and has an autosomal dominant inheritance. Type II PCT is related to a mutation at the UROD 
locus and the activity of erythrocyte UROD is reduced to 50% of the normal range (Elder 1998). 
In type III PCT, which is the other form of familial PCT, the patient has the family history of 
PCT but the erythrocyte UROD activity is normal (Elder 1998). The fourth type of PCT is toxic 
caused by environmental exposure to polyhalogenated aromatic hydrocarbons which are able to 
inhibit UROD leading to accumulation of uroporphyrin (Moore et al. 1987). The most serious 
instance of toxic PCT was an outbreak of PCT in Turkey 50 years ago followed by treatment of 
wheat seeds with a hexachlorobenzene containing fungicide (Cripps et al. 1984). The 
hexachlorobenzene induced PCT in mouse has been utilised as an experimental model for human 
type I PCT (Smith and Francis 1983). 
Based on the enzyme analysis 50-80% of patients with PCT has been classified to have type I 
with normal UROD activity measured in patients’ erythrocytes (Doss et al. 1991; Koszo et al. 
1992; Elder 1998; Cruz-Rojo et al. 2002; Tavazzi et al. 2002). In Spanish series of 118 patients 
studied by enzyme analysis the proportions of types I, II and III  have been 47%, 37% and 16% 
respectively (Cruz-Rojo et al. 2002). In contrast, mutation analysis of the UROD gene in 61 
Spanish patients’ samples revealed the corresponding  proportions 66%, 26% and 8% (Mendez 
et al. 2007). A mutation in the UROD gene could be identified in 25% of the Danish patients 
with PCT indicating  that  the  familial type is more  common  than  previously  presumed (11%) 
34
(Bygum et al. 2003). Respectively, in Chile the frequency of type II PCT was approximately 
50% based on mutation analysis (Poblete-Gutierrez et al. 2004).
Table 6. Classification of UROD related disorders1
Disease  Mode of inheritance UROD activity  Mutations2
Liver Erythrocytes
PCT 63
   Type I  Sporadic, other genes involved  Decreased Normal 
   Type II  Autosomal dominant  Decreased Decreased
   Type III  Autosomal dominant  Decreased Normal 
Toxic PCT  Acquired  Probably 
 decreased1
HEP  Homozygous or compound  
 heterozygous 
 Decreased Decreased 10
1Anderson et al. (2001); 2http://www.hgmd.cf.ac.uk/ac/all.php 
Hepatoerythropoietic porphyria (HEP) is an uncommon variant of PCT caused by 
homozygous or compound heterozygous defects in the UROD gene leading to a severe 
deficiency of the UROD activity. To date less than 40 patients with HEP have been reported 
(Phillips et al. 2007a). HEP is manifested in the early childhood and characterised by severe 
photosensitivity and red-coloured urine resembling congenital erythropoietic porphyria (Phillips 
et al. 2007a). 
Human UROD is a 42 kD polypeptide encoded by a single gene which contains 10 exons 
spread over 3 kb of DNA. The UROD gene has been mapped to chromosome 1p34 (Human 
Gene Mutation Database:http://www.hgmd.org). By October 2007 a total of 73 mutations 
including 10 mutations in the phenotype of HEP have been identified in the UROD gene (Human 
Gene Mutation Database:http://www.hgmd.org). As in other porphyrias, UROD mutations are 
usually family-specific. A mouse with the heterozygous null-mutation at the UROD locus has 
been developed for a model of familial PCT and used for studies of the mechanism of inhibition 
of UROD in the liver (Phillips et al. 2001; Phillips et al. 2007b).
3.3. Risk factors and associated conditions in PCT 
3.3.1. Mechanism of UROD inactivation
UROD inactivation is usually induced by a combination of various factors such as exogenic 
compounds, mutations in the genes associated with liver metabolism or chronic viral infections 
(Table 7). The existence of UROD-inhibitor produced by hepatocytes has been suggested, since 
the protein level of UROD remains unchanged even if the catalytic activity decreases (Elder 
1998). Based on more recent experimental studies in animal models and liver cell cultures, 
hepatic UROD can be inhibited by uroporphomethene which originates from uroporphyrinogen 
by iron-dependent oxidation (Phillips et al. 2007b). In addition, an induction of CYP1A2 may 
accelerate the inhibition of UROD (Smith and De Matteis 1990; Elder 1998). Certain 
polymorphisms in the CYP1A2 and CYP P4501A1 genes may be associated with the 






3.3.2. Alcohol intake 
 
Alcohol is the major risk factor but not a prerequisite for development of PCT. According to 
different series in 30–90% of the cases the daily consumption of alcohol exceeds 40 g, but a 
dose-response relationship between alcohol intake and manifestations of PCT has not been 
confirmed (Elder 1999). On the contrary, PCT is a rare disease among alcoholics and additional 
predisposing factors are required. Alcohol most likely contributes to the inhibition of hepatic 
UROD in susceptible individuals by oxidative and CYP-mediated processes (Elder 1999).
 
Table 7. Risk factors of PCT
Predisposing factor Frequency among PCT patients 
based on different patient series  
Genetic  
Mutations in the UROD gene     20-50% 
Mutations in the HFE gene     60-70%  
Certain CYP1A2 polymorphisms    70% 
Exposures  
Alcohol    30-90% 
Oestrogen    55-70% of females 
Iron overload    60-90% 
Chronic viral infections  
Hepatitis B    20-70% 
Hepatitis C    20-90% 
HIV    15-25% 
Other   
Ascorbic acid deficiency    60%1 
Smoking    90%2 
Haemodialysis    1-18%  




An intake of oestrogen preparations for contraception and a hormone replacement has been 
identified as a risk factor in 55-70% of female patients with PCT (Egger et al. 2002; Rossmann-
Ringdahl and Olsson 2005). Oestrogen intake has been the solitary risk factor in more than 25% 
of female patients (Bulaj et al. 2000) especially among those with the familial type of PCT 
(Sixel-Dietrich and Doss 1985). Men treated with oestrogen preparations for prostate cancer 
have rarely developed PCT  (Sixel-Dietrich and Doss 1985). The mechanism by which the intake 
of oestrogens induces UROD deficiency is unclear (Bulaj et al. 2000).  
 
3.3.4. Iron overload 
 
Iron has probably an essential role in the inhibition of the hepatic UROD (Phillips et al 2007b).
The importance of iron for pathogenesis of PCT is supported by the fact that diminishing iron 
stores by venesections is curative for PCT (Elder 1990; Sarkany 2001). The majority of the 
patients with PCT have a direct or indirect evidence of iron load in the liver. Increased serum 





Rocchi et al. 1986; Fargion et al. 1996; Bulaj et al. 2000). In liver biopsy hepatic siderosis has 
been demonstrated up to 95-100% of PCT patients (Rocchi et al. 1991; Siersema et al. 1995; 
Bulaj et al. 2000).  HFE mutations, which are associated with clinical hemochromatosis, are 
probably most commonly responsible for iron overload in PCT (Bulaj et al. 2000). At least one 
HFE mutation has been identified in 60-70% of  patients with PCT in Europe and USA (Bulaj et 
al. 2000; Egger et al. 2002; Harper et al. 2004; Kratka et al. 2008) 
The frequency of  the C282Y mutation among the patients with PCT varies from 20% to 60% 
and that of the H63D mutation up to 50%, respectively (Sampietro et al. 1998; Bulaj et al. 2000; 
Cruz-Rojo et al. 2002; Egger et al. 2002; Kratka et al. 2008). The homozygous state of the 
C282Y mutation or the compound heterozygous state of the C282Y and H63D mutations in 
patients with PCT have been demonstrated in several series, and these genotypes associate 
particularly with abnormal iron status (Bulaj et al. 2000; Harper et al. 2004). The homozygosity 
for the C282Y mutation has been shown to accelerate clinical manifestations in the familiar type 
II of PCT (Brady et al. 2000). The S65C mutation in the HFE gene has no significant role in the 
pathogenesis of PCT (Lamoril et al. 2002; Harper et al. 2004). To date, no mutation in the 
transferring receptor 2 (TFR2) gene has been detected among patients with PCT (Kratka et al. 
2008). Independently from the HFE mutations, hepatic siderosis in PCT may associate with 
polymorphism in the transferrin receptor-1 gene (Lamoril et al. 2002) and down-regulation of 
hepcidin in hepatocytes (Ajioka et al. 2008). In addition, iron overload can be induced by oral or 
intravenous iron preparations and by repeated transfusions especially in those having genetic 
vulnerability (Shehan and Huerter 2001).  
 
3.3.5. Viral hepatitis  
 
High frequencies of hepatitis B virus (HBV) and C virus (HCV) infections in PCT patients have 
been reported in several studies. A serologic evidence of HBV infection has been found in 20 -
70% of the PCT patients; the highest frequency has been reported from southern Europe (Rocchi 
et al. 1986; Stransky et al. 2000). Based on the published data, the frequency of HCV infection 
in patients with PCT has been estimated at 50%, but the  frequency varies significantly 
depending on the country and the type of PCT (Gisbert et al. 2003). The highest frequencies of 
HCV infection have been reported from southern Europe (66-91%), USA (56-76%) and Japan 
(85%), while in northern Europe and Scandinavian countries the frequencies of HCV infection 
have been below 30% (Gisbert et al. 2003; Rossmann-Ringdahl and Olsson 2005). Calculated 
from the published data  the prevalence of HCV infection in patients with type I PCT was 2-fold 
compared to that reported from patients with type II PCT (57% vs. 26%) (Gisbert et al. 2003). In 
Sweden the prevalence of HCV infection among patients with type I PCT was 36% but only 4% 
among those with type II PCT (Linde et al. 2005) 
 
 
3.3.6. HIV infection 
 
Around 100 cases of PCT have been reported among patients with human immunodeficiency 
virus (HIV) infection (Mansourati et al. 1999). In a small American series 25% of 24 patients 
with PCT tested for HIV was positive (Egger et al. 2002).  Additional risk factors for PCT such 
as HBV, HCV and alcohol use were present approximately in half of HIV patients with PCT. 
This suggests that HIV infection may have  an independent causative effect on the development 
of PCT (Mansourati et al. 1999). The proposed mechanisms which could lead to an alteration in 





oxidase system by HIV infection or by associated opportunistic infections, alteration of hepatic 
oestrogen metabolism and increase of hepatic iron store as a result in ineffective haematopoiesis 




Haemodialysis for chronic renal failure may precipitate PCT. The frequency of PCT varies from 
1  to 18% of the patients receiving haemodialysis (Shieh et al. 2000). The development of PCT 
in haemodialysed patients may be related to latent PCT or to the deficient UROD activity caused 
by azothemia and accumulation of porphyrins because of impaired excretion and poor dialysis 
(Shieh et al. 2000). Aluminium intoxication from the equipment used for dialysis may also 
disturb haem synthesis (Shieh et al. 2000).  
 
3.4. Skin Symptoms of PCT 
 
3.4.1. Clinical manifestations of skin symptoms 
 
Skin symptoms in PCT of different subtypes are similar. The onset is usually after the fourth 
decade of life, but in type II disease can manifest earlier than in type I, sometimes even in 
childhood (Elder 1998). The characteristic skin signs include blistering and fragility of the sun-
exposed skin resulting in raw erosions after minor trauma (Table 8) (Grossman et al 1979, Poh-
Fitzpatrick 1982). Occasionally the blisters may develop to large bullae. The eroded skin lesions 
heal slowly with crusting, scarring and milia formation like in VP. The skin lesions occur 
regularly on the dorsal sides of the hands and fingers, but also on the other chronically sun-
exposed areas as the face, neck, arms, legs and feet. The skin symptoms arise in summer and 
continue in autumn beyond the sunny season.  
The chronic skin signs of PCT comprise hypertrichosis, hyperpigmentation, solar elastosis 
and scleroderma-like changes (Table 8). Hypertrichosis on the face skin is a frequent finding 
reported in two-thirds of PCT patients (Grossman et al. 1979; Boffa et al. 1995). Usually it is 
located in the upper cheek and the periorbital areas. Hyperpigmentation on the face skin without 
preceding bullae or erosions in the same region has been identified in half of patients (Grossman 
et al. 1979). It is usually mottled in appearance, but more diffuse and reticulated pattern has also 
been described (Grossman et al. 1979; Sarkany 2001). Hypertrichosis and/or hyperpigmentation 
may be the only clinical signs of PCT (Fritsch et al. 1998). In 1.6-18% of PCT patients sclero-
derma-like lesions occur both in the light exposed and covered skin, most commonly on the head 
and upper chest (Grossman et al. 1979; Friedman and Doyle 1985). In single cases the localised 
scleroderma has been the only cutaneous manifestation concomitant with the increased 
uroporphyrin excretion in the urine (Friedman and Doyle 1985).  Scleroderma-like changes 
preceed typical signs of PCT or develop during years after the onset of typical skin symptoms of 







Figure 8.  Typical blisters and bullae on the dorsal sides of the hands in a  
patient with PCT (on the courtesy of the patient) 
 
The skin symptoms of PCT are indistinguishable from those in VP and HCP. Moreover, in 
pseudoporphyria induced by various drugs and long-term haemodialysis identical to those of 
PCT skin symptoms occur but no biochemical porphyrin abnormalities can be found (Green and 
Manders 2001).  PCT has been reported to be associated with systemic lupus erythematosus 
(Cram et al 1973) although no definite relationship has been found (Griso et al 1989). 
Photodamage of the conjunctiva has been suspected in a few patients with PCT related to high 




Table 8. Skin symptoms in PCT   
Skin fragility of the sun-exposed skin  
Erosions and blistering  in the the sun-exposed skin 
Scarring and hypopigmentation on the old skin lesions 
Milia formation on the old skin lesions 
Hypertrichosis on the face skin 
Hyperpigmentation on the face skin 






3.5. Histopathology of the skin in PCT 
 
LM  of the blister in PCT reveals that it has subepidermal localisation with scanty inflammatory 
cells (Kemmer et al. 1988; Maynard and Peters 1992). Collagen IV and laminin have been 
demonstrated at the base of the blister by immunohistochemical studies suggesting that the 
blister develops at the level of lamina lucida above lamina densa  (Pardo and Penneys 1990; 
Dabski and Beutner 1991). In EM the level of cleavage has been identified both above the basal 
lamina and in the dermal site (Kint and De Weert 1978; Klein et al. 1983). The initial stage of 
the split formation has been hypothesised to arise above the basal lamina, and then additional 
factors such as the light energy and mechanical trauma aggravate the injury to more profound 
dermolytic blister (Klein et al. 1983; Nagato et al. 1987). A characteristic morphologic feature of 
PCT blister is that dermal papillae beneath the blister retain their original configuration resulting 
in undulating appearance of the blister floor (Maynard and Peters 1992). In addition, caterpillar 
bodies, which are eosinophilic bodies containing degenerating keratinocytes and basement 
membrane material  have been demonstrated in the epidermis overlying the blister (Egbert et al. 
1993; Raso et al. 1996). They are considered highly specific for PCT but have been found only 
in around 40% of cases (Fung et al. 2003). 
 In the vessel walls of the sun exposed skin homogenous thickening containing PAS positive 
material has been identified  (Epstein et al. 1973; Kemmer et al. 1988). EM has demonstrated 
that thickening of the vessel walls is caused by reduplication of basal lamina of the basement 
membrane zone and excess of fine fibrillar and an amorphous material around the vessels 
(Epstein et al. 1973; Kemmer et al. 1988). No microscopic changes have been observed in the 
vessel walls in the covered skin (Rimington et al. 1967; Epstein et al. 1973).  
DIF reveals depositions of IgG and variably C3 and fibrin in the vessel walls of the upper 
dermis in the skin lesion (Epstein et al. 1973; Kemmer et al. 1988). Deposits of 
immunoglobulins and complement have been considered to originate from circulation rather than 
from the activation of complement system (Epstein et al. 1973). Deposits of complement 5b-9 in 
the vessel walls has been demonstrated in skin samples of patients with PCT similar to those 
with diabetes mellitus, in which vascular changes of the skin are comparable to PCT (Vasil and 
Magro 2007). The authors propose that complement is activated by irradiated uroporphyrins 
resulting in complement 5b-9 deposits in the vessel walls. Thus, similar complement activation 
and histological changes may also occur by glycolysation as in diabetes. In the epidermal 
basement membrane zone IgG and C3 have been variably found  (Epstein et al. 1973). 
The deposits of the vessel walls except immunoglobulins have been characterised 
incompletely in PCT. Collagen IV has been demonstrated in the vessel walls in a single case 
(Krajnc et al. 1998). Vitronectin, which is a cell-adhesive glycoprotein in plasma and dermal 
elastic fibres, has been demonstrated in the perivascular deposits in PCT probably because it can 
attach abnormal protein deposits (Dahlbäck et al. 1988). The presence of vitronectin has been 
hypothesised to be associated with the late-stage inhibition of the activated complement system 










In addition to skin symptoms the liver disease is another major clinical manifestation of PCT and 
occurs in 80-90% of the cases (Sarkany 2001).  Alcohol ingestion, viral hepatitis and iron 
overload are often present concomitantly contributing to the development of the liver disease. 
Serum transaminase levels are increased in 50-80% of patients (Grossman et al 1979; Moore et 
al. 1987). Abnormalities in the liver function tests occur also in those patients with PCT who 
have no overt liver disease or known risk factors suggesting that excess of uroporphyrin itself 
may cause hepatopathy (Campo et al. 1990).  The liver disease in untreated PCT can progress to 
cirrhosis which has been reported in 20-30% of the patients (Grossman et al 1979; Cortes et al 
1980). Antibodies to human liver cytosolic antigens are present frequently in type I PCT  and 
they are associated with HCV infection and the severity of liver disease (Ma et al. 2001).   
                                             
3.6.2. Liver histology 
 
Increased iron deposits are nearly always present in liver biopsy specimens of patients with PCT 
(Campo et al. 1990). Different non-specific morphological changes including fatty degeneration, 
focal lobular necrosis, portal inflammation and fibrosis have been demonstrated in up to 90% of 
the patients and they can vary from negligible to severe (Campo et al. 1990).  Needle-shaped 
uroporphyrin crystals can be demonstrated in cytoplasm of hepatocytes (Cortes et al. 1980; 
Fakan et al. 1998). In EM uroporphyrin crystals are located close to ferritin-like iron deposits 
indicating the crucial role of iron in pathogenesis of PCT (Siersema et al. 1995). The 
simultaneous presence of haemosiderin in periportal hepatocytes, fatty changes and portal 
inflammation has been demonstrated to be more common in PCT than in other liver diseases. In 
the latter group haemosiderin is more often present in Kupfer cells (Campo et al. 1990) 
 
3.6.3. Hepatocellular carcinoma 
 
Patients with PCT have a high prevalence of hepatocellular carcinoma (HCC). The highest 
frequency of HCC, 47% of the patients with PCT, was reported from the autopsy series done in 
former Czechoslovakia (Kordac 1972). HCC has been identified in 13-24% of PCT patients in 
various small series (Solis et al. 1982; Siersema et al. 1992; Linet et al. 1999).  Patients with 
PCT and chronic hepatopathy who have been treated with phlebotomies to remission still have a 
4-fold risk for HCC in comparison to control patients with chronic liver disease but no PCT 
(Fracanzani et al. 2001). In a recent survey from Spain HCC was detected only in one of 39 
patients (2.6%) during the 10-year follow-up (Gisbert et al. 2004). Thus, the incidence of HCC 
was less than 1% per patient-year of the follow-up.  A long symptomatic period before the 
treatment, the presence of cirrhosis and the chronic HCV infection are the major risk factors for 






3.7. Diagnostics of PCT 
 
The biochemical hallmark of PCT is overproduction of uroporphyrin in the liver which is 
released into circulation and excreted into the urine. Urine contains uroporphyrin, predominantly 
isomer I, and 7-carboxyl porphyrin, and lesser amount of 6- and 5-carbpoxyl porphyrins (Moore 
et al. 1987).  
Isocoproporphyrin is a typical finding in faeces in PCT, because in the lack of UROD the 
propionic side chains of 5-carboxylate intermediate are decarboxylated and oxidised to a vinyl 
group probably by coproporphyrinogen oxidase resulting in dehydroisocoproporphyrinogen. The 
latter is converted to isocoproporphyrin probably by bacterial degradation in the bowel and can 
be identified (Moore et al. 1987; Cooper et al. 2005). 
Plasma porphyrin content is a mixture of porphyrins, uroporphyrin being the main 
component. The spectrofluorometric assay of plasma porphyrins detects fluorescence maximum 
at 619 nm (Figure 7) (Poh-Fitzpatrick and Lamola 1976). The elevation of urinary uroporphyrin 
and 7-carboxyl porphyrin level and the demonstration of typical plasma fluorescence in an 
individual with typical skin lesions confirm the diagnosis of PCT.  Measurement of UROD 
activity is used to distinguish type II PCT (Elder et al. 1989). 
3.8. Treatment in PCT 
Elimination of exogenous precipitating factors such as alcohol, oestrogen compounds and iron 
supplements improves the effect of active therapy and prolongs the duration of remission after 
treatment (Sarkany 2001). In some cases, cessation of alcohol intake and predisposing drugs can 
result, although slowly, in clinical and biochemical remission without other treatment action. In 
the majority of patients with PCT, active treatment such as phlebotomy or low dose chloroquine 
are required and has been used successfully for years. 
Phlebotomy corrects the overproduction of porphyrins probably via reduction of the hepatic 
iron stores (Grossman and Poh-Fitzpatrick 1986). Phlebotomies are performed at weekly or 
biweekly intervals (400-500 ml/phlebotomy) until the haemoglobin concentration falls to 100-
110 g/l or serum ferritin level is below the normal reference value (Sarkany 2001). Four to 10 
litre of blood must usually be removed for the therapeutic effect. The improvement of clinical 
symptoms after starting of phlebotomies occurs usually within 6 months, and excretion of 
porphyrins normalises within a year in general. In haemodialysis-associated PCT small volume 
phlebotomies in combination with the high-dose erythropoietin administration have been 
effective (Shieh et al. 2000). 
A dose of 125-250 mg of chloroquine twice a week usually produces clinical improvement 
during four months and biochemical remission (urinary uroporphyrin excretion below 100 
nmol/d) within a year (Sarkany 2001). The effect of low-dose chloroquine is probably related to 
the formation of porphyrin complexes in the liver cells (Scholnick et al 1973), and the 
compounds are excreted massively at the beginning of the treatment via bile and urine 
(Rossmann-Ringdahl and Olsson 2007). Simultaneously transient increase of the serum 





AIMS OF THE PRESENT STUDY 
1. To study occurrence of cutaneous porhyrias in Finland 
2. To study  etiological factors including genetical changes associated with cutaneous 
porphyrias 
3. To study clinical manifestations of  VP, EPP and  PCT and their response to treatment  
4. To investigate the histopathological changes and  pathogenesis of the skin lesions in VP, EPP 
and PCT 
 
In the beginning of this study no detailed information about Finnish patients with cutaneous 
porphyrias was available except 55 patients with VP studied by Professor Pertti Mustajoki 
(Mustajoki 1980) and one Finnish family with EPP reported by Professor Väinö Hopsu-Havu 









     1.1. Variegate porphyria
 
Of total of 156 Finnish VP patients (von und zu Fraunberg et al. 2002) belonging to 22 different 
families, 20 patients were selected for the histolopathological studies. One of the patients with 
VP was homozygous for the deficient PPOX (Mustajoki et al. 1987). All patients with VP were 
diagnosed at the University Central Hospital of Helsinki during the period 1966-2006. 
The diagnosis of VP in symptomatic patients was based on the fragility of the sun-exposed 
skin and/or acute neurovisceral attacks and on increased protoporphyrin excretion exceeding 
coproporphyrin excretion in the faeces (Li et al. 1986). Chracateristic plasma porphyrin 
fluorescence emission spectrum (maximum at 626 nm) confirmed the diagnosis of VP (Poh-
Fitzpatrick 1980). Decreased lymphocyte PPOX activity (Deybach et al. 1981) was observed in 
at least one of the family members.  
In symptom-free patients the diagnosis was based on the family history of VP and on 
increased faecal protoporphyrin excretion and/or a decreased lymphocyte PPOX activity or on 
mutation analyses (von und zu Fraunberg et al. 2002). The diagnosis of the homozygous patient 
was based on the extremely low (10%) lymphocyte PPOX activity in the proband and on half 
normal enzyme activity in his parents who were cousins (Mustajoki et al. 1987). The information 
on the clinical symptoms was obtained by clinical examination, by telephone interview and/or 




Of 48 Finnish patients with EPP belonging to 15 different families, eight patients were studied 
using histopathological methods. Finnish EPP patients were diagnosed at the University Central 
Hospitals in Helsinki, Turku, Tampere and Oulu and in the Central Hospitals in Joensuu, Vaasa 
and Pori since the 1970’s.   
The diagnosis of EPP in symptomatic patients was based on acute photoreactions   
characterised by painful swelling and erythema of the sun-exposed skin and on increased 
erythrocyte protoporphyrin concentration (Li et al. 1986). Chracateristic plasma fluorescence 
emission spectrum (maximum at 634 nm) (Poh-Fitzpatrick and Lamola 1976), a low reticulocyte 
ferrrochelatase activity (Pasanen et al. 1980) and the family history of EPP confirmed the 
diagnosis. If erythrocyte protoporphyrin concentration was <10 000 nmol/l (normal 200-1010 
nmol/l) in patients with photosensitivity but no family history of EPP, a proportion of zinc-
chelated protoporphyrin was determined (Orfanos et al. 1989). In symptom-free patients the 
diagnosis was based on the family history of EPP, decreased reticulocyte ferrochelatase activity 





1.3. Porphyria cutanea tarda 
 
Of a total of 85 Finnish patients with PCT who were included for clinical and biochemical 
studies during 1966-2006, five patients were studied using histopathological methods. Forty-
three patients were diagnosed and investigated at Helsinki University Central Hospital. Clinical 
data from 42 patients were assembled by direct contact with the heads of the Departments of 
Dermatology and Medicine at the University and other Central Hospitals and using the write-off 
register for the hospitalised patients in National Board of Health. To improve the validity of the 
series data for increased excretion of urinary uroporphyrin were collected from two laboratories 
(United Laboratories Inc, Helsinki and laboratory of Helsinki University Central Hospital) that 
have facilities in analysing porphyrin excretion using high performance liquid chromatography 
(HPLC) technique in Finland. 
 The diagnosis of symptomatic PCT was based on blistering and erosive lesions and/or 
excessive hyperpigmentation on the sun-exposed skin and increased excretion of urine 
uroporphyrin with predominance of 7-carboxyl porphyrin (Lim and Peters 1984). In plasma 
porphyrin fluorescence assay, emission maximum at 617-619 nm supported the diagnosis of PCT 
(Poh-Fitzpatrick 1980). In symptom-free patients the diagnosis was based on the family history 
of PCT and the decreased erythrocyte UROD activity (Elder et al. 1989). 
 plasma fluorescence emission spectrum Chracateristic plasma fluorescence emission spectrum  
2. BIOCHEMICAL ANALYSES 
 
2.1. Porphyrin analyses 
 
The erythrocyte and plasma protoporphyrin contents were determined by HPLC (Salmi and 
Tenhunen 1980; Li et al. 1986). Fluorescence emission spectrum of plasma porphyrins was 
assayed by direct spectrofluorometry (Schimatzu RF-540, Hitachi F 4010) (Poh-Fitzpatrick and 
Lamola 1976; Poh-Fitzpatrick 1980). Twenty-four-hour excretion of urine coproporphyrin and 
uroporphyrin was measured using either spectrophotometry after extraction with ether (With 
1968) or HPLC (Sandberg et al. 1982). Faecal coproporphyrin and protoporphyrin were 
determined either by spectrophotometric assay (Rimington 1958) or by HPLC (Li et al. 1986).  
     
2.2. Enzyme analyses     
 
The lymphocyte PPOX activity  was measured by fluorometric assay which measures the 
oxidation of the non-fluorescent protoporphyrinogen to the fluorescent protoporphyrin (Deybach 
et al. 1981). One unit of the enzyme activity was defined as the amount of enzyme required to 
form one nmol protoporphyrin in an hour. The formation of protoporphyrin was determined by 
fluorescence using Hitachi spectrofluorometer (wavelength of excitation 403 nm, emission 631 
nm) and protein concentration was measured using Bio-RAD protein assay (Bio-Rad 
Laboratories, CA, USA).  
The activity of reticulocyte ferrochelatase was measured by radiochemical method 
(Bonkowsky et al. 1975). Radioactive iron was used in the reaction mixture and the radioactivity 
of the 59Fe-labelled haem was measured by the Compugamma (LKB-Wallac) sample counter. 
The enzyme activity was expressed as one pmol 59Fe-labelled haem formed per 106 reticulocytes 





The activity of erythrocyte UROD was assayed by measuring the rate of conversion of 
uroporphyrinogen I to coproporphyrinogen I (Romeo and Levin 1971; Pasanen et al. 1980). 
Coproporphyrin formed from coproporphyrinogen by iodine oxidation was measured by 
spectrophotometry. One unit of the enzyme activity was defined as the amount of enzyme 
required to form one pmol coproporphyrin in an hour. Protein concentrations were measured 
using Folin reagent (Lowry et al. 1951). 
 
3. SKIN BIOPSIES 
3.1. Tissue samples 
  
In publication I the skin samples were obtained from the back of the hand with signs of old 
lesions and from the sun-protected gluteal skin in 12 patients with VP who experienced skin 
fragility. Of eight patients with VP but no skin fragility, the biopsy specimens were taken only 
from the normal looking back of the hand. In publication V the skin samples were taken from the 
back of the hand during symptom-free period in eight patients with EPP who experienced 
photosensitivity and in five cases from the gluteal skin also. In publication VI the skin samples 
were obtained from the back of the hand and gluteal skin before treatment, at the time of 
remission and six months later in three patients with PCT treated with chloroquine. In two 
additional patients with PCT treated with chloroquine, skin biopsies were taken from the back of 
the hand before treatment and after one year’s remission.       
3.2. Tissue processing 
 
The formalin-fixed tissue sections were stained with haematoxylin-eosin and PAS as performed 
routinely. In addition, the samples of VP patients were stained with Alcian blue and those of 
EPP patients with Congo red and elastin. Direct fluorescence staining of frozen sections was 
performed with fluorescein isothiocyanate-labeled antibodies to IgA, IgG, IgM and complement.  
Samples for EM were fixed overnight or longer in 2.5% glutaraldehyde in ice-cold 0.1mol 
phosphate buffer (pH 7.2) and postfixed in 1-2 % osmium tetroxide. The specimens were stained 
with 5% uranyl acetate and lead citrate and examined using JEOL 1200X electron microscope 
operated at an accelerating voltage of 60 kV.  
For immunohistochemistry the paraffin-embedded tissue sections were processed according 
to the avidin-biotin peroxidase staining method (Wood and Warnke 1981) using 
StreptABComplex/HRP-Kits (DAKO, Glostrup, Denmark) with primary antibodies. Collagen 
IV, SAP, kappa and lambda antibodies were obtained from DAKO, laminin from Sigma (St 
Louis, Mo), versican from Seikagagu (Tokyo, Japan). The samples were incubated with primary 
antibodies for one hour at room temperature. Aminoethylcarbazole was used as  chromogenic 
substrate. Sections were counterstained with Mayer’s haematoxylin. The detailed information of 





4. DNA ANALYSIS 
4.1. DNA and RNA extraction and cDNA synthesis 
 
Leucocyte DNA was extracted from the venous blood samples with EDTA as an anticoagulant 
using the QIAmp Blood Kit (Qiagen, Germany) or released from lysates (Higuchi 1989). Total 
RNA was extracted from Epstein-Barr virus transfected lymphoblast cell lines (Chirgwin et al. 
1979; Sambrook et al. 1989). Complementary DNA (cDNA) was synthesised from patients’ total 
lymphoblast RNA by Superscript II RNAse transcriptase (Gibco/BRL, USA) using random 
hexamers. 
 
4.2. DNA amplification 
 
The polymerase chain reactions (PCR) were performed using 100 ng DNA, 0.2 mM NTPs, 20 
pmol of primers and 1U of DNA-polymerase in 50 l of the enzyme buffer. The primer 
sequences used for amplification of the cDNA and genomic DNA samples and detailed 
information of PCR conditions are given in publications III and IV. Radioactive PCR for single 
strand conformation polymorphism (SSCP) was performed by adding 1 Ci of 32P dCTP 
(Amersham, Buckinghamshire U.K) in to a reaction mixture.  
  
4.3. Mutation screening using restriction enzymes, SSCP and sequencing 
 
Mutations were identified by restriction enzymes whenever available. Ten l of PCR product 
and 20 U of a restriction enzyme in 30 l of the enzyme buffer were incubated for an hour at the 
temperature specific for the enzyme used (New England Biolabs, MA, USA).  
The resulting fragments were run in 1-4% agarose gel stained with ethidium bromide 
(Pharmacia Biotech, Uppsala, Sweden) and visualised using UV light. Mutations of the 
ferrochelatase gene were also analysed using SSCP (Orita et al. 1989). Diluted and denatured 
PCR products were run in a single-strand separation gel containing 5% or 10% glycerol. Bands 
were visualised by autoradiography.  
The PCR products were purified using Qiaquick PCR Purification Kit (Qiagen, Germany) or 
Magic PCR Prep Kit (Promega, USA). If PCR was performed with biotinylated primers, 
purification for single strand sequencing was carried out with streptavidin-coated microbeds 
(Fluoricon; Idexx, USA). The DNA was sequenced directly by the dideoxynucleotide chain 
termination method either with Amplicycle Sequencing Kit (Perkin Elmer, NJ, USA) or 
manually using Sequenase 2.0 Sequencing Kit (USB, Ohio, USA). Each sample included 5 Ci 
- 33P-dATP (Amersham, UK).  A mutation site was sequenced both with sense and anti-sense 






5. TREATMENT WITH HAEM
 
5.1. Haem administration 
 
In four VP patients infusions of haem arginate (NormosangR, Leiras) 3mg/kg of body weight 
were initially given daily for four consecutive days, and then once a week for four weeks. 
Ampoules of haem arginate were diluted in 100 ml physiological saline and given intravenously 
into a peripheral vein over 15 min. The homozygous VP patient was treated with haem arginate 
2 mg/kg for four consecutive days. 
 
5.2. Laboratory measurements 
 
Faecal porphyrins were measured from three samples before haem treatment, after starting the 
treatment from daily samples for the first 10 days, followed by twice a week sampling up to 
three weeks after the last infusion. Plasma protoporphyrin and haemopexin, which were  
analysed by immunodiffusion (Non-Partigen, Hoechst, Germany), were measured before 
treatment, after four daily infusions, before each weekly infusion and one week after the last 
infusion.  Blood haemoglobin, leukocyte and platelet counts, serum iron, ferritin, transferrin, 
aspartate aminotransferase, alanine aminotransferase and glutamyltransferase levels were 




In phototesting a metal halogen lamp (Epolux, 2000 W, Airam, Finland) was used as a source of 
the light.  Emission spectrum of the lamp ranged from 390 to 720 nm with peak at 400-420 nm. 
The irradiance of the lamp at 400-410 nm varied from 21 to 53 W/m2 at the distance of 15 cm 
which was used in the tests. The phototests were performed on the inner side of the forearm 
before treatment, after four daily infusions of haem, after the second weekly infusion and one 
week after the last infusion. The shortest time of irradiation capable to induce erythema was 
taken as the threshold dose. 
6. STATISTICAL AND COMPUTER-BASED ANALYSES 
 
Student’s t-test was used to compare the means of porphyrin excretions in VP patients with or 
without skin symptoms. Parameters before and after haem arginate treatment were compared 
using Student’s t-test for paired data.  
 
7. ETHICAL ASPECTS
The study has been approved by the Ethics Committee of the Departments of Medicine and 







1. PREVALENCE AND INCIDENCE OF CUTANEOUS PORPHYRIAS IN FINLAND
1.1. Variegate porphyria 
 




































 Figure 9. The new patients with VP identified from 1960 to 2006.  
 
The prevalence of VP estimated in 1978 was based on the analysis of 48 patients and equalled 
1.3 per 100 000 Finnish population older than 14 (Mustajoki 1980). A total of 73 VP cases were 
diagnosed in Finland in 1989 (Kauppinen and Mustajoki 1992). During the last two decades the 
majority of the new patients have been asymptomatic (Figure 9). Since the 1960’s altogether 156 
patients with VP have been revealed in 22 families. At the end of 2006 108 patients were alive. 
Thus, the current prevalence of VP including both symptomatic and asymptomatic cases is 
approximately 2.1:100 000 in the Finnish population of 5.2 million indicating still a slight 
increase in the number of patients because of genetic testing (von und zu Fraunberg et al. 2002).
Of 70 new patients diagnosed since 1980, 22 were symptomatic (Figure 9) providing the 
incidence of 0.2:1 000 000 calculated in the population older than 14. The increase in the 
number of patients since 1970’s reflects the activity of finding new cases by means of 
biochemical analyses and mutation screening. Moreover, contemporary information and 
knowledge about porphyrias among physicians have contributed to the number of new patients. 
Although several VP series have been published in Western Europe (Whatley et al. 1999; 
D'Amato et al. 2003; Lecha et al. 2006), VP is still far more frequent in Finland than in other 
countries outside South Africa (Elder et al. 1997; Wiman et al. 2003b). This may result from a 
founder effect since the major mutation characterised in 11 families follows the settlement of the 
Finnish population during the last 500 years in the southern-western part of the country (von und 
zu Fraunberg and Kauppinen 2000). Although their pedigrees could not be united and 
haplotyping  analysis  was not  performed, they most  likely have a common  ancestor in Finland. 
Interestingly, the Finnish major mutation was also reported from France and in USA (Frank et al. 
1998b; Whatley et al. 1999). In Sweden approximately 80 VP patients have been diagnosed in 



































Figure 10.  The new patients with EPP identified from 1970 to 2006. 
 
 
Previously only one Finnish EPP family including one patient with a manifest disease and her 
five symptom-free family members has been described (Hopsu-Havu et al. 1973). Although EPP 
has been screened since 1970’s among patients with photosensitivity in the dermatological 
departments of University Central Hospitals (Hopsu-Havu et al. 1973), the number of EPP 
patients is low in our country. To date we have enrolled 45 EPP patients belonging to 15 
families, of whom 39 patients were alive at the end of 2006. Thus, the prevalence of EPP in 
Finland is approximately 0.8:100 000 including both symptomatic and asymptomatic patients. If 
only symptomatic patients (n=23) are included as in the surveys from other countries, the 
estimated prevalence is 0,4:100 000. This is lower than reported from the Netherlands (1:75000) 
and the United Kingdom (1:136 000) (Todd 1994; Holme et al. 2006b) but comparable to that 
reported from Sweden (0,5:100 000) (Wiman et al. 2003a).  Approximately one symptomatic 
patient has been diagnosed every second year providing the incidence of 0.1:1 000 000 but in the 
majority of the families new asymptomatic individuals have been identified by mutation 







1.3. Porphyria cutanea tarda 






























Figure 11.  The new patients with PCT identified from 1970 to 2006. 
 
During 1972-2006, 85 patients with PCT were diagnosed in Finland (Figure 11). Of the patients, 
81 subjects had skin symptoms, three subjects were asymptomatic family members identified 
only by enzyme or mutation analysis and one case had biochemical chracteristics of PCT, but no 
skin symptoms. The data indicates that two to three new patients with PCT have been diagnosed 
in Finland yearly during the last 2.5 decades. Sixty three patients were alive at the end of 2006. 
According to these figures the prevalence of PCT to date is 1.2:100 000 in the Finnish 
population of 5.2 million and the incidence 0.5:1 000 000 per year. The estimated prevalence of 
PCT in the capital region including 1.5 million inhabitants is 1.2:100 000 on the bases of 18 
living patients which is comparable to the figures of the whole country. These numbers are 
considerably lower than elsewhere in Western Europe, where the prevalence of PCT ranges from 
1: 1000 in the former Czechoslovakia (Martasek et al. 1987) to 1: 25 000 in the United Kingdom 
(Elder 1990). Incidence of PCT in the United Kingdom (Elder 1998) has been estimated at 2-5: 1 
000 000 per year, which is more than 4-fold compared to that of  Finland. 
 The causes for the low incidence of PCT in Finland may be related to varying presence of 
associating or genetic factors. Hepatitis C infection is uncommon in Finland in contrast to the 
Southern Europe (Cruz-Rojo et al. 2002). Increasing consumption of alcohol is comparable to 
that the other European countries (Helasoja et al. 2007), which suggests that alcohol is not the 
major factor at the epidemiological level. Moreover, the frequency of HFE mutations in the 
Finnish population is comparable to that in Europe and the United States of America (US) 
(Parkkila et al. 2001). Currently unidentified genetic factors, which may explain the low 
morbidity of PCT in Finland, cannot be excluded.
In Finland the occurrence of subtypes of porphyria differs from that of other countries. AIP is 
the most common porphyria in Finland (Kauppinen and Mustajoki 1992), Sweden (Andersson et 
al. 1995) and Germany, while PCT is the most common form of porphyria in US and Southern 
Europe (Elder 1998). In Finland the prevalence of VP is 2-fold compared to that of PCT (2.1 vs. 
1:100 000), but the estimated incidence of PCT exceeds 2-fold that of VP (0.5 vs. 0.2:1 000 000 
per year). The lower incidence number of VP is probably attributed to a few symptomatic 
patients diagnosed during last decades. EPP is the second commonest cutaneous porphyria in 
many countries after PCT, which may be caused by infrequency of VP in those countries In 
Finland EPP is clearly less frequent in comparison to other types of cutaneous porprhyria. To 





2. DIAGNOSTICS OF CUTANEOUS PORPHYRIAS
(Article I, IV and V) 
 
2.1. Biochemical and mutation analyses of VP 
The results of the biochemical analyses in 91 patients with VP tested in remission are presented 
in Table 9 and those who have experienced skin symptoms are presented in Table 10. Plasma 
porphyrin fluorescence assay showed the characteristic peak at 626 nm in 21 of 30 patients 
examined. In all symptomatic patients (n=19) the plasma fluorescence scanning was positive. 
Two of the patients with a positive result and all the patients with negative plasma porphyrin 
fluorescence (n=9) were asymptomatic family members screened by DNA analysis and their 
faecal and urinary porphyrin excretions were also within the normal range. The results indicate 
that plasma porphyrin scanning detects reliably the symptomatic patients but it is not sensitive 
enough to identify asymptomatic family members. In the assays of the urinary and faecal 
porphyrins the typical findings were the increased excretions of faecal protoporphyrin and 
urinary coproporphyrin (Article I). The mean faecal protoporphyrin level was 3.5-fold compared 
to the normal upper limit exceeding distinctly that of coproporphyrin which was only slightly 
increased (1.6-fold) (Table 9). The means of urinary coproporphyrin and uroporphyrin levels 
increased in a same proportion compared to the normal upper limits (2.7- and 2.5-fold 
respectively), but the total increase of coproporphyrin level exceeded distinctly that of 
uroporphyrin which remained near to the normal range. In 40% (30/75) of the patients urinary 
coproporphyrin excretion was within the normal range and correspondingly in 49% (32/65) of 
the patients of urinary uroporphyrin excretion was within the normal range or only slightly 
increased (<60 nmol/d). Urinary coproporphyrin level more than 1000 nmol/d was associated 
with an increased risk of clinical symptoms (von und zu Fraunberg et al. 2002). 
The patients with skin symptoms had a higher excretion level of urinary and faecal 
porphyrins compared to that of all patients measured (Table 9 and 10). Urinary coproporphyrin 
(3.9-fold) excretion exceeded that of uroporphyrins (3.6-fold) and faecal protoporphyrins (4.8-
fold) that of coproporphyrins (2.4-fold), respectively (Table 10). Excretion of urinary 
porphobilinogen and was normal in 31% of the cases (10/32) and only slightly increased in the 
others. The increased excretion of faecal protoporphyrin was found in all patients with skin 
symptoms except one who was symptom-free at the time of the examination. He had experienced 
skin symptoms for several years earlier suggesting that normal faecal excretion of 
protoporphyrin predicts freedom of symptoms (von und zu Fraunberg et al. 2002). These results 
indicate that after a mutation has been identified in the asymptomatic family member, 
biochemical tests should be done in the adult individual to predict risk for clinical 
manifestations.
The results demonstrated that the constant finding in patients with VP and the current skin 
symptoms was the typical plasma porphyrin fluorescence and increased level of faecal 
protoporphyrin excretion. The plasma fluorescence at 626 nm is specific for VP and the test 
covers also patients with acute symptoms and commonly also those, who have had symptoms 
earlier. Plasma porphyrin fluorescence may be positive in symptom-free patients (Da Silva et al. 
1995) and thus, it cannot be used solely in the diagnostics of skin symptoms. Furthermore, faecal 
analysis alone does not exclude the secondary increase of protoporphyrins caused by intestinal 
flora and haemoglobin in the faeces (Moore et al. 1987). In conclusion, the diagnosis of 
symptomatic VP should be based on both of these assays before the causality of the skin 
symptoms and abnormal porphyrin profile can be established. The urinary porphyrin analysis is 





The mean activity of lymphocyte PPOX was approximately 60% of the normal level (Table 
11). However, in six (17%) of the 35 patients the enzyme activity was either normal or near the 
upper normal limit (> 3.0 nmol proto/h/mg protein) overlapping with the levels of healthy family 
members. Thus, the PPOX activity is insufficient as a sole investigation for the diagnosis of VP. 
Of note, 18 (70%) of 25 patients with VP had also a low erythrocyte FECH activity (mean 3.7 
pmol/haem/h retic), which may be a secondary phenomenon to the deficient PPOX activity or it 
may reflect the low normal FECH activity reported among healthy controls due to a 
polymorphism in the FECH gene (Gouya et al. 2002).  
 Mutation screening in the PPOX gene can be used to confirm the diagnosis, but a typical 
biochemical profile of VP is mandatory in order to prove the causality of skin manifestations to 
VP. A total of nine mutations have been identified among Finnish patients with VP (von und zu 
Fraunberg and Kauppinen 2000; von und zu Fraunberg et al. 2001). The major mutation 
(R152C) in the western part of Finland and the knowledge about the region from which the 
families originate facilitates DNA analysis in our country. However, the biochemical 
abnormalities must always be detected in an index case before sequencing of the PPOX gene is 
reasonable. Thereafter, the information about the family specific mutation can be used in family 
screening. The purpose of DNA analysis is to find the patients, who are at risk for acute attacks 
and should avoid precipitating factors. If a patient has skin symptoms, plasma porphyrin 
fluorescence assay and analysis of urinary and faecal porphyrins are the methods of choice.  
 
 
2.2. Biochemical and mutation analyses of EPP 
The increase of erythrocyte protoporphyrin concentration was shown to be the principal 
abnormality in EPP (Table 9). The mean value of erythrocyte protoporphyrins (40 968 nmol/l) in 
the patients with skin symptoms was 40-fold compared to the normal, but there was a wide 
variation in the levels (Table 18). The lowest value of erythrocyte protoporphyrin associated 
with skin symptoms was 5-fold (4847 nmol/l) the normal (Table 18). Of note, at the time of 
diagnosis in this case erythrocyte protoporphyrin concentration measured by semiquantitave 
method exceeded 60–fold the normal (data not shown). In asymptomatic patients the erythrocyte 
protoporphyrin levels were constantly on the upper limit of the reference value or slightly 
increased exceeding up to 3-fold the normal (Table 18).  The mean of erythrocyte 
protoporphyrin concentrations among symptomatic patients was 25-fold compared to that of 
asymptomatic patients (mean 40 968 vs. 1668 nmol/l, Table 18). 
The plasma porphyrin fluorescence assay studied in 20 patients with skin symptoms showed 
a characteristic peak at 634 nm in all of them (Table 9). The excretion of urinary uroporphyrin 
was only slightly increased in five (6%) of the 18 patients analysed and that of urinary 
coproporphyrin was within normal range (Table 9). The mean of faecal protoporphyrin excretion 
was slightly (2.7-fold) increased among symptomatic patients (mean 354 nmol/g dry weight). Of 
note, it was normal in five symptomatic patients. 
 Erythrocyte FECH activity was decreased in all patients with the skin symptoms and the 
mean activity was 13% of the normal (Table 11) mimicking the recessive pattern of inheritance. 
In six cases, the enzyme activity was measured from the lymphocytes. In DNA analysis four 
novel mutations (751delGAGAA, 1122Tdel, C286T, C343T) were identified in the FECH gene 
in 10 patients of the four families studied (IV). All symptomatic patients had dramatically 
increased levels of erythrocyte protoporphyrins (Table 18), and thus, the mutation analysis 
provided no additional information for the clinical diagnosis of EPP in these patients.  Twelve 





increased (mean 1.7-fold increase compared to normal, Table 18), could be diagnosed as carriers 
of a mutation. Of note, one of the mutations, 1122delT, was a de novo mutation. 
 In symptomatic patients with EPP the biochemical diagnosis is based on the high 
concentration of erythrocyte protoporphyrins usually more than a 5-fold increase compared to 
normal. If the increase is less than 10-fold, plasma porphyrin spectrum should be performed to 
confirm the diagnosis of EPP. Less than a 5-fold increase can be also related to iron deficiency, 
lead intoxication or homozygous porphyrias other than EPP (Zaider and Bickers 1998) and thus, 
the ratio of the free and zinc chelated protoporphyrin should be measured (in EPP the ratio <1) 
before the diagnosis of EPP can be established (Orfanos et al 1989). Biochemical methods 
poorly recognize asymptomatic patients carrying the affected gene, and thus, mutation analysis 
can be used to identify these family members if necessary for genetic counselling but typical 
clinical symptoms and accurate biochemical findings are usually sufficient to confirm EPP.   
 
   
2.3. Biochemical analyses of PCT 
In the patients with PCT the biochemical hallmark was the increased excretion of urinary 
uroporphyrin and 7-carboxyl porphyrins (Table 9). The excretion of urinary uroporphyrin varied 
from 15 to 350 (mean 110)-fold compared to that of normal. The excretion of 7-carboxyl 
porphyrin was increased in all patients with PCT analysed ranging from 2 to 316-fold compared 
to that of normal. In addition, urine contained excess of 6- and 5-carboxyl porphyrins but the 
level of 7-carboxyl porphyrin was higher in all individuals examined. On the whole, the levels of 
carboxylporphyrins decreased linearly compared to the level of uroporphyrin. Level of urinary 
coproporphyrin was increased (2-fold) in the majority of cases, but it was normal in 24% (17/71) 
of the patients studied. Compared to VP, the increase of urinary coproporphyrin excretion was 
less extensive. 
The mean excretion of total faecal coproporphyrin was within the normal range, but it was 
mildly increased in 10 (22 %) of the 45 patients studied up to 3-fold (mean 179, range 104-328 
nmol/g dry weight). Presence of faecal isocoproporphyrin which is dehydroisocoproporphyrin 
metabolized by bacteria in the gut, is informative for the diagnosis of PCT (Moore et al. 1987; 
Cooper et al. 2005), but it was not analysed in our series separately. Faecal protoporphyrin level 
normal in the majority of cases, but in 5 (12%) of 42 patients (mean 260 nmol/g dry weight, 
range 190-344), it was increased 2-fold indicating induced metabolism of porphyrins even 
beyond UROD. In plasma porphyrin fluorescence assay, maximum at 617-619 nm 
Scanning of plasma fluorescence emission spectrum showed a peak at 617-619 nm in all 
patients examined (n=43). This is not specific for PCT, because AIP and HCP give a similar 
plasma fluorescence pattern. The sensitivity of plasma fluorescence was 100% in symptomatic 
patients.  
Erythrocyte UROD activity was decreased in 26 of 53 patients (49%) suggesting type II 
PCT. Only two of the symptomatic patients were from the same family (father and son). Based 
on enzyme analysis the proportion of type II PCT in Finland is 2-fold compared to those reported 
from Hungary (23%, based on enzyme analysis), Italy (26%, based on enzyme analysis), 
Denmark (25%, based on mutation analysis) and Spain (26%, based on mutation analysis) 
(Koszo et al. 1992; Tavazzi et al. 2002; Bygum et al. 2003; Mendez et al. 2007). Our results are 
similar to those reported from Germany (50%, based on enzyme analysis), Spain (37%, based on 
enzyme analysis) and Chile (50%, based on mutation analysis) (Doss et al. 1991; Cruz-Rojo et 







The mutation analysis revealed a C304T mutation in the UROD gene in a patient with PCT 
and his asymptomatic daughter. Since both of them had normal erythrocyte UROD activity, PCT 
was classified as type III. Currently, the clinical relevance of the mutation analysis is uncertain 
since the biochemical abnormalities are essential in the diagnosis of PCT. In asymptomatic 
family members, the significance of a carrier status of a mutation is even more troublesome to 
interpret. No information is available about the risk of developing symptomatic PCT in 
mutations carriers. Mutation screening may be an additional screening method for the 
measurement of the UROD activity in order to classify the subtypes of PCT (Bygum et al. 2003; 
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3. CLINICAL MANIFESTATIONS  
3.1. Variegate porphyria
3.1.1 Occurrence of the symptoms   
 
Of the total of 156 VP patients (Table 12), 90 (58%) were women and 66 men (42%) and full 
clinical information was available in 112 cases (Table 13 and 14). Fifty-four percent (61/112) of 
them experienced clinical symptoms (Table 13). Of symptomatic patients, 64% had acute attacks 
and 67% skin symptoms, respectively. However, the occurrence of acute attacks decreased 
dramatically from 51% to 18% during the last decades (Table 12). The occurrence of skin 
symptoms decreased only slightly from 44% to 30% at the same time. The frequency of 
photosensitivity as the only clinical sign was stable during the follow-up before or after 1980 
(22% vs. 21%), but acute attacks became rare (29% vs. 7%) during the last two decades. The 
number of patients having both acute attacks and photosensitivity decreased substantially (22% 
vs. 11%), but still 30% of the symptomatic patients have both skin symptoms and acute attacks 
(Table 13).  
 
 
Table 12.  The clinical manifestations of VP patients during the follow-up  
                                                                         Year of diagnosis and number of the patients 
 Before 1980 
 N     % 
 1980-2006  
   N     %  
  Total 
   N     % 
Acute attacks only  16    29     4      7   20    18 
Photosensitivity only  12    22   11    19   23    21 
Photosensitivity and acute attacks  12    22     6    11   18    16 
No symptoms  15    27   36    63   51    46 
No information about clinical manifestations1  21       5    26 
No information about acute attacks/skin 
symptoms1 
 4/7   0/0   4/7 
Age < 15 years1   -     7     7 
Total  87   69 156 
Mutation known  21   60   81 
1Excluded   from the percentages; the majority of  the patients were diagnosed using pedigree analysis      
 
The penetrance rates of VP have varied from series to series (von und zu Fraunberg et al. 
2002; Hift et al. 2004b;Whatley et al. 1999). The frequency of acute attacks has varied from 4% 
to 38% and skin symptoms from 40% to 70%, respectively, depending on the ratio of 
asymptomatic and symptomatic patients and active mutation screening in these families. If 
careful mutation screening has been performed as described in one South African (Hift et al. 
2004b) or several Finnish families (von und zu Fraunberg et al. 2002), the clinical manifestations 
occur in 40 % of the mutation carriers. Current results suggest a descending tendency for 






Table 13. The clinical manifestations of symptomatic patients with VP during the follow-up 
                                               Year of diagnosis and number of the patients  
 Before 1980 
  N     %              
    1980-2006 
       N    % 
    Total  
    N    % 
Acute attacks  28    70       11    48    39    64 
Photosensitivity  24    60       17    81    41    67 
Subgroups    
Acute attacks only 16    40        4     19    20    33 
Photosensitivity only 12    30      11     52    23    38 
Photosensitivity and 
acute attacks 
12    30        6     29    18    30 
Total              40      21      61 
 
Of 61 symptomatic patients, 30% experienced both symptoms, 33% only acute attacks and 
38% skin symptoms respectively (Table 13). Among symptomatic patients the occurrence of 
acute attacks has decreased from 70% to 48% during the last two decades and thus, the 
proportion of skin symptoms has increased from 60% to 81%, respectively. These numbers are 
comparable to other series (Whatley et al. 1999) indicating that acute attacks have become less 
frequent especially if acute porphyria has been diagnosed at the asymptomatic phase and the 
patients can avoid precipitating factors (Kauppinen and Mustajoki 1992).  
     In six patients who had both skin symptoms and acute attacks after 1980 the skin symptoms 
were present before the acute attacks manifested. Of the 21 patients diagnosed after 1980, nine 
symptomatic patients (45%) had no family history of VP. Therefore, lack of family history does 
not exclude acute porphyria. Both symptomatic and asymptomatic patients with VP were 
identified later among family members in five of these cases.  The other four were still single 
patients in the family, but no extensive mutation screening has been performed.  
 
 
Table 14. Frequency of skin symptoms and acute attacks by gender and follow-up periods  
 Male                    Female  
Symptom  Before 1980 
    N     % 
 1980-2006 
   N     % 
 Before 1980 
  N     % 
 1980-2006 
   N    % 
Acute attacks only      4    20    1      4  12    34    3     9 
Photosensitivity only     5    25    4    17    7    20    7    21 
Photosensitivity and acute attacks     4    20    0    8    23    6    18 
No symptoms     7    35  18    78    8    23  18    53 
No full information1   14    4  18    1 
Children1    -    5   -    2 
Total number of patients   34  32  53  37 
1Excluded  from the percentages 
 
Of the 61 symptomatic patients 70% (43) were women and 30% (18) men. No difference in 
gender was observed in the frequency of skin symptoms, but the low number of acute attacks 
was especially obvious among men who can avoid most of the precipitating factors. In women 







3.1.2. Skin symptoms 
 
Of 41 patients detailed information about skin symptoms was available (Table 15). The onset of 
the photosensitivity varied from 14 to 53 years (mean 23 years). In five cases (11%) skin 
symptoms did not manifest until the age of 30. The majority of the patients were women (30 
women, 68%, vs. 12 men, 32%).  The predominance of women has been explained by the 
presumption that women are more vulnerable for minor trauma in their daily work compared to 
men (Mustajoki 1980). 
Ninety five percent of the patients experienced photosensitivity which manifested as 
excessive fragility resulting in erosions and blistering on the sun-exposed skin (Table 15). Skin 
fragility occurred constantly on the backs of the fingers and hands and to lesser extent on the 
face and the arms despite chronic sun exposure. Less than half of the patients experienced 
blisters on the back of the hands, which probably was a sign of more severe photosensitivity.  
Blisters never occurred as a sole symptom, but always together with erosions after minor trauma. 
In a half of the patients the skin symptoms showed seasonal variation increasing in late summer 
and autumn. However, a similar proportion of the patients reported skin fragility throughout the 
year.  Typical skin symptoms in the selected group, which was studied for histological changes, 
were comparable to those of the total group, and thus, the results gained from the selected group 
were representative for more general conclusions (Table 15).   
 
 
Table 15. The characteristics of skin symptoms in heterozygous patients with VP  
 Selected group in the 
histological studies1   
All patients with the detailed 
information about skin 
symptoms 







Hand 12 100 37 90 
Arm 5 42 14 34 
Face 7 50 17 41 
Foot 3 25 7 17 
Leg 1 8 1 2 
Blisters2  
Hand 5 42 19 46 
Face 0 1 2 
No seasonal variation 5 42 24 59 
Hypertrichosis 5    42 14 34 






Previously skin symptoms which were studied in 53 Finnish patients with VP have been 
considered mild and less common (45%) (Mustajoki 1980) than in those from the other countries 
(80%) (Eales et al. 1980; Whatley et al. 1999) where the sun exposure is stronger. Only 17% 
(4/24) of Finnish patients had contacted a physician because of their skin symptoms before 1980, 
which is comparable to our present results (17%, 7/41). The recent series including 28 adult 
family members with South African founder mutation demonstrated that 40% of them 
experienced skin symptoms which located in the hands in 90% of patients (Hift et al. 2004b). 
The site of skin symptoms in the Finnish patients was comparable to the results obtained from 
South African patient data: the dorsal side of the hand was affected constantly and the face in 
less than half of the cases. The hands are probably affected more commonly than the face 
because of the exposure to minor trauma (Mustajoki 1980).  
Although clinical manifestations of the skin symptoms have remained the same throughout 
the five decades in Finland, early diagnostics may reveal more patients with milder skin 
symptoms and genetic counselling may diminish the severity of the skin symptoms when the 
patients are guided to protect their skin with clothes. Currently the majority of the patients with 
VP have been diagnosed using biochemical or mutation screening methods at the asymptomatic 
phase. 
Of 41 patients with skin symptoms, seven patients (17%) had a history of acute transient 
light eruption in the early summer. Since light eruptions are as common as in 20 % of normal 
population (Jansen and Karvonen 1984), they may not be directly associated with porphyria in 
these patients, although it has been suggested (Day 1986). 
Hypertrichosis was present in the face skin in the third of the patients with VP (Table 15). 
Only two of the 14 patients were men indicating that hormonal factors may influence the 
presence of hypertrichosis as described in that of other origin (Ramos-e-Silva et al. 2008). It was 
mostly mild lanugo-type together with long hairs locating on the cheeks, periorbital and 
temporal areas.  
Hyperpigmentation occurred in the fifth of the patients, mainly in the face and cheeks, which 
could be difficult to distinguish from melasma and hyperpigmentation related to systemic 
diseases (Ramos-e-Silva et al. 2008). It was the only presentation of the skin symptoms in two 
patients, and the association of hyperpigmentation with porphyria was supported by the highly 
increased excretion of coproporphyrins in the urine (>1000 nmol/d), which  predicted symptoms 
of porphyria among patients with VP (von und zu Fraunberg et al. 2002)  The presence of 
hypertrichosis and hyperpigmentation did not seem to be associated with the severity of the skin 
fragility. 
Hypertrichosis and hyperpigmentation are much rarer (up to 30%) than photosensitivity in 
South African patient series  (Eales et al. 1980; Hift et al. 2004b)  but they can easily be 
neglected even by questionnaires. Patients with VP seldom complain of them spontaneously.  
   
3.1.3. The homozygous patient    
(Article III) 
 
The homozygous patient was followed clinically and biochemically for 20 years. He 
developed a severe bullous skin disease post partum followed by increased fragility and cheloid-
like scarring (Mustajoki et al. 1987). Up to five years of age he also experienced acute 
photoreactions. Severe blistering and fragility of the sun exposed skin have continued during the 
follow-up in the summer and autumn. Skin lesions were complicated by deep erosions and 





including dorsal parts of the hands, ears, neck, and the scalp accompanied by partial alopecia 
(Figure 12). Radial deep furrows around the mouth developed gradually. Four subsequent haem 
arginate infusions corrected only partially porphyrin metabolism for a few days (Article II).  
The fingers of the patient were markedly shortened and thickened with flexion impairment. 
Early closure of the phalangeal epiphyses was detected by radiographs. Mental status, EEG and 
CT of the head remained normal, but sensory polyneuropathy was shown in nerve conduction and 
sensory evoked potential studies especially in the upper extremities. Fine motor-coordination 
disturbances were accompanied by minor verbal and visuospatial deficiencies. Raised intra-
ocular pressure responding to a beta-blocking agent and myopia were detected at the age of six 
(vision 0.7). The patient never experienced acute attacks indicating that the clinical 
manifestations were chronic and neurological and cutaneous in origin.  
Since age of 20 serum creatinine level was constantly increased accompanied by 
haematuria, proteinuria and increase of blood pressure (BP 140/90) indicating a renal failure. 
Renal biopsy revealed sclerotic changes in glomeruli. Using immunofluorescence techniques a 
strong IgA and moderate C3 depositions were found in mesangium and paramesangium areas 
confirming IgA-nephropathy. Renal failure progressed to oliguria and the patient was treated 
with peritoneal dialysis for the last three years before kidney transplantation. Cholecystectomia 
was performed before transplantation because of cholelithiasis. Traditional operation techniques 
and filters in the lamps of the operating room were used successfully without phototoxic 
complications.  
Like the other patients with homozygous VP, our patient had severe photosensitivity from the 
early childhood in addition to deformities of the hands (Hift et al. 1993). Scar formation is a 
constant phenomenon among these patients (Table 4), but scarring alopecia has been described 
earlier only in one patient (D'Alessandro Gandolfo et al. 1991). Sensory neuropathy has occurred 
only in one additional patient earlier (Hift et al. 1993). Our patient had no mental retardation and 
convulsions, which have been present in half of the cases reported (Table 4). Acute attacks have 
been described in one patient with an adult onset of clinical manifestations (Corrigall et al. 2000) 
and in the other patient with uncertain diagnosis of homozygous VP (Coakley et al. 1990) but not 
in the characteristic patients with severe photosensitivity since the childhood (Table 4).  
Renal failure has not been reported in the other patients with homozygous VP (Table 4) but it 
is not rare finding among patients with acute porphyria (Kauppinen and Mustajoki 1992; 
Andersson et al. 2000). The histology of renal biopsies from these patients varies from 
glomerulonephritis to tubular fibrosis, but IgA nephropathy has not been documented among 
other patients with porphyria.  
All our patient’s relatives have been symptom-free throughout the follow-up years. Only one 
of 12 patients, who have the same mutation (I12T) at the heterozygous state, has experienced two 
acute attacks at the time of the diagnosis but no skin symptoms. She belonged to another family 
and the pedigrees could not be united suggesting that other modifying genes interfere with the 
phenotype. These results demonstrated that the I12T mutation is clinically milder at the 






















After initial four daily doses of intravenous haem arginate, the excretion of faecal 
protoporphyrin (mean 579 nmol/g dry weight) fell to an almost normal level (mean 123 nmol/g 
dry weight), and that of coproporphyrin (mean 162 nmol/g dry weight) to the normal level (mean 
21 nmol/g dry weight) in all patients. During the period of four weekly infusions of haem the 
excretions of faecal porphyrins initially fell in three patients but returned within a week to almost 
the pretreatment level. In one patient the weekly infusions had no effect on protoporphyrin 
excretions. The excretion of faecal porphyrins after treatment remained at the pretreatment levels 
in all patients. Similarly, the plasma protoporphyrin concentrations decreased initially 
significantly but increased to the pretreatment levels during weekly infusions.  
The biochemical effect of haem arginate infusion did not differ from that described in the 
previous series in which the compound was tested in acute attacks of patients with VP (Mustajoki 
et al. 1989). 
Clinical effects 
In phototesting, in which the source of light emitted radiation at visible region peaking at 400-
420 nm (covering the Soret band), the time for the erythema threshold at the initial phase of 
treatment in patients with VP was lower than in healthy controls. These results are in 
concordance with those reported earlier (Mustajoki 1980) suggesting that patients with VP may 
also have a predisposition to transient photoreactions on the basis of phototoxicity. During the 
haem arginate treatment no constant improvement in photoreactivity could be found, although 
the levels of plasma protoporphyrin temporarily decreased. The skin symptoms disappeared in 
one patient only but remained unchanged in the others indicating a poor clinical effect. The only 
side effect was a mild thrombophlebitis in one patient. Thrombophlebitis related to infusions of 
haem arginate has been reported earlier in occasional cases (Mustajoki and Nordmann 1993).  
 The results of the present study demonstrate that daily infusions of haem can produce 
transient biochemical remission as in the use in acute attacks (Mustajoki et al. 1989) but the 
weekly infusions do not maintain the plasma protoporphyrin concentration and the faecal 
porphyrin content at the low level. More frequent infusions of haem e.g. twice a week are 
probably required to obtain long-lasting biochemical remission in VP but frequent infusions of 
haem may induce haemosiderosis. Transient normalisation of porphyrin excretion and plasma 
protoporphyrin concentration had no effects on phototesting or clinical symptoms. To date no 







3.2.1. Skin symptoms  
 
Of 45 patients with EPP 25 individuals experienced photosensitivity (Table 16). The others were 
symptom-free family members or their clinical manifestations were unknown. In the whole 
group more than half of the patients were male. Among symptomatic patients the sex distribution 
was similar. The onset of photosensitivity varied from 6 months to 23 years of age (mean 4.6 
years). In all except one patient it became manifest by 10 years of age.  In 17 (68%) patients the 
onset was in the early childhood before 6 years of age.   
 
Table 16. Clinical data of patients with EPP  
    Male 
  N    %     
 Female 
 N    % 
 Total 
 N    %       
Symptomatic  14   56 11   44 25    64 
      Onset at <6 years old    9   36   8   32 17    68 
Asymptomatic    9   64   5   36 14    36 
No information of clinical manifestations1    4       2   6 
Total number of patients  27   60 18   40 45   
1Excluded from calculations 
 
The details of the skin symptoms are presented in Table 17. The skin symptoms occurred 
within fifteen minutes to six hours after sun exposure and usually lasted 1 to 2 days. The 
exposure time needed for provoking skin symptoms varied intra-individually. The main 
symptom was a stinging or burning pain (96 %) in the exposed skin followed by swelling (Table 
17, Figure 13). Itching was reported by one fourth of the patients, but only in two patients 
itching was more intensive sensation than pain. In addition to the characteristic swelling three 
patients experienced superficial erosions in the bridge of the nose. One of them also had 
petechial reactions after prolonged sun exposure (Figure 14). Chronic skin changes including 
thickening of the knuckles and furrows in the lips were found in nine patients. The youngest of 
them was four years old.  
 
 
Table 17. The clinical characteristics of photosensitivity in EPP patients  
Sign Number of symptomatic 
patients       % 
Other series in Table 5 
        % 
Burning pain       24        96     85-100 
Itching         6        24     24 
Swelling       24        96     65-94 
Erythema         9        36     20-85 
Erosions         3        12     14-15 
Blisters         1          4       3-17 
Petechia         1          4       3-15 
Chronic changes 
               Face 
               Hand 
        9        36 
        4 
        7 
    15-67 







Figure 13.  Acute swelling of the hand in a patient with EPP 
(on the courtesy of the patient) 
 
 
Figure 14. Petechial photoreaction on the face skin of a patient with EPP 
(on the courtesy of the patient) 
 
Profile of skin manifestations in Finnish patients with EPP did not differ from those reported 
in other series (de Leo et al. 1976; Lehmann et al. 1991; Holme et al. 2006a) and thus, our 
patients represented general features of the disease. The Finnish patients with EPP have had skin 





The severity of the photosensitivity correlated to the erythrocyte protoporphyrin 
concentration (Article V, Figure 15). The patients with high erythrocyte protoporphyrin levels (> 
50 000 nmol/l) experienced more severe photosensitivity than the patients with moderate levels. 
The severity and frequency of skin symptoms also varied according to the individual sun 
exposure and annual variation of the sunny weather.  
 
 
Figure 15. Blood protoporphyrin levels in subgroups of the patients with EPP.
3.2.2. Liver disease 
 
Hepatopathy related to EPP occurred only in one of the 25 symptomatic patients. He was 20-
years-old patient with moderate photosensitivity and high levels of erythrocyte protoporpnhyrin 
(mean 87 000 nmol/l). Since the age of 12 the serum transaminase levels have fluctuated up to 6-
fold concomitantly with the increased level of erythrocyte protoporphyrin (up to 100 000 nmol/l). 
In liver biopsy increased pigmentation in hepatocytes and Kupfer cells could be demonstrated 
suggesting accumulation of protoporphyrin. Only mild inflammatory changes without cholestasis 
could be observed. 
A temporary increase of serum transaminase levels occurred in an adult man with severe skin 
symptoms and constantly high level of erythrocyte protoporphyrin. In addition, a 13-year-old boy 
at his puberty experienced a slight and transient increase of serum alanine transaminase level and 
a simultaneous increase of the erythrocyte protoporphyrin level. In liver biopsy the histology and 
ultrastructure of the liver were normal. The majority of the patients with high erythrocyte 
protoporphyrin concentrations (>50 000 nmol/l) had normal liver function during the follow-up. 
Bile stones were operated in one female patient only. 





N=4            N=21 N=12             
Severe        Mild-     Asymptomatic 








the frequency of liver disease. In our small series the occurrence of hepatopathy is comparable to 
that reported from the Netherlands, where 5–10% of EPP patients experienced liver disease 
(Baart de la Faille et al. 1991). So far, cases of liver failure have not occurred in Finland. 
Compared to Germany, where up to 30% of EPP patients have hepatopathy (Doss and Frank 
1989), liver complications appear to be less common in Finland. The exact pathogenesis of the 
liver disease in EPP has not been clarified entirely. It has been hypothesized, that hepatic injury 
is caused by crystalline deposits of protoporphyrins in the hepatocytes and bile canaliculi 
accompanied by hepatobiliary obstruction (Bloomer et al. 2005). The development of a liver 
disease also may be influenced by inter-individual variation of hepatic production, clearance and 
excretion of porphyrins determined by genetic factors (de Verneuil et al. 1995). Further, 
protoporphyrin may have a toxic hepatocellular effect via generation of oxygen free radicals 
resulting in oxidative damage (Koningsberger et al. 1995). High levels of erythrocyte 
protoporphyrins may be associated with development of the liver disease but the values cannot 
be used to predict it. 
 
 
Table 18. The results of the liver function tests and the haematological measurements in 
37 EPP patients during the follow-up  
 Clinical manifestations  
  No symptoms 
      
        N=12 
 Mean (range) 
  Mild-moderate 





         N=4 




        1668 
   (1000-3153)    
   
        36114 
    (4847-99369) 
       66453 
(38000-102699) 
      
0.0000021 
0.032 
Liver tests         N=2             
 AST, <50 U/l     41 (23-58)      30 (17-62)      33 (29-37)  
 ALT, <50 U/l     38 (20-55)      29 (12-103)      32 (17-45)  
 GGT, <50 U/l          n.a.      35 (10-153)      17 (14-19)  
Haematological  tests    
  
Hb, 117-164g/l 
        N=4  
   136 (116-154) 
          
    128 (97-150) 
 
   131 (126-140) 
 
 MCV, 80-95 fl      89 (83-97)       80 (65-87)      79 (78-79) 0.0031 
 MCH, 27-32 pg      30 (27-33)       26 (21-29)      27 (27-27)  
  
S-Ferritin,           
male 10-200 ug/l 
female 5-90 ug/l 
children > 6 ug/l 
         
        N=1  
         235  
    
    Male N=74  
    31 (7-74)  
    Female N=7 
    20 (13-37) 
    Total  23 (7-74)
     
    Male N=3 
    13 (12-14)    
    Female N=1 
     7    
    Total 11 (7-14)  
 
n.a. not applicable,  
1ANOVA used in comparison of the patient groups,  
2Mann-Whitney test used to compare of the symptomatic patient groups,  
3Severe: pain, oedema and/or erythema in less than 15 min after exposure to the sun 






3.2.3. Haematological findings in patients with EPP 
 
The means of haemoglobin values were within the normal levels in the majority (77%) of the 
patients, although many of them were at the low level of normal range (Table 18). Serum ferritin 
levels were within the current normal range, but in 10 of the 18 patients (56%) the means were 
near the lower limit of normal (7-15  ug/l).  
In the peripheral blood smear of, hypochromacy and microcytes were a constant finding in 
symptomatic patients and occurred in all eight cases examined. Ovalocytes were quite frequent 
(38%) resembling iron deficiency. In one of three asymptomatic patients a few microcytes were 
found, otherwise the red cell morphology was normal. In other series mild anaemia was found in 
20-50% of  the patients (de Leo et al. 1976; Went and Klasen 1984; Baart de la Faille et al. 
1991), which is in accordance with our results.  
 
 
3.3. Porphyria cutanea tarda
 
3.3.1. Skin symptoms 
 
Of 85 patients with PCT 81 subjects experienced skin symptom. In three patients of them (one 
type I and two unclassified cases) no detailed clinical information was available but the 
diagnosis of PCT was confirmed in dermatological units. Forty five patients were examined 
clinically by the author. The information about 33 patients was collected from the patient records 
and consequently the data could be incomplete.  
 
Table 19. Demographic data of patients with PCT1 
Number of patients   Males Females   Total Mean age, y ( range) 
Type I 27 9 36    55 (28-71) 
Type II 19 7 26    52 (30-73) 
Type III 1 1 2    43 and 70 
Unclassified  17 4 21    50 (25-66) 2 
Total number of patients 64 21 85  
1including asymptomatic patients (no UROD activity known) 
2Two patients without information exluded 
 
Men were more commonly affected compared to women (76 % to 24 %) in all subgroups of 
PCT. The number of patients having the sporadic type of PCT (Type I) was comparable to that 
of the familiar type (type II), but 25 % of the cases could not be classified because their UROD 
activities had not been measured. Only one family with normal UROD activity in erythrocytes 
was identified in Finland. The age of the onset of the skin symptoms varied substantially in all 
groups. In men the mean age was 52 (25 to 71) years and in women 55 (28 to 73) years 
respectively. No difference at the age of the onset was observed between the groups.  
The major skin manifestations in the patients with PCT were the blistering (95%) and skin 
fragility (93%) on the back of the fingers and the hands (Table 20). Most of the blisters were 
small (=<1cm) in size, but in 44 % of the patients bullous lesions also (blisters exceeding 1 cm 
up to 4-5 cm in diameter) were present. All patients, except two, who experienced skin fragility 
on the back of the hands, had also blistering lesions. One patient with blistering lesions on the 
back of the hands reported no skin fragility. In four patients who had blistering lesions, the 





skin fragility the information about blisters was lacking. One third of the patients experienced 
skin fragility on the face and 36% (10/27) of them had blistering lesions too. The minority of the 
patients experienced skin fragility and/or blistering in other sun-exposed areas including arms, 
legs and feet (Table 20). The erosions and blisters left initially dark red scars which could 
commonly be found on the back of the hands even in absence of erosions. Red colour faded 
gradually within months and could disappear completely during remission. The milia formation 
on the scars was quite common.  
 
Table 20. Characteristics of skin symptoms in PCT 
           Number of symptomatic patients                       Other series1
 
Symptom T I  T II  T III  Unclassified   Total % % 
Erosions (fragility)  31   22 1 15 69 932  
 Hand  31   22 1 15 69 93 93 
 Arm    5     4 -   2 11 15  
 Face  15     6 -   6 27 36 62 
 Foot /leg    2     3 - -   5 7  
Blisters in the hand skin  33   22 1 17 73 953 93 
       Bullae  14   12 -   8 34 44  
Scars  31   22 1 14 68 87  
Milia  13     9 1   7 30 38 36 
Sclerodermoid changes    1     - -   1   2 3 4 
Hypertrichosis  18     9 -   4 31 704 56 
Hyperpigmentation    2     5 -   4 11 245 33 
Total number of 
patients 
 34   24 1 19 78   
1Bygum et al. (2003)  2Four patients without information about skin fragility and 3one patient  
without information about blisters were excluded from the percentages 
4,5Calculated on the bases of 444/465 patients with information  
 
The data about hypertrichosis and hyperpigmentaton were documented in less than 60% of 
the patients and thus, the results may be biased. Hypertrichosis was noted in two thirds of the 
cases (Table 20). The location was most frequently periorbital areas preferably on the top of the 
cheeks but also other malar areas, and in women, the chin was affected. Hypertrichosis varied 
from lanugo to long, dark and thick hairs. The presence of hyperpigmentation on the face was 
noted in one fourth of the cases (Table 20), of which six were women. It occurred as brownish 
pigmented blotches on the temporal and malar areas or it was evenly distributed over the whole 
face skin like a dark tanning.  Of note, in one patient hyperpigmentation was the only skin 
manifestation of PCT. Another patient also had hypertrichosis in addition to hyperpigmentation, 
but no skin fragility. Both of them were hospitalized because of other diseases and thus, they 
were not exposed to the sunlight, which would explain the absence of phototoxic reactions.  
The frequency of blistering and fragility of the hand skin was similar in the subgroups of 
PCT (Table 20).  The presence of hyperpigmentation was more common in type II than type I 
PCT (5/17 and 2/21 respectively), while in the frequency of hypertrichosis was no signicant 
difference between types I and II PCT (18/23 and 9/15 respectively). The clinical manifestations 





1979; Bygum et al. 2003). Compared to VP the blisters were present nearly in all patients with 
PCT, but in less than half of the patients with VP.  
       Two patients with photosensitivity were excluded from our series since their skin lesions 
were atypical despite the typical porphyrin pattern in their plasma and porphyrin excretion in 
urine. A 66-year-old man who had no typical photosensitivity of PCT experienced 
polymorphous light eruption and eczema-like skin lesions. The profile of urinary excretion of 
porphyrins was typical for PCT (60-fold increase of uroporphyrin, increased 7-carboxyl 
porphyrin, and 2-fold increase of coproporphyrin) with normal faecal porphyrin excretion. The 
other patient, who was a 48-year-old man with polymorphous light eruption, had an increased 
excretion of urinary uroporphyrin (40-fold) and 7-carboxyl porphyrin (139-fold), plasma 
porphyrin emission peak at 617 and normal faecal porhyrin excretion. Because lichenoid scars 
on the back of the hands were noted, it was possible that he also experienced fragility or 
blistering of the skin which were ignored. These patients did not co-operate for treatment of PCT 
or for further investigations such as liver ultrasound in order to exclude liver tumours. The 
association of abnormal porphyrin pattern and their skin lesion is uncertain and may have been 
found only by chance in plasma and urine analysis.     
 
3.3.2. Liver disease 
 
The serum transaminase levels were increased in the majority of patients examined (Table 21) as 
in previous series (Sarkany 2001). The levels of alanine transaminase and gamma- glutamyl 
transferase were more commonly increased than that of aspartate transaminase. The mean levels 
of transaminases were increased in greater degree in type II PCT than in type I, or in the 
unclassified group or in a single case of type III. However, great variation of values existed in all 
subgroups of PCT. The results indicate that the patients with type I and II are similarly affected 
by a liver disease. Liver imaging, mostly by ultrasound was performed in 80 % of the patients 
(Table 22). Abnormal findings occurred approximately in half of the patients and their  
frequency  was  similar  in  type I  and  II groups  (64% vs. 52%). The most common ab-
normality was fatty degeneration (48%). No hepatoma was found, but one patient had metastasis 
in the liver, and thus, imaging should always be performed to look for paraneoplastic etiology of 
increased porphyrin excretion. 
 












  N=1 
  Unclassified 
Mean (range) 
N=18 




  values 
     % 
AST, <50 U/l   60 (28-148)   78 (28-211)    21   53 (27-95)   64 (21-211)     57 
ALT, <50 U/l   82 (22-186) 111 (16-283)    26   88 (30-173)   91 (16-283)     82 
GGT, <50 U/l   97 (16-495) 120 (28-318)    65 104 (28-268) 105 (16-495)     78 
S-Ferritin, 
male 10-200 μg/l 
female 5-90 μg/l 




  48 (24-87)   51 (33-77)    39   46 (27-89)   47 (24-89)     38 
Hb, 117-164 g/l 152 (107-182) 158 (138-185)  142 153 (136-173) 154 (107-185)  








Table 22. Results of liver imaging in patients with PCT  
 Type I Type II Type III Unclassified Total % 
Ultrasound, scintigraphy, 
computed tomography,  
N=28 N=21 N=1 N=13 N=63  
Finding       
 I. Normal 10 10 1 6 27 43 
 II: Abnormal 18 11  7 36 57 
 Fatty degeneration 13 10  7 30 48 
 Gall stones 1 1   2 3 
 Metastasis 1    1 2 
 Peliosis 1    1 2 
 Cysts 2 2   4 6 
 
 Liver biopsy was carried out in 21 patients (Table 23). Histological changes were observed in 
all samples studied as in previous series of 16 patients (Campo et al. 1990). The most common 
finding was siderosis (67%) and fatty degeneration (67%) in our series. Fibrosis suggesting a 
cirrhotic stage of the liver damage was present in 14 % of the patients. Porphyrin crystals (Cortes 
et al. 1980) were identified in two samples. Periportal deposits of haemosiderin in hepatocytes 
may be a more specific sign of hepatopathy related to PCT (Campo et al. 1990) especially when 
associated with fatty changes and portal inflammatory process.    
 
 
Table 23. Results of the liver biopsy in patients with PCT 
 Type I Type II Type III Unclassified Total % 
Liver biopsy N=7 N=7  N=7 N=21  
 I. Normal        
 II. Abnormal 7 7  7 21  
 Fatty degeneration 2 7  5 14 67 
 Inflammation 2 1     3 14 
 Siderosis 3 5  6 14 67 
 Fluorescence    1   1 5 
 Peliosis 1      1 5 
 Fibrosis 2 1      3 4 
 Lymphoma 1      1 5 
 
3.3.3. Associated factors 
 
The level of serum ferritin were increased in the majority (93%) of the patients with PCT (Table 
21) as reported elsewhere (Bulaj et al. 2000). The mean level of serum ferritin was 3-fold 
compared to the normal range. Around half of the Finnish patients with PCT have at least one of 
the mutations associated with hemochromatosis. The frequency of the C282Y mutation in our 
patients (30%) was increased 3-fold compared to that of the normal Finnish population (10%), 
while the frequency of the H63D mutation (20 %) was similar as estimated in the normal Finnish 
population (Parkkila et al. 2001). The frequencies of homozygous C282Y mutation (9%) and 
compound heterozygous C282Y/H63D mutations (6%) among patients exceeded distinctly those 
estimated in the normal Finnish population (0,4% and 2 % respectively) (Parkkila et al. 2001). 





than the figures presented from US or Sweden (Bulaj et al. 2000; Egger et al. 2002; Harper et al. 
2004). The results support the hypothesis that liver siderosis in PCT associates with HFE 
mutations in the significant number of patients. Iron metabolism including the HFE genotyping 
should be investigated in the patients with PCT in order to reveal potential hemochromatosis in 
these patients.  
A low frequency of viral hepatitis among Finnish patients with PCT could explain the low 
occurrence of PCT.  In other countries, where the prevalence of HCV infection is also low, e.g. 
in the United Kingdom (Elder 1998) and Germany (Stolzel et al. 1995), the frequency of PCT is 
significantly higher than in Finland.  The chronic hepatitis B and C infections are more common 
in Mediterranean countries (Rocchi et al. 1986; Stransky et al. 2000) than in the northern part of 
Europe, and  this may partly explain high prevalence of PCT in the southern part of Europe.  
The use of oestrogen preparations for contraception and postmenopausal replacement therapy 
is in Finland as widespread as in other western countries (Topo et al. 1991). Thus, the known 
risk factors poorly explain the low prevalence of PCT in Finland. A specific gene defect linked 
to a deficient liver UROD in addition to the associating factors is probably required for 
manifestation of the disease. At present the major triggering factors for manifestation of PCT in 
Finnish patients with PCT is the use of alcohol and siderosis, and oestrogen therapy. Despite 




Table 24. Associated factors in different subgroups of patients with PCT  
   T I  T II    T III Unclassified   
                                                Number of patients with information in each  
                                                group /positive finding 
 
Total number of 
patients/positive
  finding                
                      % 
Alcohol intake increased N=30/23 N=23/16 N=1/1  N=17/15  71/55     78 
Number of females/use of 
oestrogen preparations  
N=9/2 N=7/2   N=4/1    20/5    25 
              
                                                Number of patients studied/positive finding 
Viral hepatitis       
              A N=9/2 N=6/3 N=1/0  N=4/0 20/5 25 
              B N=28/5 N=17/0 N=1/0  N=3/0 47/5 11 
              C N=23/3 N=17/2 N=1/0  N=1/1 42/6 14 
Hemochromatosis  
diagnosed clinically 
N=3  N=1 N=0  N=1       5  
C282Y mutation       
  Homozygotes N=13/3  N=18/0 N=1/0  N=1/0 33/3   9 
   Heterozygotes N=13/4  N=18/3 N=1/0  N=1/0 33/7 21 
H63D mutation       
  Homozygotes N=14/0  N=18/0 N=1/0  N=1/0 34/0  0 
   Heterozygotes N=14/1  N=18/5 N=1/0  N=1/1 34/6 18 
C282Y/H63D compound 
heterozygotes        
N=1  N=2 N=0  N=0 33/2 
 






4. THE HISTOPATHOLOGY OF THE SKIN
(Articles I, V, VI) 




When the histological study was performed in 1989 no DNA analysis of PPOX gene was done 
and mutations were identified only  later (Table 25) (von und zu Fraunberg et al. 2002; von und 
zu Fraunberg et al. 2005). The numbers in each group were small except in the group of the 
major mutation (C454T) found in Finland, and thus, no comparison between genotype and 
histological findings in the groups could be performed.  In Group III only parents with a 
homozygous child (Article III) were included because they were obligatory gene carriers and 
later on their mutation was characterised. It was hard to find such patients in other families and 
only later on more patients were characterised with mutation screening.  
 
Table 25. Mutations identified in the patients with VP in the groups I-III 
Mutation C454T G338C T35C A470C 
N= 20, patients     
Group I, current skin symptoms,  
mean age  41 years 
   10 1 0 1 
Group II, no skin symptoms but increased 
porphyrin excretions, mean age 50 years 
     5 0 1 0 
Group III, no skin symptoms and normal 
porphyrin analyses, mean age 36 years 
     0 0 2 0 
Total number of patients     15 1 3 1 
Controls N=5, mean age 45 years     
 
 
4.1.1. Light microscopy 
 
Patients with VP were grouped into three categories based on their skin symptoms and 
biochemical findings (Tables 1 and 3, I). The histopathological, immunohistological and 
ultrastructural changes of the skin were evaluated in each group (Tables 3 and 4, I). In all 
patients with the skin fragility (Group I, I) the principal finding of the previously affected 
unbroken skin was thickening of the superficial dermal vessel walls. The change was best 
demonstrated in PAS-staining (Figure 1, I). Mild thickening of the epidermal basement 
membrane was only occasionally observed in symptomatic patients. 
In the non-exposed skin mild thickening of the vessel walls could be demonstrated in the 
majority (70%, 8/12) of the patients. In the others, the vessels were normal. The sun-exposed 
skin of the symptom-free patients with an increased faecal protoporphyrin excretion (Group II, I) 
showed thickening of the vessel walls in 80 % (5/6) of the patients. In the symptom-free family 
members with normal porphyrin excretions (Group III, I and III), the vessels were normal. In the 
epidermal basement membrane zone pronounced PAS-positive findings were detected in two 






4.1.2. Electron microscopy 
 
Electron microscopic examination demonstrated that thickening of the vessel walls was caused 
by multilayering of the basal lamina and deposit of an amorphous material around a vessel (Fig 
2a-c, I). In the affected skin (Group I) thickness of the vessel walls was 2-3 fold compared to 
that of normal (Braverman and Keh-Yen 1984) and the changes were graded as moderate or 
severe (>5m) in the majority (80%, 10/12 patients) of the cases (Table 3, I). The basal lamina 
consisted of 5-10 layers usually, but in most extensively altered vessels up to 20 layers. Electron 
dense amorphous material was observed as a broad belt around the basal lamina zone. Thin 
collagen fibres were found in this material. Perivascular dendrocytes (veil cells) surrounded the 
excess material and separated vessels from dermal collagen. Endothelial cells and pericytes were 
intact in the vessels studied. 
In the non-exposed skin the vessel walls showed thickening, which was overall slight, in 
60% (7/12) of the patients. In the others the vessels were classified as normal. Thus, the 
ultrastructural findings were in accordance with those observed by LM. The morphology of the 
thickened vessel walls resembled that of the sun-exposed skin, but scanty perivascular material 
was demonstrated only in two patients. 
In the group II the vessel walls exhibited thickening graded moderate or severe, in 70 % (4/6) 
of the cases (Table 3, I) in accordance with the findings of the LM. The reduplication of the 
basal lamina was less marked in this group compared to the affected skin of the symptomatic 
patients suggesting that basal lamina was spared from serous injury. Amorphous extra material 
was present, but not so abundantly in comparison to the symptomatic patients.  
The blister of exposed skin studied in three patients located under the lamina densa of the 
epidermal basement membrane. In the blistered area basal keratinocytes were normal and basal 
lamina was intact with normal haemidesmosomes or it was discontinuous. The basal lamina 
seemed to rupture when the substantial amount of blister liquid accumulated under the 
epidermis.   
 
4.1.3. Direct immunofluorescence 
 
DIF revealed homogenous IgG deposits constantly in the vessel walls of the sun-exposed skin in 
the symptomatic patients (Group I) (Table 4, I). IgA and IgM deposits could be demonstrated 
less commonly (7/12 and 5/12 respectively) and C3 was seldom present. IgG was identified in 
the vessel walls only in one fourth of the patients in the sun-protected skin. IgG deposits in the 
vessel walls could also be demonstrated in the samples of four symptom-free patients studied 
(Group II). In the epidermal basement membrane IgG was demonstrated in half of the 








According to our series of 12 symptomatic patients with VP and nine additional patients with 
skin symptoms reported by other groups (Rimington et al. 1967; Epstein et al. 1973; Corey et al. 
1980; Westerhof and Smit 1981; Maynard and Peters 1992; Grabczynska et al. 1996), the major 
histopathological abnormality of the affected skin is the thickening of superficial dermal vessel 
walls in the dorsal side of the hand which suggests that the vessel walls are the most susceptible 
to photodamage in VP. The electron microscopic examination revealed that the principally 
injured region is the basal lamina zone. The most prominent changes could be demonstrated in 
venules, which are physiologically the most reactive part of microcirculation in the skin and 
thus, more vulnerable than arterioles (Braverman and Keh-Yen 1984). In the sun-exposed skin of 
a sole patient with VP studied previously by EM, the basal lamina of the vascular basement 
membrane was as extensively reduplicated as in our patients (Epstein et al. 1973). The excess 
material within and beyond the widened perivascular spaces was described as finely fibrillar in 
samples of this subject, but irregular clumps of dense amorphous material also were noted in 
perivascular deposits (Epstein et al. 1973). In our samples the excess material had a more 
amorphous appearance and it was ranged regularly outside the basal laminae.  
The results of DIF in the sun-exposed skin of 12 patients with VP were comparable to the six 
patients described previously (Epstein et al. 1973; Corey et al. 1980; Maynard and Peters 1992; 
Grabczynska et al. 1996).  The common finding has been IgG and/or IgM deposits in the vessel 
walls of the upper dermis in the sun-exposed skin. Complement deposits in the vessel walls were 
found infrequently in our patients’ samples which is in agreement with a few cases reported 
previously (Epstein et al. 1973). The invasion of immunoglobulins in the skin is probably only a 
secondary phenomenon due to the damage of the vessel walls. The lack of inflammatory cells 
also in the skin samples taken during blistering phase, suggests that the presence of 
immunoglobulins originates from serum. The less common presence of IgA and IgM compared 
to IgG is probably due to their larger molecular size hindering the migration outside the lumen. 
Other authors have also proposed that deposition of immunoglobulins in the vessel walls is 
rather derived from circulation than related to immune response based on the lack of circulating 
antibodies and an irregular attendance of complement (Epstein et al. 1973). Thus, our and the 
earlier results do not directly support the hypothesis of the activation of the complement cascade 
by porphyrin induced phototoxic reaction as presented in PCT and EPP (Gigli et al. 1980; Lim 
1989).  
According to our results, the morphological changes detected in the vessel walls were 
chronic, because they were present also in old lesions without coincident fragility. The vascular 
changes could also be demonstrated in those skin samples which were taken during blistering 
and eroding phase showing that vascular changes were present in the early phase of skin 
damage. However, it is still obscure, how vascular changes are related to the skin fragility and 
blistering. The blister location under the lamina densa of the epidermal basement membrane 
suggests that the blister formation arises from the dermal side. Photodamage may be initiated in 
the vessel walls via interaction of circulating porphyrins and solar radiation (Poh-Fitzpatrick 
1985) but no experimental studies have been performed in VP to clarify this hypothesis. Thus, 
the exact mechanism of the damage in the epidermal basement membrane zone is still unclear. 
Studies with the long-term follow-up including repeated skin biopsies would elucidate more 
precisely the natural course of microscopic alterations but they have not been reported so far.  
 In our series the changes of the sun-exposed skin were definitely more prominent than those 
of the non-exposed skin indicating that sun exposition is crucial in development of microscopic 
changes in the skin. Because the basal lamina of the normal venule wall is multilayered 





reduplication as an abnormal finding should be done with caution.  
Based on our results the slight changes detected in the light and EM suggest that 
photoactivated porphyrins may cause changes in the non-exposed skin via circulation or an 
excess of porphyrins per se without photoactivation may be able to elicit vascular changes.  
However, even minor solar exposure at the presence of porphyrins could be sufficient to induce 
microscopic alterations which could explain the minor changes in the non-exposed skin. 
Uninvolved skin has been studied histologically earlier in a single patient with VP (Epstein et al. 
1973). The arm skin, which may be more exposed to the light than the gluteal skin used in our 
series, showed no histological changes.  
In the non-exposed skin immunoglobulins in the vessel walls could be demonstrated only in 
occasional cases suggesting that vascular damage was too mild for leakage of immunoglobulins.
In an earlier study IgG could be demonstrated in the vessel walls of the uninvolved arm skin in 
two patients with VP although the morphology of the vessel walls was normal (Epstein et al. 
1973).  This could be an unspecific phenomenon or a minor damage related to photoactivated 
protoporphyrins. 
The microscopic and immunofluorescent changes in the vessels of the sun-exposed skin in 
the symptom-free patients with abnormal porphyrin excretions (Group II) resembled 
considerably those of symptomatic patients indicating also the vascular damage in this group. 
The regular presence of homogenous immunoglobulin deposits in the vessel walls supports the 
hypothesis that the vascular changes are related to phototoxic injury resulting in the outflow of 
immunoglobulins. Although this group was small the histopathological finding suggested that 
characteristic vascular alterations could develop without clinical symptoms. Thus, photodamage 
at the level of dermal vessels may be a subclinical process in VP and does not occur 
concomitantly with clinical symptoms. During the follow-up of twenty years after the skin 
biopsy none of our patients experienced skin fragility indicating that microscopic alterations 
have no prognostic significance for the occurrence of the skin manifestations later. 
Since photoageing of the skin may cause similar thickening of the vessel walls as found in 
porphyria (Kumakiri et al. 1977; Braverman and Keh-Yen 1984), the relationship of vascular 
changes to porphyria is not unambiguous considering the mean age of 50 years in group II. 
Moreover, in our control patients aged over 50 years, amorphous extra material could be 
demonstrated in a few vessel walls (Article I). The symptom-free family members with normal 
porphyrin excretion and normal vessels were substantially younger (36 years old) than those 
with abnormal prophyrin metabolism. Thus, ageing could partly explain the histological changes 
in group II. Since the mean age of symptomatic patients (Group I) was 41 years and the extent of 
vascular alterations was massive, the photoageing unlikely was of any significance in these 
patients. 
It is still an open question why only 30% of the patients have skin symptoms despite 
increased porphyrin level in the circulation. A specific mutation in the PPOX gene affected the 
phenotype of the disease to some extent. For example the parents of the homozygous patient, 
who formed group III in this study, had no histological changes and none of their heterozygous 
relatives had skin symptoms during the follow-up (Article III; von und zu Fraunberg et al. 2002). 
The I12T mutation has a residual activity of 8% when measured in COS-1 cells (Article III), 
which may associate with a lack of skin symptoms at the heterozygous state or the family 
members may have inherited concomitantly currently unknown protecting agent. Of note, the 
major mutation (C454T) has also a residual activity of 5% when measured in vitro conditions 
(von und zu Fraunberg et al. 2001) and excretion of porphyrins is comparable to that of G338C 
with no residual activity indicating that the severity of histological changes does not solely 
depend on the mutation in the PPOX gene but other factors such as sun exposure and modifying 





Excretion of porphyrins especially urinary coproporphyrin and faecal porphyrins in the 
different subgroups was the most important predicting number (Article I) and this could be seen 
also in the larger series 10 years later (von und zu Fraunberg et al. 2002).  The occurrence of 
skin symptoms may be related to individual differences in acceleration of porphyrin synthesis in 
the liver and their elimination from the circulation. Modifying genes related to the function of 
cytochrome P450 enzymes may influence regulation of porphyrin metabolism in the liver (von 
und zu Fraunberg et al. 2005). In addition, the removal of porphyrins from the skin or the local 
porphyrin production in the skin may vary individually (Day 1986). The level of plasma 
porphyrin was not measured in our study and their correlation to the skin symptoms is not 
known. The main location of skin manifestations in the back of the hands and on the face 
suggests that skin symptoms are related only to the chronic sun exposure. The more frequent 
localization of skin symptoms on the hands compared to the face indicates that mechanical 
trauma aggravates skin damage in consequence of foregoing or concomitant phototoxic reaction.  
 




After the histological study was done, the mutation analysis was performed in four families 
(Table 26). In three cases the patients were the only symptomatic patient in the family, and thus, 
comparison of the histological findings between different mutations was not done but the results 
were pooled. The age of the patients varied from 7 to 43 years and the gender distribution was 
similar (Table I, V). Duration of the symptoms varied considerably 3-43 years (Table I, V). 
 
Table 26. Mutations, clinical and histological findings in patients with EPP1     
Mutation Patients studied/ 
symptomatic 
patients 
in the family  
B-Protoporphyrins 
mean value during the 
follow-up 1988-1999  
(normal range  
200-1010 nmol/l) 
Severity of    
photosensitivity 






C286T      1/1        31316 ++ ++  ++ 
C343T      1/2        78785 +++ +++ +++ 
751GAGAA      2/3        48916 
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4.2.2. Light microscopy 
 
In LM of the sun-exposed skin of EPP patients the most striking changes were massive PAS-
positive homogenous deposits around the vessels and thickening of the superficial vessel walls 
(Fig 1, V). The deposits located both in the close vicinity to basement membrane zone and 
separately from vessels (Fig 1, V). The changes were present distinctly in the superficial part of 
papillary dermis also. The severity of the histological changes did not clearly correlate with the 
age of a patient or duration of the skin symptoms in this series (Table I, V). Moreover, the levels 
of erythrocyte protoporphyrin did not predict the severity of the microscopic changes. The vessel 
walls were normal in thickness in the non-exposed skin and no abnormal deposits could be 
identified. 
 
4.2.3. Electron microscopy 
In the EM, thickening of the vessel walls was caused by concentric reduplication of basal lamina 
and excess of the fine granular and homogenous material between the layers of basal lamina and 
around the basal membrane zone (Fig 2, V). The thickness of the vessel walls varied from 3 to 8 
m. The deposits appeared as broad bands in the perivascular space and as large clumps with no 
direct contact with the vessel walls (Fig 3, V). The clumps were more homogenous and electron 
dense than deposits in the vessel walls. Fibroblasts and their projections surrounded these 
masses. The morphology of fibroblasts and collagen bundles near the deposits was normal. Mast 
cells occurred close to the vessels in both sun-exposed and non-exposed samples. Endothelial 
cells were normal indicating that the damage caused by the solar exposure is an acute and 
transient phenomenon.  
 
4.2.4. Direct immunofluorescence 
 
DIF examination demonstrated that IgG deposits in the vessel walls were a constant finding 
(Table II, V). In addition, a weak or moderate IgA and IgM fluorescence was found in the 




The immunohistochemical study confirmed that the thickened vessel walls and amorphous 
material around them composed of the excess of the basement membrane materials and proteins 
derived from the circulation. Collagen IV and laminin, which are normal constituents of the 
vascular basement membrane, were most extensively expressed (Fig 4-5, V).  Collagen IV was 
expressed in the vessel walls and in the depositions outside the vessels, while laminin was 
confined in the vessel walls. In addition, constituents derived from the circulation including 
serum amyloid protein (SAP) and light chains kappa and lambda were demonstrated in the 
amorphous material around the vessels (Figs 6-8, V). Light chains kappa and lambda were 
identified in the vessel walls and in trace quantity in the surrounding material. The 90 kD 
glycoprotein associated with hyalinosis could be sparsely demonstrated in the amorphous 







The major abnormalities of the sun-exposed skin in our eight EPP patients included the 
extensive reduplication of basal lamina and homogenous deposits around the vascular basal 
membrane zone indicating that the main damage in EPP arises in the upper dermal vessels, 
which are affected by interaction of circulating protoporphyrin and  solar radiation (Poh-
Fitzpatrick 1985). These findings are in accordance with the previous studies in which PAS-
positive amorphous material was demonstrated in and around vessel walls of the upper dermis of 
the sun-exposed skin of EPP patients (Peterka et al. 1965; Findlay et al. 1966; Ryan 1966; 
Anton-Lambrecht and Bersch 1971; Epstein et al. 1973; Baart de la Faile 1975). Of note, the 
microscopical changes were demonstrated in our series during asymptomatic phase in normal 
looking skin suggesting that the changes are chronic. Based on our results the level of 
erythrocyte protoporphyrin showed no clear correlation with the severity of the microscopical 
findings.  
In the non-exposed skin, the vessel walls were normal in thickness and no abnormal deposits 
could be identified in accordance with an earlier histopathological study including eight patients 
with EPP (Rimington et al. 1967). These findings indicate that the solar exposure is mandatory 
for the development of the vascular changes and probably the most important factor in the 
variance of histopathological findings in patients’ samples. The target for the phototoxic damage 
is probably an endothelial cell resulting in widening of the intercellular gaps and a leakage of 
circulating material from the lumen to the extracellular space as demonstrated earlier (Gschnait 
et al. 1975). Since the sun-protected skin was normal, the excess of free circulating 
protoporphyrin is non-toxic to endothelial cells per se, but solar exposition is needed for the 
damage. In our study, which was carried out at the asymptomatic phase, the endothelial cells 
were intact and no gaps between them were found indicating that the endothelial damage is an 
acute and reversible phenomenon. Because mast cells were present both in the sun-exposed and 
non-exposed samples, the results did not clarify the role of mast cells, which had been connected 
previously to acute phototoxic reaction  (Glover et al. 1990).  
The presence of PAS-positive material in the vessel walls and deposits suggests the 
accumulation of neutral mucopolysaccharides or glycoproteins, but the precise constitution of 
the deposits has been poorly characterised. Our results revealed that the material in the affected 
vessel walls and deposits contains various serum originating proteins such as immunoglobulins, 
complement and kappa and lambda light chains and serum amyloid protein (SAP) in addition to 
the normal basal membrane components. The more frequent occurrence of IgA and IgM in EPP 
compared to VP may be due to a more severe damage in the vascular wall in EPP allowing 
migration of larger proteins. The normal amount of immunoglobulins in the serum, a lack of 
inflammatory cells in the dermis and irregular occurrence of C3 in the vessel walls identified in 
our patients suggest that an immunological reaction is unlikely to be responsible for the 
accumulation of immunoglobulins in the vessel walls. This is more likely a result from a 
secondary leakage of the immunoreactants from the circulation. In the earlier study including 12 
EPP patients, IgG has been demonstrated as a homogenous pattern in the vessel walls similar  to 
our results (Epstein et al. 1973; Baart de la Faile 1975). In contrast to our study, IgG was present 
also in the epidermal basement zone. 
 Elastic fibre components e.g., SAP, fibronectin and vitronectin have been demonstrated in the 
peripheral part of perivascular deposit in the sun-exposed skin of EPP patients (Breathnach et al. 
1983; Dahlbäck and Sakai 1990). Of the basal membrane components, accumulation of collagen 
type IV and laminin has been identified earlier in the affected vessel walls in two patients with 





most likely synthesised locally by fibroblasts, endothelial cells and pericytes during the multiple 
repairing processes after the phototoxic damage in the vessel wall. Our results and those reported 
by other groups (Ryan 1966; Epstein et al. 1973) indicate that the vascular thickening with 
perivascular deposits in EPP is secondary and irreversible phenomena resulting from the acute 
leakage and accumulation of different serum components and from the local production of basal 
membrane components. The 90 kD glycoprotein associating with hyalinosis could be sparsely 
demonstrated in the amorphous material (Fig 8, V) suggesting that the dermal deposits in EPP 
have different pathogenesis compared to cutaneous hyalinosis (Maury and Teppo 1984). 
Furthermore, absence of versican indicates that the acute phototoxic reaction found in EPP 
differs from that of the photoaged skin, in which versican is commonly expressed (Hasegawa et 
al. 2007).   
4.3. Porphyria cutanea tarda 
 
4.3.1 Subjects     
Five patients with PCT who had experienced characteristic blistering and fragility of the sun- 
exposed skin from three months to two years before the diagnosis were subjected to repeated 
histopathological studies (Table 27). The erythrocyte UROD activity was normal in each of them 
suggesting type I of PCT. The urinary uroporphyrin excretion was increased 80-200-fold 
corresponding to moderate to severe increase of uroporphyrin excretion and responded well to 
choloroquine treatment (250 mg twice a week) within 6-17 months. Plasma porphyrin spectrum, 
showing fluorescence maximum at 617 nm, was measured initially only in one patient. It was 
later found in two additional patients during a relapse.  
 
 
Table 27. Biochemical results and clinical information about five patients with PCT 
Patients Sex and age at 















male 10-200 ug/l 




1  M, 36 y   7890     69   1120 C282Y +/+ and 
hemochromatosis 
alcohol1 
2  M, 63 y    3697     98   ND alcohol 
3  F, 62 y   4681     68   148 C282Y +/+1 
4  F, 29 y   4280     72   ND Hepatitis B  and 
alcohol 
5  M, 62 y   2778     60   158 alcohol 
1After the study the patient was treated with phlebotomies   
 
Skin biopsies were taken at the time of diagnosis of PCT in all patients, and as soon as 
biochemical remission (dU-Uroporphyrin 100 nmol/24h) was achieved in three patients, and 






4.3.2. Light microscopy 
 
A principal finding in PCT on the light microscopic examination was a PAS-positive thickening 
of the superficial dermal vessel walls of the back of the hand (affected skin) (Fig 1, VI). In 
pretreatment phase the thickness of vessel walls was estimated to be moderate or severe in three 
out of five patients (Table 27, patients 1,2 and 5) and slight in the others (Table 27, patients 3 
and 4). Comparison of histological findings in 2-3 consecutive samples of each patient 
demonstrated that vascular changes were not improved during remission except one case in 
which a severe vascular thickening was reduced to a slight degree (Fig 1, VI). In the non-
exposed skin (gluteal area) thickness of the vessel walls was within the normal range before the 
treatment and during remission in three patients studied. The epidermal basement membrane 
showed no significant abnormalities.  
 
4.3.3. Electron microscopy 
 
The electron microscopic examination performed in the pretreatment phase displayed an 
abnormal reduplication of the basal lamina with 5-10 layers in the upper dermal vessels of the 
affected skin (Fig 2, VI, Table 27, Patient 1). The laminae were partially disrupted, but a 
concentric figure remained. The fine granular material was present between the layers. The basal 
lamina zone was surrounded by a broad belt of more amorphous material, which also contained a 
fine-grained substance. Perivascular dendrocytes (veil cells) surrounded this material and 
separated the vessels from dermal collagen. The thickness of vessel walls was calculated to be 5-
8 m in three, and 3-4 m in one out of four patients examined (Fig 5, VI). Comparable 
morphological changes were demonstrated in the samples taken during remission in all patients 
(Figs 3-4, VI). At the end of the follow-up, the thickness of vessel walls was slightly reduced 
only in two cases, but exceeded 5 m in all patients. Thus, no significant improvement was noted 
during remission. In the sun-protected skin the vessels showed a slight thickening throughout the 
study in one of three patients examined, and they were normal in the two others.  
The blisters of the exposed skin studied in two patients in the pretreatment phase located 
under the lamina densa, which could not been demonstrated at the blister roof. A reduplication of 
the lamina densa close to blister was observed in the one of them. In other patients the epidermal 




DIF examination demonstrated that before treatment a homogenous deposit of IgG was present 
in the vessel walls in the back of the hand in three of four patients examined. At the beginning of 
remission IgG was still expressed in the samples of the same patients, but at the end of the 
follow-up it was present only in one patient’s sample. A prominent IgG deposit could be 
detected after one year remission in the fourth patient whose sample was negative for IgG before 
treatment. A slight deposit of IgA was demonstrated in one patient before treatment was still 
present at the beginning of remission but not at the end of the follow-up. In another patient a 
slight deposit of IgA was present first time at the beginning of remission and still after six 
months remission.  IgM staining was negative in the vessel walls of all samples. In the sun-
protected (gluteal) skin deposit of IgG was present in one patient in all consecutive samples. No 
immunoreactants could be demonstrated in the sun-protected skin throughout the study in the 








In our series of five subjects who represent clinically and biochemically typical patients with 
PCT, the most important histopathological findings are thickening of the vessel walls in the back 
of the hands and formation of subepidermal blister. Our results correspond well with the 
previous histopathological studies describing skin changes in patients with PCT (Epstein et al. 
1973; Kemmer et al. 1988; Maynard and Peters 1992; Vasil and Magro 2007). A few 
immunohistochemical studies, in which laminin, SAP and vitronectin have been demonstrated in 
the thickened vessel walls or in their vicinity, have been done to clarify the composition of the 
thickened vessel wall in PCT (Breathnach et al. 1983; Dahlbäck and Sakai 1990). Accumulation 
of collagen IV has been revealed in the thickened vessel wall in one patient with PCT  (Krajnc et 
al. 1998). These findings could indicate that the components are present because of active 
scarring process but also because of the leakage from the circulation. The blisters studied in a 
few patients with PCT had a subepidermal location, under the basal lamina. 
 Electron microscopic investigation demonstrated that the thickening of the vessel walls was 
related to multilayering of the basal lamina and accumulation of amorphous material at the basal 
membrane zone in our series. Reduplication of vascular basement membrane and excess of fine 
fibrillar or amorphous material between and outside the reduplicated basal laminae have been 
identified also in other samples (Epstein et al. 1973; Kint and De Weert 1978; Kemmer et al. 
1988). Occasionally irregular clumps of dense amorphous material have been described in 
perivascular deposits (Epstein et al. 1973). In our patients this excess material appeared mostly 
as a uniform band between outermost basal laminae and pericytes and it had a denser structure 
than fine granular material substance between basal laminae.  
Our results of DIF are in accordance with that of three earlier series, in which a homogenous 
deposit of IgG in the vessel walls of the hand skin has been demonstrated in all 54 patients with 
PCT. In contrast, the presence of other immunoglobulins and complement has varied in different 
studies (Epstein et al. 1973; Kemmer et al. 1988; Vasil and Magro 2007). In an additional series 
including 16 patients with PCT, IgM (9/16) and C3 (11/16) could be demonstrated in the vessel 
walls of the hand skin in the majority of the cases, but IgG was present only in 44% of them 
(7/16) (Maynard and Peters 1992). Each sample, however, was positive for a deposit of one of 
the immunoglobulins with or without complement. In the same study IgG was expressed in the 
epidermal basement membrane in the minority of the cases (4/16), while C3 was present more 
frequently (9/16). Weak IgG deposit in the epidermal basement membrane of the dorsal side of 
hand has been demonstrated in 60-95% of cases of PCT in previous series (Epstein et al. 1973; 
Kemmer et al. 1988; Vasil and Magro 2007) but it could be demonstrated only in one of our four 
patients’ samples. The variation in the results of direct immunofluorescense studies advocates 
the theory that occurrence of immunoglobulins and complement in the epidermal basement 
membrane and the vessel walls is an unspecific phenomenon and according to our results does 
not correlate with clinical remission.    
The vessels in the non-exposed skin (the gluteal area) in our series were normal in thickness 
indicating that the repeated solar exposure is mandatory for developing of skin changes. This 
hypothesis is supported by the fact that immunoglobulin depositions were an uncommon finding 
in the non-exposed skin. In an earlier study the vessels of the normal skin in the medial arm have 
been normal in thickness (Epstein et al. 1973). The results of the direct immunofluorescencic 
studies have been negative in the majority of these cases, although electron microscopic studies 
have revealed mild changes in the basement membrane zone. Because the arms may have not 
been completely sun-protected, the electron microscopic findings suggest that vascular changes 





The preceding symptomatic phase at the time of biopsy was an average of 11 months in our 
study (range 3-24 months) and 5,2 years in the earlier study including 22 patients with active 
PCT (Epstein et al. 1973). Because the histopathological changes were comparable in both 
series, duration of the overt disease appeared to have no significant influence on the vascular 
changes. Moreover, the vascular changes arise already at the early stage of the clinically 
manifest disease. The duration of period during which the level of circulating uroporphyrin is 
elevated before the disease become manifest has been unclear. Possibly, the microscopical 
changes evolve concomitantly with the rise of the porphyrin levels because of developing 
hepatopathy and the sun exposure similarly as hypothesised in asymptomatic patients with VP 
(Article I). The development of vascular alterations may be a subclinical process beginning in 
the early stage of phototoxic damage which leads by additional currently unknown mechanisms 
to the cleavage of the epidermal basement membrane.  
In the repeated biopsies taken in remission in patients with PCT, the vascular changes 
studied by LM remained similar to those seen before treatment in all patients except in one, in 
whom the vascular thickening was reduced. No improvement could be found in ultrastructural 
studies either. The duration of remission (6 vs. 12 months) had no effect on the histological 
results (Figs 3-4, VI). Thus, the clinical improvement of the skin symptoms and the biochemical 
remission had no significant effect on the histopathological changes in PCT during the short-
term follow-up. The results indicate that the thickening of the vessel walls is chronic, possibly 
permanent phenomenon and does not directly correlate with clinical and biochemical activity of 
the disease.  
Our findings are in accordance with a histopathological study performed in post-phlebotomy 
 remission of patients with PCT. Remission of the disease had lasted from seven months to six 
years (Epstein et al. 1973). In that series, which included seven patients, thickening of the vessel 
walls could be demonstrated by LM in the dorsal side of the hand in five cases. These changes 
were  milder when compared to those in an active PCT. In addition, weak deposition of IgG in 
the vessel walls could be demonstrated in the majority of the patients in remission (7/10) 
(Epstein et al. 1973). Although no repeated biopsies have been analysed during the follow-up of 
these patients, their and our results suggest that vascular changes are long-lasting after acute 
phase.  
4.4. Comparison of the histopathological changes of the skin in VP, EPP and PCT
 
If our results obtained by different histopathological methods are evaluated as a group, the most 
prominent changes in EPP, VP and PCT are identified in the superficial dermal vessels walls 
(Table 28) suggesting that the vessels are prone to the photodamage in the skin. By LM 
thickening of the vessel walls is the major change in all porphyria types, and it is best 
demonstrated by PAS-staining. The most severe alterations were detected in EPP indicating that 
the phototoxic reaction is the most powerful in this patient group. The vascular changes were 
evident in the papillary dermis, but in EPP the changes were present more frequently in the 
superficial part of papillary dermis also than in VP and PCT. EPP was characterised by 
amorphous perivascular deposits  extending also to the extravascular space, but no such deposits 
could be demonstrated in VP and PCT. This was the most striking difference between EPP and 
other porphyrias. Consequently, the light microscopic examination distinguishes clearly EPP 
from VP and PCT, but the changes found in VP and PCT are indistinguishable from each other 
corresponding to the similar clinical manifestations despite different mixture of circulating 
porphyrins (Poh-Fitzpatrick 1980). The absence of the inflammatory changes was a common 





The fine structure of the vessel wall was similar in VP and PCT consisting of the 
multilayered basement membrane and excess of fine granular substance between the layers, 
which were surrounded by the band of homogenous material. EPP was characterised by massive 
amorphous deposits outside the vessel walls in addition to similar alterations in the vessel walls 
as in VP and PCT. The ultrastructural findings were in accordance with the results obtained by 
LM and confirmed that the morphological changes in EPP differ clearly from those in VP and 
PCT and are the most severe of them.  
 
Table 28. Histopathological changes of dermal vessel walls of the sun-exposed skin in patients 
with EPP, VP and PCT   
 Dermal vessel wall 
Type of 
porphyria 














Normal Multilayering of 
basal laminae 
Broad belt of 
amorphous  material 
Amorphous deposits 





















Thickening Normal Multilayering of 
basal laminae 
Belt of amorphous 
material  
Normal IgG, (IgA, 
C3) 
(IgG) 
1(IgG), (IgA), (IgM), (C3)<50% of the patients studied 
 
In the DIF study, the constant finding was the homogenous IgG depositions in the vessel walls in 
each type of porphyria. IgA, IgM and C3 were present more frequently in EPP than in PCT and 
VP.  This was probably related to the more severe vascular damage in EPP resulting in an 
abundant leakage of immunoreactants from circulation. Almost identical findings suggest a 
common pathogenetic mechanism, which underlie the damage in the dermal vessels. On the 
whole our results are in accordance with the earlier studies, in which the regular presence of 
immunoreactants in the vessel walls has been demonstrated in all types of cutaneous porphyrias 
(Epstein et al. 1973; Maynard and Peters 1992).  
Vascular changes of the exposed skin were observed in each type of porphyria also in the 
patients with no current skin symptoms suggesting that vascular changes are not directly 
correlated to the contemporary clinical condition and they are chronic in character. The follow-
up of symptom-free VP patients suggests that the presence of microscopic changes does not 
predict the development of skin fragility later.  
A mild thickening of the vessel walls could be demonstrated in the sun-protected skin of the 
patients with VP in contrast to the patients with EPP and PCT in whom thickness of the vessel 
walls was normal. The difference between PCT and VP might be related to a shorter duration of 
the disease in PCT, which usually manifests later in the life span compared to VP. In EPP the 
duration of the disease seemed to have no effect on the non-exposed skin, because the adult 






 The epidermal basement membrane of the sun-exposed skin showed no notable 
histopathological abnormalities outside the blister and erosion except a local reduplication of 
lamina densa close to blister in VP and PCT. Hyperkeratosis, hypergranulosis and acanthosis in 
the epidermis and a mild thickening of the epidermal basement membrane have been observed in 
  series of samples of patients with EPP, VP and PCT (Epstein et al. 1973). No such changes, 
however, could be demonstrated in our study or in another study including patient samples with 
various cutaneous porphyrias  (Maynard and Peters 1992).  
The blisters studied in our patients with VP and PCT had a subepidermal localization as 
described in other patients (Dabski and Beutner 1991; Maynard and Peters 1992). In electron 
microscopic studies the blisters situated under the basal lamina in all our samples. In previous 
studies the blister formation in PCT has also been identified above lamina densa (Klein et al. 
1983; Nagato et al. 1987). It has been postulated that the initial damage occurs at the level of 
lamina lucida and mechanical stimulus results in a damage under the basal lamina (Klein et al. 
1983; Nagato et al. 1987).  
The microscopical changes found in our studies are not specific for porphyrias. Similar 
thickening of the vessel walls and by DIF homogenous mantles of IgG and C5b-9 has been 
demonstrated in skin manifestations of diabetes mellitus and PCT (Vasil and Magro 2007). 
Electron microscopic studies of the gluteal skin of the patients with diabetes mellitus or 
photoaged skin have revealed multilayering of the basement membrane of the vessel walls  
surrounded by excess basement membrane like material mimicking  vascular changes in 
porphyria  (Braverman and Keh-Yen 1984). DIF testing is useful in differentiating VP and PCT 
from autoimmune subepidermal blistering diseases which are characterised by the presence of 
linear IgG and/or C3 at the epidermal basement membrane zone and usually the presence of  
inflammatory cells in the blistering area (Maynard and Peters 1992; Mutasim and Adams 2001). 
Classic type of epidermolysis bullosa acquisita, which clinically mimics PCT and VP presenting 
skin fragility, blistering, scarring and milia formation on the backs of the hands, is characterised 
by noninflammatory subepidermal blister formation as in PCT and VP. Direct 
immunofluorescence shows linear IgG and immunohistochemical staining type VII collagen in 
the epidermal basement membrane, but in the vessel walls can not been demonstrated 
immunoglobulins (Mutasim and Adams 2001). Porphyria is the only blistering disease in which 
homogenous deposits of immunoglobulins and complements can be demonstrated in the 
superficial dermal vessel walls. In pseudoporphyria clinical, histopathological and 
immunohistological changes are comparable to those found in PCT and VP (Maynard and Peters 
1992). In that case porphyrin analyses from plasma, urine and faeces are normal and crucial to 
exclude a true porphyria.  
The diagnosis of cutaneous porphyrias should always be based on the biochemical analyses 
only. Because taking a skin biopsy is an invasive procedure and represents a risk for scar 
formation and delayed wound closure especially in patients with cutaneous porphyrias who are 
prone to scarring after trauma, the non-invasive biochemical analyses should always be carried 
out first. The histopathological examination of the skin can provide supplementary information 
in the diagnostics and differential diagnostics of cutaneous porphyrias, but is not necessary for 









 In 2006 156 Finnish patients with VP have been diagnosed since the 1960’s, and to date 
108 of them are alive. The estimated prevalence of VP is 2.1:100 000 and the incidence 
            0.2:1 000 000 (per year).
 In 2006 85 Finnish patients with PCT have been diagnosed, and to date 63 of them are 
alive. The prevalence is 1.2:100 000 and the incidence 0.5:1 000 000 (per year). Based 
on measurements of the UROD activity in patients’ erythrocytes, 49% of patients with 
PCT has the familial form type II.
 In 2006 48 Finnish patients with EPP have been diagnosed, and 39 of them are alive. The 
prevalence is 0.8:100 000 and the incidence 0.1:1 000 000 (per year).   
 Of the mutation carriers 37% have a manifest disease in VP. Frequency of skin 
symptoms has been stable during the follow-up, but acute attacks have become 
infrequent (51% vs. 18%) during the last two decades. Of the mutation carriers 30% 
manifest with skin symptoms and they represent currently 80% of symptomatic patients.  
 In the patients with VP the major skin symptom was fragility (95%) of the skin in the 
backs of the hands. Blisters occurred in less than half of the patients. 
 The patient with homozygous VP is a different entity with severe chronic skin lesions 
and demyelinating neuropathy without acute attacks.  The I12T mutation could be 
detected in both of his alleles in the PPOX gene. In his family members at the 
heterozygous state no skin lesions or acute attacks could be detected.  
 Transient correction of porphyrin metabolism by eight haem arginate infusions did not 
alleviate skin symptoms in four patients with VP except in one patient whose skin 
lesions disappeared transiently.  
 In the patients with EPP the major skin symptoms were burning pain (96%) and swelling 
(92%) of the skin immediately after the sun exposure. The severity of photosensitivity 
correlated with the level of erythrocyte protoporphyrin concentration. More than a 50-
fold increase predicted severe skin symptoms but manifestations were clearly affected by 
sun exposure. Hepatopathy appeared only in one patient.  
 Four mutations (751delGAGAA, 1122delT, C286T, C343T) were characterised in four 
of 15 families with EPP.  
 In the patients with PCT blistering (95%) and fragility (93%) of the skin in the backs of 
the hands occurred equally. The majority of the patients had one to three precipitating 
factors, of which alcohol was the commonest (78%). Hemochromatosis associated 
mutations were also frequent (50 %) but use of oestrogen (25%) and HCV or HBV 
infections (25%) were less common.  
 In PCT, fatty liver disease was present in 48% of the 63 patients examined by imaging 
and was confirmed by liver biopsy in 67% of the 21 cases studied. Haemosiderosis was 
common (67%) in liver biopsy but no hepatoma could be found.  
 In histopathological examinations studied in 20 patients with VP, eight patients with EPP 
and five patients with PCT, the major changes of the sun-exposed skin were thickening 
of the vessel walls of the upper dermis suggesting that this is the primary site of the 
phototoxic reaction in each type of porphyria. EPP was characterised by amorphous 
perivascular deposits also extending to the extravascular space, but no such deposits 







 The fine structure of the vessel wall was similar in VP and PCT consisting of the 
multilayered basement membrane and excess of finely granular substance between the 
layers, which were surrounded by the band of homogenous material. EPP was 
characterised by massive amorphous deposits outside of the vessel walls in addition to 
similar alterations in the vessel walls as in VP and PCT.  
 In the DIF study, the constant finding was the homogenous IgG deposits in the vessel 
walls in each type of porphyria. IgA, IgM and C3 were present more frequently in EPP 
than in PCT and VP suggesting that the most severe vascular damage in EPP causes an 
abundant leakage of immunoreactants from the circulation.  
 In VP, the microscopic changes were not predictive for later skin manifestations.  
 In PCT, no remarkable improvement of vascular changes was found during clinical and 
biochemical remission indicating that microscopic changes are irreversible.  
 The excess material in and around vessel walls consists of immunoglobulins and other 
proteins derived from the circulation in addition to basement membrane constituents 
produced locally by fibroblasts.  These finding suggest that thickening of the vessel wall 









This work was carried out at the Departments of Medicine and Dermatology, University of 
Helsinki, Finland, during 1987-2008. Many Heads of the Department of Dermatology are 
thanked for providing me an opportunity and inspiring work atmosphere throughout these years. 
I want to express my gratitude particularly to Professor, emeritus Kimmo Mustakallio, the 
previous Head of the Department of Dermatology for his support at the early phase of my study, 
and Professor Reijo Tilvis, the previous Head of Institute of Clinical Medicine for excellent 
research facilities in Meilahti Hospital and Biomedicum-Helsinki. I am very grateful to the 
Heads of the Department of Dermatology, Professor Timo Reunala and Professor Annamari 
Ranki, for the chance to work in the clinic and their long-lasting belief in me finalizing my 
thesis. 
My special thanks are to Docent Kirsti-Maria Niemi, my supervisor, because she was first to 
suggest the histopathological study of porphyrias to me. She introduced me to the world of light 
and electron microscopy. Her intelligence, vast knowledge of dermatopathology and 
uncompromising attitude towards scientific work has been admirable. 
I express my warmest thanks to Professor Pertti Mustajoki, the supervisor for the first ten 
years, for guiding me to the secrets of metabolism and clinical manifestations of porphyrias and 
an opportunity to utilize his unique and internationally recognized patient material. His 
enthusiasm was encouraging and his warm personality supported me on this zigzag way. 
Most of all I am indebted to Docent Raili Kauppinen, my supervisor during the last 15 years. 
She has guided me in interpreting the results of molecular genetics and she has been a valuable 
source of information in various aspects of medicine in addition to porphyrias. Her never-ending 
energy, vivid personality and persistence have supported me throughout these -sometimes even 
desperate - years and she has not let me lay down the whole work. I am very grateful for her 
patience and readiness whenever to discuss about research and topics extending beyond the 
everyday work. Fortunately, we have had a sense of humour during this long journey!  
I thank warmly Docent Arja-Leena Kariniemi, my co-author, who supported me enormously 
especially by teaching dermatopathology. Her valuable comments during writing the manuscript 
clarified my ideas of porphyria and her optimistic attitude helped me to endure to the end. We 
have shared many delightful times travelling in a congress-group and learned also new aspects of 
life outside dermatology.  
I am very grateful to Professor Aarne Oikarinen for his careful dissection of my manuscript 
and valuable comments to improve the final version, and for his encouraging attitude to this 
work. I appreciate Professor Jorge Frank who is known for his special interest in inherited skin 
diseases such as porphyrias, his positive attitude to my thesis and important comments. I would 
like thank Dr Yevgeny Pavlushkov (MD, Master of Philosophy) for his careful examination of 
my English in the manuscript. 
I am deeply grateful to Professor Raimo Tenhunen, the previous Head of the Department of 
Clinical Chemistry for the kindness providing me excellent service in his biochemical 
laboratory. His knowledge of haem metabolism was enormous help and his friendly 
encouragement supported me all the time. The positive atmosphere and extremely skilful staff in 
his laboratory have made my study easy to perform. I thank warmly his personal including 
laboratory nurses Tarja Andersson and Aila Åkerlund and chemist Eila Laitinen for their 
competent assistance with biochemical analyses and friendship. I wish to thank chemist Sirpa 
Ranta who has joined our “porphyria family” during the recent years, for her proficiency, 
enthusiasism to porphyria and helpfulness. 
I am very grateful to MSc Helena Halme, the earlier chemist in Department of Dermatology. 





help at my first steps in the fields of porphyria.  
I have become familiar with the scientific laboratories in Meilahti Hospital and in 
Biomedicum. Pipeting was not completely impossible for me in the guidance of our skilful 
bioanalysists Hannele Pihlaja, Helena Ahola and Susanna Mehtälä who are warmly thanked.   
Young scientists Dr Sami Mustajoki, Dr Mikael von und zu Fraunberg and Dr Elena Pischik 
in our Porphyria Reseach Group have done their thesis much faster than me. I am thankful for 
their pleasant company, inspiring scientific and more personal discussions and being a part of 
this group. Mikael has shared with me the studies related to VP and his statistical skills have 
been fantastic. Dr Matti Henriksson investigated molecular genetics in our EPP study and was a 
pleasant co-author.  Elena has been worth gold since she has helped me with a computer 
finalizing the text frame and checked all the references and tables with the skills you do not learn 
in the clinic. Her brilliant intelligence not only in neurology and porphyria but in many fields of 
life and warm heart has lighted my days when we have got together.  
I wish to thank Department of Dermatology for all the support which I have got from my 
colleagues, nurses and patients with porphyria during these 25 years. Dr Terttu-Liisa Ahokas and 
Professor, emerita Leena Rechardt who have been a part of our travelling-in-congresses-group, 
have reminded me about the life outside the scientific world and I have often followed their 
advice with pleasure.  
I thank sincerely laboratory technicians Birgitta Arteva, Anna-Mari Hakulinen and Liisa 
Sundman for their excellent technical assistance with preparing skin samples for electron 
microscopy and immunohistochemistry.  
I thank warmly Ralf Baumann, Raili’s son, who provided light to the cover design and inside 
of my thesis with his skilful pictures. I express my kindly thanks to his father, Marc who has 
been a funny and encouraging company during the lunch breaks and has not hesitated to help 
whenever our computer has tilted.  
I am grateful to the colleagues in the Departments of Dermatology in Central Hospitals 
throughout Finland for providing patients with cutaneous porphyria to this stydy.  
Finally, I wish to thank my mother and sisters for their understanding on this long way. I owe 
my heartfelt thanks to Matti for his love, endless patience, sense of humour and careful 
housekeeping during these years.   
This study was financially supported by the grants of Finnish Cultural Foundation, the Sigrid 
Juselius Foundation, the Paolo Foundation, the Academy of Finland, the Research Funds and 





















Abitbol, M, Bernex, F, Puy, H, Jouault, H, Deybach, JC, Guenet, JL and Montagutelli, X (2005). A 
mouse model provides evidence that genetic background modulates anemia and liver injury in 
erythropoietic protoporphyria. Am J Physiol Gastrointest Liver Physiol 27: 1208-1216. 
Ajioka, RS, Phillips, JD and Kushner, JP (2006). Biosynthesis of heme in mammals. Biochim Biophys. 
Acta 1763(7): 723-736. 
Ajioka, RS, Phillips, JD, Weiss, RB, Dunn, DM, Smit, MW, Proll,SC, Katze, MG and Kushner, JP 
(2008). Down-regulation of hepcidin in porphyria cutanea tarda. Blood 112(12) 4723-4728.  
Almehmi, A, Deliri, H, Szego, GG, Teague, AC, Pfister, AK and Martin, SA (2005). Porphyria cutanea 
tarda in a patient with HIV-infection. W V Med J 101(1): 19-21. 
Anderson, KE, Sassa, S, Bishop, DF and Desnick, RJ (2001). Disorders of heme biosynthesis: X-linked 
sideroblastic anemia and the porphyrias. The metabolic and molecular bases of inherited disease. 
Scriver, CR, Beaudet, A, Sly, WS and Valle, D. (Eds). New York, McGraw-Hill. 2: 2991-3062. 
Andersson, C, Thunell, S, Floderus, Y, Forsell, C, Lundin, G, Anvret, M, Lannfelt, L, Wetterberg, L and 
Lithner, F (1995). Diagnosis of acute intermittent porphyria in northern Sweden: an evaluation of 
mutation analysis and biochemical methods. J Intern Med 237(3): 301-308. 
Andersson, C, Wikberg, A, Stegmayr, B and Lithner, F (2000). Renal symptomatology in patients with 
acute intermittent porphyria. A population-based study. J Intern Med 248(4): 319-325. 
Anton-Lambrecht, I and Bersch, A (1971). Histoptahologie und ultrastructure der haut bei 
protoporphyrinämie. Virchovs. Arch A Pathol Anat 352: 75-89. 
Aplin, C, Whatley, SD, Thompson, P, Hoy, T, Fisher, P, Singer, C, Lovell, CR and Elder, GH (2001). 
Late-onset erythropoietic porphyria caused by a chromosome 18q deletion in erythroid cells. J 
Invest Dermatol 117(6): 1647-1649. 
Armas, R, Wolff, C, Krause, P, Chana, P, Parraguez, A and Soto, J (1992). The hepatic porphyrias: 
experience with 105 cases. Rev Med Chil 120(3): 259-266. 
Baart de la Faille, H (1975). Erythropoetic protoporphyria. Utrecht, Oosthoek, Scheltema & Holkema. 
Book, pages 80-81. 
Baart de la Faille, H, Bijlmer-Iest, JC, van Hattum, J, Koningsberger, J, Rademakers, LH and van 
Weelden, H (1991). Erythropoietic protoporphyria: clinical aspects with emphasis on the skin. 
Curr Probl Dermatol 20: 123-134. 
Babilas, P, Karrer, S, Sidoroff, A, Landthaler, M and Szeimies, RM (2005). Photodynamic therapy in 
dermatology--an update. Photodermatol Photoimmunol Photomed 21(3): 142-149. 
Badminton, MN and Elder, GH (2005). Molecular mechanisms of dominant expression in porphyria. J 
Inherit Metab Dis 28: 277-286. 
Berroeta, L, Man, I, Goudie, DR, Whatley, SD, Elder, GH and Ibbotson, SH (2007). Late presentation of 
erythropoietic protoporphyria: case report and genetic analysis of family members. Br J Dermatol 
157(5): 1030-1031 
Bishop, DF, Henderson, AS and Astrin, KH (1990). Human delta-aminolevulinate synthase: assignment 
of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. 
Genomics 7(2): 207-214. 
Bloomer, J, Wang, Y, Singhal, A and Risheg, H (2005). Molecular studies of liver disease in 
erythropoietic protoporphyria. J Clin Gastroenterol 39 (4) Suppl 2: S167-175. 
Bloomer, JR, Wang, Y, Singhal, A and Risheg, H (2006). Biochemical abnormality in erythropoietic 
protoporphyria: cause and consequences. J Pediatr Gastroenterol Nutr 43 Suppl 1: S36-40. 
Boffa, MJ, Reed, P, Weinkove, C and Ead, RD (1995). Hypertrichosis as the presenting feature of 
porphyria cutanea tarda. Clin Exp Dermatol 20(1): 62-64. 
Boffa, MJ, Ead, RD, Reed, P and Weinkove, C (1996). A double-blind, placebo-controlled, crossover 
trial of oral vitamin C in erythropoietic protoporphyria. Photodermatol Photoimmunol Photomed 
12(1): 27-30. 
Bonkowsky, HL, Bloomer, JR, Ebert, PS and Mahoney, MJ (1975). Heme synthetase deficiency in 
human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts. J Clin 







Brady, JJ, Jackson, HA, Roberts, AG, Morgan, RR, Whatley, SD, Rowlands, GL, Darby, C, Shudell, E, 
Watson, R, Paiker, J, Worwood, MW and Elder, GH (2000). Co-inheritance of mutations in the 
uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria 
cutanea tarda. J Invest Dermatol 115(5): 868-874. 
Braverman, IM and Keh-Yen, A (1984). Ultrastructural abnormalities of the microvasculature and elastic 
fibers in the skin of juvenile diabetics. J Invest Dermatol 82(3): 270-274. 
Breathnach, SM, Bhogal, B, de Beer, FC, Melrose, SM, Black, MM and Pepys, MB (1983). 
Immunohistochemical studies of amyloid P component and fibronectin in erythropoietic 
protoporphyria. Br J Dermatol 108: 267-275. 
Brun, A, Western, A, Malik, Z and Sandberg, S (1990). Erythropoietic protoporphyria: photodynamic 
transfer of protoporphyrin from intact erythrocytes to other cells. Photochem Photobiol 51(5): 
573-577. 
Bulaj, ZJ, Phillips, JD, Ajioka, RS, Franklin, MR, Griffen, LM, Guinee, DJ, Edwards, CQ and Kushner, 
JP (2000). Hemochromatosis genes and other factors contributing to the pathogenesis of 
porphyria cutanea tarda. Blood 95(5): 1565-1571. 
Bygum, A, Christiansen, L, Petersen, NE, Horder, M, Thomsen, K and Brandrup, F (2003). Familial and 
sporadic porphyria cutanea tarda: clinical, biochemical and genetic features with emphasis on 
iron status. Acta Derm Venereol 83(2): 115-120. 
Campo, E, Bruguera, M and Rodes, J (1990). Are there diagnostic histologic features of porphyria 
cutanea tarda in liver biopsy specimens? Liver 10(3): 185-190. 
Chen, JJ (2007). Regulation of protein synthesis by the heme-regulated eIF2alpha kinase: relevance to 
anemias. Blood 109(7): 2693-2699. 
Chirgwin, JM, Przybyla, AE, MacDonald, RJ and Rutter, WJ (1979). Isolation of biologically active 
ribonucleic acid from sources enriched in ribonuclease. Biochem 18(24): 5294-5299. 
Christiansen, L, Bygum, A, Jensen, A, Thomsen, K, Brandrup, F, Horder, M and Petersen, NE (2000). 
Association between CYP1A2 polymorphism and susceptibility to porphyria cutanea tarda. Hum 
Genet 107(6): 612-614. 
Coakley, J, Hawkins, R, Crinis, N, McManus, J, Blake, D, Nordmann, Y, Sloan, L and Connelly, J 
(1990). An unusual case of variegate porphyria with possible homozygous inheritance. Aust N Z 
J Med 20(4): 587-589. 
Cooper, CL, Stob, CM, Jones, MA and Lash, TD (2005). Metabolism of pentacarboxylate 
porphyrinogens by highly purified human coproporphyrinogen oxidase: Further evidence for the 
existence of an abnormal pathway for heme biosynthesis. Bioorg Med Chem 13: 6244-6251. 
Cooperman, SS, Meyron-Holtz, EG, Olivierre-Wilson, H, Ghosh, MC, McConnell, JP and Rouault, TA 
(2005). Microcytic anemia, erythropoietic protoporphyria, and neurodegeneration in mice with 
targeted deletion of iron-regulatory protein. Blood 106(3): 1084-1091. 
Corbett, MF, Herxheimer, A, Magnus, IA, Ramsay, CA and Kobza-Black, A (1977). The long term 
treatment with beta-carotene in erythropoietic protoporphyria: a controlled trial. Br J Dermatol 
97(6): 655-662. 
Corey, TJ, DeLeo, VA, Christianson, H and Poh-Fitzpatrick, MB (1980). Variegate porphyria. Clinical 
and laboratory features. J Am Acad Dermatol 2(1): 36-43. 
Corrigall, AV, Hift, RJ, Davids, LM, Hancock, V, Meissner, D, Kirsch, RE and Meissner, PN (2000). 
Homozygous variegate porphyria in South Africa: genotypic analysis in two cases. Mol Genet 
Metab 69: 323-330. 
Cortes, JM, Oliva, H, Paradinas, FJ and Hernandez-Guio, C (1980). The pathology of the liver in 
porphyria cutanea tarda. Histopathol 4(5): 471-485. 
Cox, TM, Alexander, GJ and Sarkany, RP (1998). Protoporphyria. Semin Liver Dis 18(1): 85-93. 
Cramers, M and Jepsen, LV (1980). Porphyria variegata: failure of chloroquin treatment. Acta Derm 
Venereol 60(1): 89-91. 








Cripps, DJ, Peters, HA, Gocmen, A and Dogramici, I (1984). Porphyria turcica due to 
hexachlorobenzene: a 20 to 30 year follow-up study on 204 patients. Br J Dermatol 111(4): 413-
422. 
Cruz-Rojo, J, Fontanellas, A, Moran-Jimenez, MJ, Navarro-Ordonez, S, Garcia-Bravo, M, Mendez, M, 
Munoz-Rivero, MC and de Salamanca, RE (2002). Precipitating/aggravating factors of porphyria 
cutanea tarda in Spanish patients. Cell Mol Biol 48(8): 845-852. 
D'Alessandro Gandolfo, L, Macri, A, Biolcati, G, Griso, D, Phung, LN, Deybach, JC, Da Silva, V, 
Nordmann, Y and Topi, GC (1991). Homozygous variegate porphyria: revision of a diagnostic 
error. Br J Dermatol 124: 211. 
Da Silva, V, Simonin, S, Deybach, JC, Puy, H and Nordmann, Y (1995). Variegate porphyria: diagnostic 
value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 238(2): 163-168. 
Dabski, C and Beutner, EH (1991). Studies of laminin and type IV collagen in blisters of porphyria 
cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol 25: 28-32. 
Dahlbäck, K, Lofberg, H and Dahlbäck, B (1988). Immunohistochemical studies on vitronectin in elastic 
tissue disorders, cutaneous amyloidosis, lichen ruber planus and porphyria. Acta Derm Venereol 
68: 107-115. 
Dahlbäck, K and Sakai, L (1990). Immunohistochemical studies on fibrillin in amyloidosis, lichen ruber 
planus and porphyria. Acta Derm Venereol 70(4): 275-280. 
Dailey, TA, Woodruff, JH and Dailey, HA (2005). Examination of mitochondrial protein targeting of 
haem synthetic enzymes: in vivo identification of three functional haem-responsive motifs in 5-
aminolaevulinate synthase. Biochem J 386: 381-386. 
Dawe, RS (2006). Prevalences of the chronic idiopathic and metabolic photodermatoses in Scotland. Br J 
Dermatol 155(4): 866 (Abstract). 
Day, RS (1986). Variegate porphyria. Semin Dermatol 5: 138-154. 
de Leo, VA, Poh-Fitzpatrick, M, Mathews-Roth, M and Harber, LC (1976). Erythropoietic 
protoporphyria. 10 years experience. Am J Med 60(1): 8-22. 
de Verneuil, H, Moreau-Gaudry, F, Ged, C, Bensidhoum, M, Hombrados, I, Tricoire, J and Rolland, M 
(1995). [Congenital erythropoietic porphyria. Apropos of a fatal case in the neonatal period due 
to acute hemolysis with hepatic failure]. Arch Pediatr 2(8): 755-761. 
Dean, G (1971). Screening tests for porphyria. Lancet 1(7689): 86-87. 
Deybach, JC, de Verneuil, H and Nordmann, Y (1981). The inherited enzymatic defect in porphyria 
variegata. Hum Genet 58(4): 425-428. 
Deybach, JC, Puy, H, Robreau, AM, Lamoril, J, Da Silva, V, Grandchamp, B and Nordmann, Y (1996). 
Mutations in the protoporphyrinogen oxidase gene in patients with variegate porphyria. Hum Mol 
Gen 5(3): 407-410. 
Doss, MO and Frank, M (1989). Hepatobiliary implications and complications in protoporphyria, a 20-
year study. Clin Biochem 22(3): 223-229. 
Doss, MO, Frank, M and Braun-Falco, O (1991). Porphyria cutanea tarda: erythrocyte uroporphyrinogen 
decarboxylase activity in 471 consecutive patients. Curr Probl Dermatol 20: 97-105. 
Eales, L (1978). The effects of canthaxanthin on the photocutaneous manifestations of porphyria. S Afr 
Med J 54(25): 1050-1052. 
Eales, L, Day, RS and Blekkenhorst, GH (1980). The clinical and biochemical features of variegate 
porphyria: an analysis of 300 cases studied at Groote Schuur Hospital, Cape Town. Int J Biochem 
12(5-6): 837-853. 
Egbert, BM, LeBoit, PE and McCalmont, T (1993). Caterpillar bodies: distinctive, basement membrane-
containing structures in blisters of porphyria. Am J Dermatopathol 15: 199-202. 
Egger, NG, Goeger, DE, Payne, DA, Miskovsky, EP, Weinman, SA and Anderson, KE (2002). Porphyria 
cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited 
uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 47(2): 419-426. 
Elder, GH, Lee, GB and Tovey, JA (1978). Decreased activity of hepatic uroporphyrinogen 
decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med 299(6): 274-278. 
Elder, GH, Roberts, AG and de Salamanca, RE (1989). Genetics and pathogenesis of human 
uroporphyrinogen decarboxylase defects. Clin Biochem 22(3): 163-168. 





Elder, GH, Smith, SG and Smyth, SJ (1990). Laboratory investigation of the porphyrias. Ann Clin 
Biochem 27(5): 395-412. 
Elder, GH, Hift, RJ and Meissner, PN (1997). The acute porphyrias. Lancet 349(9065): 1613-1617. 
Elder, GH (1998). Porphyria cutanea tarda. Semin Liver Dis 18(1): 67-75. 
Elder, GH (1999). Alcohol intake and porphyria cutanea tarda. Clin Dermatol 17(4): 431-436. 
Epstein, JH, Tuffanelli, DL and Epstein, WL (1973). Cutaneous changes in the porphyrias. A microscopic 
study. Arch Dermatol 107(5): 689-698. 
Fakan, F, Chlumska, A, Krijt, J and Kocova, L (1998). Cytoplasmic liver cell inclusions--a typical feature 
of porphyria cutanea tarda--are absent in porphyria-related hepatic neoplasias. Neoplasma 45(2): 
102-106. 
Fallon, JD, Kvedar, JC, Margolis, RJ and Pathak, MA (1989). Erythropoietic protoporphyria presenting 
in adulthood. Arch Dermatol 125: 1286-1287. 
Fargion, S, Fracanzani, AL, Romano, R, Cappellini, MD, Fare, M, Mattioli, M, Piperno, A, Ronchi, G 
and Fiorelli, G (1996). Genetic hemochromatosis in Italian patients with porphyria cutanea tarda: 
possible explanation for iron overload. J Hepatol 24(5): 564-569. 
Farr, PM, Diffey, BL and Matthews, JN (1990). Inhibition of photosensitivity in erythropoietic 
protoporphyria with terfenadine. Br J Dermatol 122: 809-815. 
Findlay, GH, Scott, FP and Cripps, DJ (1966). Porphyria and lipid proteinosis. A clinical, histological and 
biochemical comparison of 19 South African cases. Br J Dermatol 78(2): 69-80. 
Fontanellas, A, Mendez, M, Mazurier, F, Cario-Andre, M, Navarro, S, Ged, C, Taine, L, Geronimi, F, 
Richard, E, Moreau-Gaudry, F, Enriquez De Salamanca, R and de Verneuil, H (2001). Successful 
therapeutic effect in a mouse model of erythropoietic protoporphyria by partial genetic correction 
and fluorescence-based selection of hematopoietic cells. Gene Ther 8(8): 618-626. 
Fracanzani, AL, Taioli, E, Sampietro, M, Fatta, E, Bertelli, C, Fiorelli, G and Fargion, S (2001). Liver 
cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control 
patients with chronic liver disease. J Hepatol 35(4): 498-503. 
Frank, J, McGrath, J, Lam, H, Graham, RM, Hawk, JL and Christiano, AM (1998a). Homozygous 
variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase 
gene in a severely affected proband. J Invest Dermatol 110(4): 452-455. 
Frank, J, Poh-Fitzpatrick, MB, King, LE, Jr. and Christiano, AM (1998b). The genetic basis of "Scarsdale 
Gourmet Diet" variegate porphyria: a missense mutation in the protoporphyrinogen oxidase gene. 
Arch Dermatol Res 290(8): 441-445. 
Frank, J, Aita, VM, Ahmad, W, Lam, H, Wolff, C and Christiano, AM (2001). Identification of a founder 
mutation in the protoporphyrinogen oxidase gene in variegate porphyria patients from Chile. 
Hum Hered 51: 160-168. 
Friedman, SJ and Doyle, JA (1985). Sclerodermoid changes of porphyria cutanea tarda: possible 
relationship to urinary uroporphyrin levels. J Am Acad Dermatol 13(1): 70-74. 
Fritsch, C, Lang, K, von Schmiedeberg, S, Bolsen, K, Merk, H, Lehmann, P and Ruzicka, T (1998). 
Porphyria cutanea tarda. Skin Pharmacol Appl Skin Physiol 11(6): 321-335. 
Fromke, VL, Bossenmaier, I, Cardinal, R and Watson, CJ (1978). Porphyria variegata. Study of a large 
kindred in the United States. Am J Med 65(1): 80-88. 
Fung, MA, Murphy, MJ, Hoss, DM, Berke, A and Grant-Kels, JM (2003). The sensitivity and specificity 
of "caterpillar bodies" in the differential diagnosis of subepidermal blistering disorders. Am J 
Dermatopathol. 25: 287-290. 
Gardlo, K, Selimovic, D, Bolsen, K, Ruzicka, T, Abel, J and Fritsch, C (2003). Cytochrome p450A1 
polymorphisms in a Caucasian population with porphyria cutanea tarda. Exp Dermatol 12(6): 
843-848. 
Garey, JR, Franklin, KF, Brown, DA, Harrison, LM, Metcalf, KM and Kushner, JP (1993). Analysis of 
uroporphyrinogen decarboxylase complementary DNAs in sporadic porphyria cutanea tarda. 
Gastroenterol 105(1): 165-169. 
Gigli, I, Schothorst, AA, Soter, NA and Pathak, MA (1980). Erythropoietic protoporphyria. 







Gisbert, JP, Garcia-Buey, L, Pajares, JM and Moreno-Otero, R (2003). Prevalence of hepatitis C virus 
infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39(4): 620-
627. 
Gisbert, JP, Garcia-Buey, L, Alonso, A, Rubio, S, Hernandez, A, Pajares, JM, Garcia-Diez, A and 
Moreno-Otero, R (2004). Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. 
Eur J Gastroenterol Hepatol 16(7): 689-692. 
Glover, RA, Bailey, CS, Barrett, KE, Wasserman, SI and Gigli, I (1990). Histamine release from rodent 
and human mast cells induced by protoporphyrin and ultraviolet light: studies of the mechanism 
of mast-cell activation in erythropoietic protoporphyria. Br J Dermatol 122(4): 501-512. 
Goerz, G, Bunselmeyer, S, Bolsen, K and Schurer, NY (1996). Ferrochelatase activities in patients with 
erythropoietic protoporphyria and their families. Br J Dermatol 134(5): 880-885. 
Goldstein, BD and Harber, LC (1972). Erythropoietic protoporphyria: lipid peroxidation and red cell 
membrane damage associated with photohemolysis. J Clin Invest 51(4): 892-902. 
Goodwin, RG, Kell, WJ, Laidler, P, Long, CC, Whatley, SD, McKinley, M, Badminton, MN, Burnett, 
AK, Williams, GT and Elder, GH (2006). Photosensitivity and acute liver injury in 
myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a 
ferrochelatase gene in hematopoietic cells. Blood 107(1): 60-62. 
Gouya, L, Puy, H, Lamoril, J, Da Silva, V, Grandchamp, B, Nordmann, Y and Deybach, JC (1999). 
Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant 
with low expression accounts for clinical manifestation. Blood 93(6): 2105-2110. 
Gouya, L, Puy, H, Robreau, AM, Bourgeois, M, Lamoril, J, Da Silva, V, Grandchamp, B and Deybach, 
JC (2002). The penetrance of dominant erythropoietic protoporphyria is modulated by expression 
of wildtype FECH. Nat Genet 30: 27-28. 
Gouya, L, Martin-Schmitt, C, Robreau, AM, Austerlitz, F, Silva, VD, Brun, P, Simonin, S, Lyoumi, S, 
Grandchamp, B, Beaumont, C, Puy, H and Deybach, JC (2006). Contribution of a common 
single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. 
Am J Hum Genet 78(1): 2-14. 
Grabczynska, SA, McGregor, JM and Hawk, JL (1996). Late onset variegate porphyria. Clin Exp 
Dermatol 21(5): 353-356. 
Green, JJ and Manders, SM (2001). Pseudoporphyria. J Am Acad Dermatol 44(1): 100-108. 
Grossman, ME, Bickers, DR, Poh-Fitzpatrick, MB, Deleo, VA and Harber, LC (1979). Porphyria cutanea 
tarda. Clinical features and laboratory findings in 40 patients. Am J Med 67(2): 277-286. 
Grossman, ME and Poh-Fitzpatrick, MB (1986). Porphyria cutanea tarda. Diagnosis, management, and 
differentiation from other hepatic porphyrias. Dermatol Clin 4(2): 297-309. 
Gschnait, FG, Wolff, K and Konrad, K (1975). Erythropoietic protoprophyria--submicroscopic events    
during the acute photosensitivity flare. Br J Dermatol 92:547-557.  
Hammer, H and Korom, I (1992). Photodamage of the conjunctiva in patients with porphyria cutanea 
tarda. Br J Ophthalmol 76(10): 592-593. 
Harper, P, Floderus, Y, Holmstrom, P, Eggertsen, G and Gafvels, M (2004). Enrichment of HFE 
mutations in Swedish patients with familial and sporadic form of porphyria cutanea tarda. J Intern 
Med 255(6): 684-688. 
Hasegawa, K, Yoneda, M, Kuwabara, H, Miyaishi, O, Itano, N, Ohno, A, Zako, M and Isogai, Z (2007). 
Versican, a major hyaluronan-binding component in the dermis, loses its hyaluronan-binding 
ability in solar elastosis. J Invest Dermatol 127(7): 1657-1663. 
He, D and Lim, HW (1991). Irradiation of protoporphyric mice induces down-regulation of epidermal 
eicosanoid metabolism. J Invest Dermatol 97: 488-494 
Helasoja, V, Lahelma, E, Prattala, R, Petkeviciene, J, Pudule, I and Tekkel, M (2007). The 
sociodemographic patterning of drinking and binge drinking in Estonia, Latvia, Lithuania and 
Finland, 1994-2002. BMC Public Health 7(147): 241. 
Henderson, CA, Jones, S, Elder, G and Ilchyshyn, A (1995). Erythropoietic protoporphyria presenting in 
an adult. J R Soc Med 88: 476-477. 
Herrmann, G, Wlaschek, M, Bolsen, K, Prenzel, K, Goerz, G and Scharffetter-Kochanek, K (1996). 
Photosensitization of uroporphyrin augments the ultraviolet A-induced synthesis of matrix 





Hift, RJ, Meissner, PN, Todd, G, Kirby, P, Bilsland, D, Collins, P, Ferguson, J and Moore, MR (1993). 
Homozygous variegate porphyria: an evolving clinical syndrome. Postgrad Med J 69(816): 781-
786. 
Hift, RJ, Todd, G, Meissner, PN and Kirsch, RE (2003). Administration of oral activated charcoal in 
variegate porphyria results in a paradoxical clinical and biochemical deterioration. Br J Dermatol 
149: 1266-1269. 
Hift, RJ, Davidson, BP, van der Hooft, C, Meissner, DM and Meissner, PN (2004a). Plasma fluorescence 
scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise 
determination of sensitivity and specificity with detection of protoporphyrinogen oxidase 
mutations as a reference standard. Clin Chem 50(5): 915-923. 
Hift, RJ, Meissner, D and Meissner, PN (2004b). A systematic study of the clinical and biochemical 
expression of variegate porphyria in a large South African family. Br J Dermatol 151(2): 465-
471. 
Higuchi, R (1989). Simple and rapid preparation of samples for PCR. PCR Technology. Principles and 
Applications for DNA Amplification. Ehrlich, HA. New York, Stockton Press: 31-38. 
Hintner, H, Breathnach, SM, Dahlbäck, K, Dahlbäck, B and Fritsch, P (1991). Vitronectin in normal 
human skin and in skin lesions. Hautarzt 42(1):16-22. 
Holme, SA, Anstey, AV, Finlay, AY, Elder, GH and Badminton, MN (2006a). Erythropoietic 
protoporphyria in the U.K.: clinical features and effect on quality of life. Br J Dermatol 155(3): 
574-581. 
Holme, SA, Anstey, AV, Finlay, AY, Elder, GH and Badminton, MN (2006b). Epidemiology of 
erythropoietic protoporphyria: the U.K. experience. Br J Dermatol 155(4): 866 (Abstract). 
Holme, SA, Worwood, M, Anstey, AV, Elder, GH and Badminton, MN (2007). Erythropoiesis and iron 
metabolism in dominant erythropoietic protoporphyria. Blood 110(12): 4108-4110. 
Hopsu-Havu, VK, Terho, PE and Hollmen, T (1973). Erythropoietic protoporphyria. The first case in 
Finland. Ann Clin Res 5: 181-185. 
Jansen, CT and Karvonen, J (1984). Polymorphous light eruption. A seven-year follow-up evaluation of 
114 patients. Arch Dermatol 120(7): 862-865. 
Kauppinen, R and Mustajoki, P (1988). Acute hepatic porphyria and hepatocellular carcinoma. Br J 
Cancer 57(1): 117-120. 
Kauppinen, R and Mustajoki, P (1992). Prognosis of acute porphyria: occurrence of acute attacks, 
precipitating factors, and associated diseases. Medicine 71(1): 1-13. 
Kauppinen, R (2005). Porphyrias. Lancet 365(9455): 241-252. 
Keller, J and Hornstein, OP (1983). Erythropoietic protoporphyria. Dtsch Med Wochenschr 3: 862-866. 
Kemmer, C, Reitmann, I, Kostler, E and Riedel, H (1988). The morphology of skin damage in porphyria 
cutanea tarda (PCT). Zentralblatt Fur Allgemeine Pathologie Und Pathologische Anatomie 
134(3): 227-234. 
Kint, A and De Weert, J (1978). Comparative morphological studies on porphyria cutanea tarda and 
erythropoietic protoporphyris. Hautarzt 29(4): 198-204. 
Kirsch, RE, Meissner, PN and Hift, RJ (1998). Variegate porphyria. Semin Liver Dis 18(1): 33-41. 
Klein, GF, Hintner, H, Schuler, G and Fritsch, P (1983). Junctional blisters in acquired bullous disorders 
of the dermal-epidermal junction zone: role of the lamina lucida as the mechanical locus minoris 
resistentiae. Br J Dermatol 109: 499-508. 
Komatsu, H, Sajima. Y, Imamura. K, Masuda. H, Yonei. Y, Dohmori. K, Kokutoh. M, Ishii. K and Ishii. 
H (2000). An ultrastructural study of the liver in erythropoietic protoporphyria. Med Electron 
Microsc 33: 32-38. 
Koningsberger, JC, Rademakers, LH, van Hattum, J, de la Faille, HB, Wiegman, LJ, Italiaander, E, van 
Berge Henegouwen, GP and Marx, JJ (1995). Exogenous protoporphyrin inhibits Hep G2 cell 
proliferation, increases the intracellular hydrogen peroxide concentration and causes 
ultrastructural alterations. J Hepatol 22(1): 57-65. 
Kordac, V (1972). Frequency of occurrence of hepatocellular carcinoma in patients with porphyria 
cutanea tarda in long-term follow-up. Neoplasma 19(2): 135-139. 
Kordac, V, Deybach, JC, Martasek, P, Zeman, J, da Silva, V, Nordmann, Y, Houstkova, H, Rubin, A and 





Kordac, V, Martasek, P, Zeman, J and Rubin, A (1985). Increased erythrocyte protoporphyrin in 
homozygous variegate porphyria. Photodermatol 2(4): 257-259. 
Kosenow, W and Treibs, A (1953). Lichtüberempfindlichkeit und Poprhyrinämie. Z Kinderheitkol 73: 
83-84. 
Koszo, F, Morvay, M, Dobozy, A and Simon, N (1992). Erythrocyte uroporphyrinogen decarboxylase 
activity in 80 unrelated patients with porphyria cutanea tarda. Br J Dermatol 126(5): 446-449. 
Krajnc, I, Vizjak, A, Hvala, A, Jurcic, V and Rozman, B (1998). The significance of histologic analysis of 
skin lesions in porphyria cutanea tarda. Light microscopy, electron microscopy, 
immunohistochemical and immunofluorescence analysis. Wien Klin Wochenschr 110(18): 651-
654. 
Kratka, K, Dostalikova-Cimburova, M, Michalikova, H, Stransky, J,Vranova, J and Horak, J          
(2008). High prevalence of HFE gene mutations in patients with porphyria cutanea tarda in the  
 Czech Republic. Br J Dermatol 159 (3):585-590.  
Kumakiri, M, Hashimoto, K and Willis, I (1977). Biologic changes due to long-wave ultraviolet 
irradiation on human skin: ultrastructural study. J Invest Dermatol 69(4): 392-400. 
Lamoril, J, Boulechfar, S, de Verneuil, H, Grandchamp, B, Nordmann, Y and Deybach, JC (1991). 
Human erythropoietic protoporphyria: two point mutations in the ferrochelatase gene. Biochem 
Biophys Res Commun 181(2): 594-599. 
Lamoril, J, Puy, H, Whatley, SD, Martin, C, Woolf, JR, Da Silva, V, Deybach, JC and Elder, GH (2001). 
Characterization of mutations in the CPO gene in British patients demonstrates absence of 
genotype-phenotype correlation and identifies relationship between hereditary coproporphyria 
and harderoporphyria. Am J Hum Genet 68(5): 1130-1138. 
Lamoril, J, Andant, C, Gouya, L, Malonova, E, Grandchamp, B, Martasek, P, Deybac, JC and Puy, H 
(2002). Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria 
cutanea tarda (sPCT). Cell Mol Biol 48(1): 33-41. 
Lecha, M, Badenas, C, Puig, S, Orfila, J, Mila, M, To-Figueras, J, Munoz, C, Mercader, P and Herrero, C 
(2006). Genetic studies in variegate porphyria in Spain. Identification of gene mutations and 
family study for carrier detection. J Eur Acad Dermatol Venereol 20(8): 974-979. 
Lehmann, P, Scharffetter, K, Kind, P and Goerz, G (1991). Erythropoietic protoporphyria: synopsis of 20 
patient. Hautarzt 42: 570-574. 
Li, F, Lim, CK and Peters, TJ (1986). Analysis of urine and faecal porphyrins by HPLC coupled to an 
advanced automated sample processor. Biomed Chromatogr 1(2): 93-94. 
Lim, CK and Peters, TJ (1984). Urine and fecal profiles by reverse-phase high performance liquid 
chromatograqphy in the porphyrias. Clin Chem Acta 139(1): 55-63. 
Lim, HW, Gigli, I and Wasserman, SI (1987). Differential effects of protoporphyrin and uroporphyrin on 
murine mast cells. J Invest Dermatol 88: 281-286. 
Lim, HW (1989). Mechanisms of phototoxicity in porphyria cutanea tarda and erythropoietic 
protoporphyria. Immunol Ser 46: 671-685. 
Lim, HW, Cooper, D, Sassa, S, Dosik, H, Buchness, MR and Soter, NA (1992). Photosensitivity, 
abnormal porphyrin profile, and sideroblastic anemia. J Am Acad Dermatol 27(2): 287-292. 
Lindberg, RL, Porcher, C, Grandchamp, B, Ledermann, B, Burki, K, Brandner, S, Aguzzi, A and Meyer, 
UA (1996). Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that 
human hepatic porphyria. Nat Genet 12(2): 195-199. 
Linde, Y, Harper, P, Floderus, Y and Ros, AM (2005). The prevalence of hepatitis C in patients with 
porphyria cutanea tarda in Stockholm, Sweden. Acta Derm Venereol 85(2): 164-166. 
Linet, MS, Gridley, G, Nyren, O, Mellemkjaer, L, Olsen, JH, Keehn, S, Adami, HO and Fraumeni, JF, Jr. 
(1999). Primary liver cancer, other malignancies, and mortality risks following porphyria: a 
cohort study in Denmark and Sweden. Am J Epidemiol 149(11): 1010-1015. 
Long, C, Smyth, SJ, Woolf, J, Murphy, GM, Finlay, AY, Newcombe, RG and Elder, GH (1993). 
Detection of latent variegate porphyria by fluorescence emission spectroscopy of plasma. Br J 
Dermatol 129(1): 9-13. 
Longas, MO and Poh-Fitzpatrick, MB (1982). A tightly bound protein-porphyrin complex isolated from 






Lowry, OH, Rosebrough, NJ, Farr, AL and Randall, RJ (1951). Protein measurement with the Folin 
phenol reagent. J Biol Chem 193(1): 265-275. 
Lyoumi, S, Abitbol, M, Andrieu, V, Henin, D, Robert, E, Schmitt, C, Gouya, L, de Verneuil, H, Deybach, 
JC, Montagutelli, X, Beaumont, C and Puy, H (2007). Increased plasma transferrin, altered body 
iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood 
109(2): 811-818. 
Ma, Y, Fracanzani, AL, Sampietro, M, Mattioli, M, Cheeseman, P, Williams, R, Mieli-Vergani, G, 
Vergani, D and Fargion, S (2001). Autoantibodies to human cytosol: a marker of sporadic 
porphyria cutanea tarda. Clin Exp Immunol 126(1): 47-53. 
MacDonald, DM, Germain, D and Perrot, H (1981). The histopathology and ultrastructure of liver disease 
in erythropoietic protoporphyria. Br J Dermatol 104(1): 7-17. 
Magness, ST and Brenner, DA (1999). Targeted disruption of the mouse ferrochelatase gene producing 
an exon 10 deletion. Biochim Biophys Acta 1453: 161-174. 
Magnus, IA (1961). Erythropoietic protoporphyria:  A new syndrome with solar urticaria due to 
protoporphyrinaemia. Lancet 2: 448-451. 
Mansourati, FF, Stone, VE and Mayer, KH (1999). Porphyria cutanea tarda and HIV/AIDS: a review of 
pathogenesis, clinical manifestations and management. Int J STD AIDS 10(1): 51-56. 
Martasek, P, Kordac, V and Zonbek, V (1987). Epidemiology of porphyria cutanea tarda in 
Czechoslovakia and Mongolia. Bolletino dell'Instituto Dermatologica S Gallicano 8: 330-331. 
Mathews-Roth, MM, Pathak, MA, Fitzpatrick, TB, Harber, LH and Kass, EH (1977). Beta carotene 
therapy for erythropoietic protoporphyria and other photosensitivity diseases. Arch Dermatol 
113: 1229-1232. 
Mathews-Roth, MM and Rosner, B (2002). Long-term treatment of erythropoietic protoporphyria with 
cysteine. Photodermatol Photoimmunol Photomed 18: 307-309. 
Maury, CP and Teppo, AM (1984). Massive cutaneous hyalinosis. Identification of the hyalin material as 
monoclonal kappa light chains, adhesive 90 kD glycoprotein, and type I collagen. Am J Clin 
Pathol 82(5): 543-551. 
Maynard, B and Peters, MS (1992). Histologic and immunofluorescence study of cutaneous porphyrias. J 
Cutan Pathol 19(1): 40-47. 
McGuire, BM, Bonkovsky, HL, Carithers, RL, Jr., Chung, RT, Goldstein, LI, Lake, JR, Lok, AS, Potter, 
CJ, Rand, E, Voigt, MD, Davis, PR and Bloomer, JR (2005). Liver transplantation for 
erythropoietic protoporphyria liver disease. Liver Transpl 11(12): 1590-1596. 
Medlock, AE, Meissner, PN, Davidson, BP, Corrigall, AV and Dailey, HA (2002). A mouse model for 
South African (R59W) variegate porphyria: construction and initial characterization. Cell Mol 
Biol 48(1): 71-78. 
Meerman, L, Koopen, NR, Bloks, V, Van Goor, H, Havinga, R, Wolthers, BG, Kramer, W, Stengelin, S, 
Muller, M, Kuipers, F and Jansen, PL (1999). Biliary fibrosis associated with altered bile 
composition in a mouse model of erythropoietic protoporphyria. Gastroenterol 117(3): 696-705. 
Meerman, L (2000). Erythropoietic protoporphyria. An overview with emphasis on the liver. Scand J 
Gastroenterol 232 Suppl: S79-85. 
Meigel, W, Schaeg, G and Goerz, G (1981). Atypically localized persistent skin changes in erythropoietic 
protoporphyria (EPP)--histologic and electron microscopic findings. Z Hautkr 56: 489-497. 
Meissner, PN, Dailey, TA, Hift, RJ, Ziman, M, Corrigall, AV, Roberts, AG, Meissner, DM, Kirsch, RE 
and Dailey, HA (1996). A R59W mutation in human protoporphyrinogen oxidase results in 
decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 
13(1): 95-97. 
Mendez, M, Poblete-Gutierrez, P, Garcia-Bravo, M, Wiederholt, T, Moran-Jimenez, MJ, Merk, HF, 
Garrido-Astray, MC, Frank, J, Fontanellas, A and Enriquez de Salamanca, R (2007). Molecular 
heterogeneity of familial porphyria cutanea tarda in Spain: characterization of 10 novel mutations 
in the UROD gene. Br J Dermatol 157(3): 501-507. 
Menon, IA, Becker, MA, Persad, SD and Haberman, HF (1990). Quantitation of hydrogen peroxide 
formed during UV-visible irradiation of protoporphyrin, coproporphyrin and uroporphyrin. Clin 






Meyer-Betz, F (1913). Untersuchungen uber die biologische (photodynamische) Wirkung des 
hamatoporphyrins und anderen derivate des Blut und Gallenfarbstoffs. Dtsch Arch Klin Med 112: 
476-503. 
Meyer, UA, Schuurmans, MM and Lindberg, RL (1998). Acute porphyrias: pathogenesis of neurological 
manifestations. Semin Liver Dis 18(1): 43-52. 
Minder, EI, Gouya, L, Schneider-Yin, X and Deybach, JC (2002). A genotype-phenotype correlation 
between null-allele mutations in the ferrochelatase gene and liver complication in patients with 
erythropoietic protoporphyria. Cell Mol Biol 48(1): 91-96. 
Moore, MR, McColl, KE, Rimington, C and Goldberg, A (1987). Disorders of porphyrin metabolism. 
New York, Plenum Publishing Corporation. 
Muhlbauer, JE, Pathak, MA, Tishler, PV and Fitzpatrick, TB (1982). Variegate porphyria in New 
England. JAMA 247(22): 3095-3102. 
Murphy, GM, Hawk, JL and Magnus, IA (1985). Late-onset erythropoietic protoporphyria with unusual 
cutaneous features. Arch Dermatol 121: 1309-1312. 
Murphy, GM, Hawk, JL, Magnus, IA, Barrett, DF, Elder, GH and Smith, SG (1986). Homozygous 
variegate porphyria: two similar cases in unrelated families. J R Soc Med 79(6): 361-363. 
Murphy, GM (1999). The cutaneous porphyrias: a review. The British Photodermatology Group. Br J 
Dermatol 140(4): 573-581. 
Murphy, GM (2003). Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther 16(1): 
57-64. 
Mustajoki, P and Koskelo, P (1976). Hereditary hepatic porphyrias in Finland. Acta Med Scand 200(3): 
171-178. 
Mustajoki, P (1978). Variegate porphyria. Ann Intern Med 89(2): 238-244. 
Mustajoki, P (1980). Variegate porphyria. Twelve years' experience in Finland.QJM 49(194): 191-203. 
Mustajoki, P, Tenhunen, R, Niemi, KM, Nordmann, Y, Kääriäinen, H and Norio, R (1987). Homozygous 
variegate porphyria. A severe skin disease of infancy. Clin Genet 32(5): 300-305. 
Mustajoki, P, Tenhunen, R, Pierach, C and Volin, L (1989). Heme in the treatment of porphyrias and 
hematological disorders. Semin Hematol 26(1): 1-9. 
Mustajoki, P and Nordmann, Y (1993). Early administration of heme arginate for acute porphyric attacks. 
Arch Intern Med 153(17): 2004-2008. 
Mutasim, DF, and Adams, BB (2001). Immunofluorescence in dermatology. J Am Acad Dermatol 45: 
803-822. 
Nagato, N, Nonaka, S, Ohgami, T, Murayama, F, Yamashita, K, Irifune, H, Watanabe, M and Yoshida, H 
(1987). Mechanism of blister formation in porphyria cutanea tarda. I. Histopathological 
observation of blisters in three cases of porphyria cutanea tarda. J Dermatol. 14: 551-555. 
Najahi-Missaoui, W and Dailey, HA (2005). Production and characterization of erythropoietic 
protoporphyric heterodimeric ferrochelatases. Blood 14: 1098-1104. 
Nakahashi, Y, Taketani, S, Okuda, M, Inoue, K and Tokunaga, R (1990). Molecular cloning and 
sequence analysis of cDNA encoding human ferrochelatas. Biochem Biophys Res Commun 173: 
748-755. 
Nishimura, K, Taketani, S and Inokuchi, H (1995). Cloning of a human cDNA for protoporphyrinogen 
oxidase by complementation in vivo of a hemG mutant of Escherichia coli. J Biol Chem 270(14): 
8076-8080. 
Nordmann, Y and Puy, H (2002). Human hereditary hepatic porphyrias Clin Chim Acta 325(1-2): 17-37. 
Norris, PG, Elder, GH and Hawk, JL (1990a). Homozygous variegate porphyria: a case report. Br J 
Dermatol 122(2): 253-257. 
Norris, PG, Nunn, AV, Hawk, JL and Cox, TM (1990b). Genetic heterogeneity in erythropoietic 
protoporphyria: a study of the enzymatic defect in nine affected families. J Invest Dermatol 95(3): 
260-263 
. 
Orfanos, AP, Guthrie, R, Jinks, DC and Vollmer, DW (1989). Simultaneous assay of zinc protoporphyrin 
and protoporphyrin IX in dried blood. Clin Chim Acta 181(2): 213-217. 
Orita, M, Suzuki, Y, Sekiya, T and Hayashi, K (1989). Rapid and sensitive detectio of point mutations 





Palmer, RA, Elder, GH, Barrett, DF and Keohane, SG (2001). Homozygous variegate porphyria: a 
compound heterozygote with novel mutations in the protoporphyrinogen oxidase gene. Br J 
Dermatol 144: 866-869. 
Pardo, RJ and Penneys, NS (1990). Location of basement membrane type IV collagen beneath 
subepidermal bullous diseases. J Cutan Pathol 17: 336-341. 
Parera, VE, De Siervi, A, Varela, L, Rossetti, MV and Batlle, AM (2003). Acute porphyrias in the 
Argentinean population: a review. Cell Mol Biol 49: 493-500. 
Pasanen, AV, Salmi, M, Vuopio, P and Tenhunen, R (1980). Heme biosynthesis in sideroblastic anemia. 
Int J Biochem 12(5-6): 969-974. 
Patel, GK, Weston, J, Derrick, EK and Hawk, JL (2000). An unusual case of purpuric erythropoietic 
protoporphyria. Clin Exp Dermatol 25: 406-408. 
Pawliuk, R, Bachelot, T, Wise, RJ, Mathews-Roth, MM and Leboulch, P (1999). Long-term cure of the 
photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 
5(7): 768-773. 
Peterka, ES, Fusaro, RM and Goltz, RW (1965). Erythropoietic protoporphyria. II. Histological and 
histochemical studies of cutaneous lesions. Arch Dermatol 92(4): 357-361. 
Parkkila, S, Niemelä, O, Savolainen, ER and Koistinen, P (2001). HFE mutations do not account for 
transfusional iron overload in patients with acute myeloid leukemia. Transfusion 41(6):828-831. 
Phillips, JD, Jackson, LK, Bunting, M, Franklin, MR, Thomas, KR, Levy, JE, Andrews, NC and Kushner, 
JP (2001). A mouse model of familial porphyria cutanea tarda. Proc Natl Acad Sci U S A 98(1): 
259-264. 
Phillips, JD, Whitby, FG, Stadtmueller, BM, Edwards, CQ, Hill, CP and Kushner, JP (2007a). Two novel 
uroporphyrinogen decarboxylase (URO-D) mutations causing hepatoerythropoietic porphyria 
(HEP). Transl Res 149(2): 85-91. 
Phillips, JD,Bergonia, HA, Reilly, CA, Franklin, MR and Kushner, JP (2007b). A porphomethene 
inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda.Proc Natl Acad Sci 
U S A 104 (12):5079-5084. 
Poblete-Gutierrez, P, Mendez, M, Wiederholt, T, Merk, HF, Fontanellas, A, Wolff, C and Frank, J 
(2004). The molecular basis of porphyria cutanea tarda in Chile: identification and functional 
characterization of mutations in the uroporphyrinogen decarboxylase gene. Exp Dermatol 13(6): 
372-379. 
Poblete-Gutierrez, P, Wolff, C, Farias, R and Frank, J (2006). A Chilean boy with severe photosensitivity 
and finger shortening: the first case of homozygous variegate porphyria in South America. Br J 
Dermatol 154(2): 368-371. 
Poh-Fitzpatrick, MB and Lamola, AA (1976). Direct spectrofluorometry of diluted erythrocytes and 
plasma: a rapid diagnostic method in primary and secondary porphyrinemias. J Lab Clin Med 
87(2): 362-370. 
Poh-Fitzpatrick, MB (1980). A plasma porphyrin fluorescence marker for variegate porphyria. Arch 
Dermatol 116(5): 543-547. 
Poh-Fitzpatrick, MB (1982). Pathogenesis and treatment of photocutaneous manifestations of the 
porphyrias. Semin Liver Dis 2(2): 164-176. 
Poh-Fitzpatrick, MB (1985). Porphyrin-sensitized cutaneous photosensitivity: pathogenesis and 
treatment.Clin Dermatol 3(2): 41-82. 
Poh-Fitzpatrick, MB (1986). Molecular and cellular mechanisms of porphyrin photosensitization. 
Photodermatol 3(3): 148-157. 
Poh-Fitzpatrick, MB (1989). The "priming phenomenon" in the acute phototoxicity of erythropoietic 
protoporphyria. J Am Acad Dermatol 21: 311. 
Poh-Fitzpatrick, MB, Wang, X, Anderson, KE, Bloomer, JR, Bolwell, B and Lichtin, AE (2002). 
Erythropoietic protoporphyria: altered phenotype after bone marrow transplantation for 
myelogenous leukemia in a patient heteroallelic for ferrochelatase gene mutations. J Am Acad 
Dermatol 46(6): 861-866. 
Puy, H, Robreau, AM, Rosipal, R, Nordmann, Y and Deybach, JC (1996). Protoporphyrinogen oxidase: 
complete genomic sequence and polymorphisms in the human gene. Biochem Biophys Res 





Rademakers, LH, Cleton, MI, Kooijman, C, Baart de la Faille, H and van Hattum, J (1990). Early 
involvement of hepatic parenchymal cells in erythrohepatic protoporphyria? An ultrastructural 
study of patients with and without overt liver disease and the effect of chenodeoxycholic acid 
treatment. Hepatol 11(3): 449-457. 
Ramos-e-Silva, M, Chaves Azevedo-e-Silva, M and Carneiro CR (2008). Hair, nail and pigment changes 
in major systemic disease. Clin Dermatol 26(3):296-305. 
Raso, DS, Greene, WB, Maize, JC, McGown, ST and Metcalf, JS (1996). Caterpillar bodies of porphyria 
cutanea tarda ultrastructurally represent a unique arrangement of colloid and basement membrane 
bodies. Am J Dermatopathol 18(1): 24-29. 
Richard, E, Robert, E, Cario-Andre, M, Ged, C, Geronimi, F, Gerson, SL, de Verneuil, H and F., M-G 
(2004). Hematopoietic stem cell gene therapy of murine protoporphyria by methylguanine-DNA-
methyltransferase-mediated in vivo drug selection. Gene Ther 11: 1638-1647. 
Rimington, C (1958). Quantitative determination of porphobilinogen and porphyrin in urine and faeces. 
Assoc Clin Path Broadsheet No. 21.  
Rimington, C, Magnus, IA, Ryan, EA and Cropps, DJ (1967). Porphyria and photosensitivity. QJM 36: 
29-56. 
Risheg, H, Chen, FP and Bloomer, JR (2003). Genotypic determinants of phenotype in North American 
patients with erythropoietic protoporphyria. Mol Genet Metab 80: 196-206. 
Roberts, AG, Whatley, SD, Daniels, J, Holmans, P, Fenton, I, Owen, MJ, Thompson, P, Long, C and 
Elder, GH (1995). Partial characterization and assignment of the gene for protoporphyrinogen 
oxidase and variegate porphyria to human chromosome 1q23. Hum Mol Genet 4(12): 2387-2390. 
Roberts, AG, Puy, H, Dailey, TA, Morgan, RR, Whatley, SD, Dailey, HA, Martasek, P, Nordmann, Y, 
Deybach, JC and Elder, GH (1998). Molecular characterization of homozygous variegate 
porphyria. Hum Mol Genet 7(12): 1921-1925. 
Rocchi, E, Gibertini, P, Cassanelli, M, Pietrangelo, A, Borghi, A and Ventura, E (1986). Serum ferritin in 
the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. J Lab 
Clin Med 107(1): 36-42. 
Rocchi, E, Cassanelli, M, Borghi, A, Paolillo, F, Pradelli, M, Pellizzardi, S, Vezzosi, A, Gallo, E, 
Baccarani Contri, M and Ventura, E (1991). Liver iron overload and desferrioxamine treatment of 
porphyria cutanea tarda. Dermatol 182(1): 27-31. 
Romeo, G and Levin, EY (1971). Uroporphyrinogen decarboxylase from mouse spleen. Biochim Biophys 
Acta 230(2): 330-341. 
Ros, AM (1988). PUVA therapy for erythropoietic protoporphyria. Photodermatol 5(3): 148-149. 
Ross, JB and Moss, MA (1990). Relief of the photosensitivity of erythropoietic protoporphyria by 
pyridoxine. J Am Acad Dermatol 22(2): 340-342. 
Rossmann-Ringdahl, I and Olsson, R (2005). Porphyria cutanea tarda in a Swedish population: risk 
factors and complications. Acta Derm Venereol 85(4): 337-341. 
Rossmann-Ringdahl, I and Olsson, R (2007). Porphyria cutanea tarda: effects and risk factors for 
hepatotoxicity from high-dose chloroquine treatment. Acta Derm Venereol 87(5): 401-405. 
Ryan, EA (1966). Histochemistry of the skin in erythropoietic protoporphyria. Br J Dermatol 78(10): 
501-518. 
Ryan, EA and Madill, GT (1968). Electron microscopy of the skin in erythropoietic protoporphyria. Br J 
Dermatol 80(9): 561-570. 
Sadlon, TJ, Dell'Oso, T, Surinya, KH and May, BK (1999). Regulation of erythroid 5-aminolevulinate 
synthase expression during erythropoiesis. Int J Biochem Cell Biol 31(10): 1153-1167. 
Salmi, M and Tenhunen, R (1980). New method for liquid-chromatographic measurement of erythrocyte 
protoporphyrin and coproporphyrin. Clin Chem 26(13): 1832-1835. 
Sampietro, M, Piperno, A, Lupica, L, Arosio, C, Vergabi, A, Corbetta, N, Malosio, I, Mattioli, M, 
Fracanzai, AL, Cappellini, MD, Fiorelli, G and Fargion, S (1998). High prevalence of the 
His63Asp HFE mutation in Italian patients with porphyria cutanea tarda. Hepatology 27(1):181-
184. 
Sambrook, J, Fritsch, EF and Maniatis, T (1989). Molecular cloning: A laboratory manual. New York, 
Cold Spring Harbour, Cold Spring Harbour Laboratory Press,pp.9.16-9.19.                                    





Sandberg, S, Romslo, I, Hovding, G and Bjorndal, T (1982). Porphyrin-induced photodamage as related 
to the subcellular localization of the porphyrins. Acta Derm Venereol. 100 Suppl: S75-80. 
Sarkany, RP (2001). The management of porphyria cutanea tarda. Clin Exp Dermatol 26(3): 225-232. 
Sarkany, RP, Ross, G and Willis, F (2006). Acquired erythropoietic protoporphyria as a result of 
myelodysplasia causing loss of chromosome 18. Br J Dermatol 155(2): 464-466. 
Sassa, S and Nagai, T (1996). The role of heme in gene expression. Int J Hematol 63(3): 167-178. 
Schneider-Yin, X, Schafer, BW, Mohr, P, Burg, G and Minder, EI (1994). Molecular defects in 
erythropoietic protoporphyria with terminal liver failure. Hum Genet 93(6): 711-713. 
Schneider-Yin, X, Gouya, L, Meier-Weinand, A, Deybach, JC and Minder, EI (2000). New insights into 
the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 
159(10): 719-725. 
Scholnick, PL, Epstein, J and Marver, HS (1973). The molecular basis of the action of chloroquine in 
porphyria cutanea tarda. J Invest Dermatol 61(4):226-232. 
Seth, AK, Badminton, MN, Mirza, D, Russell, S and Elias, E (2007). Liver transplantation for porphyria: 
who, when, and how? Liver Transpl 13(9): 1219-1227. 
Shehan, JM and Huerter, CJ (2001). Porphyria cutanea tarda associated with an acute gastrointestinal 
bleed: the roles of supplemental iron and blood transfusion. Cutis 68(2): 147-150. 
Shieh, S, Cohen, JL and Lim, HW (2000). Management of porphyria cutanea tarda in the setting of 
chronic renal failure: a case report and review. J Am Acad Dermatol 42(4): 645-652. 
Shirota, T, Yamamoto, H, Hayashi, S, Fujimoto, H, Harada, Y and Hayashi, T (2000). Myelodysplastic 
syndrome terminating in erythropoietic protoporphyria after 15 years of aplastic anemia. Int J 
Hematol 72(1): 44-47. 
Siersema, PD, ten Kate, FJ, Mulder, PG and Wilson, JH (1992). Hepatocellular carcinoma in porphyria 
cutanea tarda: frequency and factors related to its occurrence. Liver 12(2): 56-61. 
Siersema, PD, Rademakers, LH, Cleton, MI, ten Kate, FJ, de Bruijn, WC, Marx, JJ and Wilson, JH 
(1995). The difference in liver pathology between sporadic and familial forms of porphyria 
cutanea tarda: the role of iron. J Hepatol 23(3): 259-267. 
Sinclair, PR, Gorman, N, Shedlofsky, SI, Honsinger, CP, Sinclair, JF, Karagas, MR and Anderson, KE 
(1997). Ascorbic acid deficiency in porphyria cutanea tarda. J Lab Clin Med 130(2): 197-201. 
Sixel-Dietrich, F and Doss, M (1985). Hereditary uroporphyrinogen-decarboxylase deficiency 
predisposing porphyria cutanea tarda (chronic hepatic porphyria) in females after oral 
contraceptive medication. Arch Dermatol Res 278(1): 13-16. 
Smith, AG and Francis, JE (1983). Synergism of iron and hexachlorobenzene inhibits hepatic 
uroporphyrinogen decarboxylase in inbred mice. Biochem J 15: 909-913. 
Smith, AG and De Matteis, F (1990). Oxidative injury mediated by the hepatic cytochrome P-450 system 
in conjunction with cellular iron. Effects on the pathway of haem biosynthesis. Xenobiotica 20: 
865-877. 
Solis, JA, Betancor, P, Campos, R, Enriquez de Salamanca, RE, Rojo, P, Marin, I and Schuller, A (1982). 
Association of porphyria cutanea tarda and primary liver cancer: report of ten cases. J Dermatol 
9(2): 131-137. 
Spikes, JD (1983). A preliminary comparison of the photosensitizing properties of porphyrins in aqueous 
solution and liposomal systems. Adv Exp Med Biol 160: 181-192. 
Stolzel, U, Kostler, E, Koszka, C, Stoffler-Meilicke, M, Schuppan, D, Somasundaram, R, Doss, MO, 
Habermehl, KO and Riecken, EO (1995). Low prevalence of hepatitis C virus infection in 
porphyria cutanea tarda in Germany. Hepatol 21(6): 1500-1503. 
Stransky, J, Malina, L, Cieslarova, B, Stritesky, J, Putova, I and Horak, J (2000). Overt and hidden 
coinfection with hepatitis B and C viruses in chronic liver disease and porphyria cutanea tarda. 
Acta Virol 44: 23-28. 
Takeshita, K, Takajo, T, Hirata, H, Ono, M and Utsumi, H (2004). In vivo oxygen radical generation in 
the skin of the protoporphyria model mouse with visible light exposure: an L-band ESR study. J 
Invest Dermatol 122(6): 1463-1470. 
Taketani, S and Fujita, H (1995). The ferrochelatase gene structure and molecular defects associated with 






Tavazzi, D, Martinez di Montemuros, F, Fargion, S, Fracanzani, AL, Fiorelli, G and Cappellini, MD 
(2002). Levels of uroporphyrinogen decarboxylase (URO-D) in erythrocytes of Italian porphyria 
cutanea tarda patients. Cell Mol Biol 48(1): 27-32. 
Tidman, MJ, Higgins, EM, Elder, GH and MacDonald, DM (1989). Variegate porphyria associated with 
hepatocellular carcinoma. Br J Dermatol 121(4): 503-505. 
Todd, D, J. (1994). Erythropoietic protoporphyria. Br J Dermatol 131(6): 751-766. 
Topo, P, Klaukka, T, Hemminki, E and Uutela, A (1991). Use of hormone replacement therapy in 1976-
89 by 45-64 year old Finnish women. J Epidemiol Community Health 45(4): 277-280. 
Torinuki, W and Miura, T (1983). Erythropoietic protoporphyria showing solar purpura. Dermatologica 
167(220-2). 
Tutois, S, Montagutelli, X, Da Silva, V, Jouault, H, Rouyer-Fessard, P, Leroy-Viard, K, Guenet, JL, 
Nordmann, Y, Beuzard, Y and Deybach, JC (1991). Erythropoietic protoporphyria in the house 
mouse. A recessive inherited ferrochelatase deficiency with anemia, photosensitivity, and liver 
disease. J Clin Invest 88(5): 1730-1736. 
van der Bergh, AAH and Grotepass, W (1937). Ein bemerkswerter Fall von Porphyrie. Wien Klin 
Wochensch 50: 830-831. 
Varigos, G, Schiltz, JR and Bickers, DR (1982). Uroporphyrin I stimulation of collagen biosynthesis in 
human skin fibroblasts. A unique dark effect of porphyrin. J Clin Invest 69(1): 129-135. 
Vasil, KE and Magro, CM (2007). Cutaneous vascular deposition of C5b-9 and its role as a diagnostic 
adjunct in the setting of diabetes mellitus and porphyria cutanea tarda. J Am Acad Dermatol 
56(1): 96-104. 
Wahlin, S, Aschan, J, Bjornstedt, M, Broome, U and Harper, P (2007). Curative bone marrow 
transplantation in erythropoietic protoporphyria after reversal of severe cholestasis. J Hepatol 
46(1): 174-179. 
Waldenström, J (1937). Studien uber Porphyrie. Acta Med Scand 92 Suppl: S1-254. 
Warner, CA, Yoo, HW, Roberts, AG and Desnick, RJ (1992). Congenital erythropoietic porphyria: 
identification and expression of exonic mutations in the uroporphyrinogen III synthase gene. J 
Clin Invest 89(2): 693-700. 
Warnich, L, Kotze, MJ, Groenewald, IM, Groenewald, JZ, van Brakel, MG, van Heerden, CJ, de Villiers, 
JN, van de Ven, WJ, Schoenmakers, EF, Taketani, S and Retief, AE (1996). Identification of 
three mutations and associated haplotypes in the protoporphyrinogen oxidase gene in South 
African families with variegate porphyria. Hum Mol Genet 5(7): 981-984. 
Warren, LJ and George, S (1998). Erythropoietic protoporphyria treated with narrow-band (TL-01) UVB 
phototherapy. Australas J Dermatol 39(3): 179-182. 
Watson, CJ, Pierach, CA and Bossenmaier, I (1978). Use of hematin in the acute attack of the "inducible" 
hepatic porphyrias. Adv Intern Med 23: 265-285. 
Wechsler, HL (1975). Variegate porphyria. Letter. Arch Dermatol 111(7): 926-927. 
Went, LN and Klasen, EC (1984). Genetic aspects of erythropoietic protoporphyria. Ann Hum Genet 
48(2): 105-117. 
Westerhof, W and Smit, EM (1981). Variegate porphyria; a family study. Nederlands Tijdschrift voor 
Geneeskunde 125(31): 1235-1241. 
Whatley, SD, Puy, H, Morgan, RR, Robreau, AM, Roberts, AG, Nordmann, Y, Elder, GH and Deybach, 
JC (1999). Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 
families, extent of allelic heterogeneity, and absence of correlation between phenotype and type 
of mutation. Am J Hum Genet 65(4): 984-994. 
Whatley, SD, Mason, NG, Khan, M, Zamiri, M, Badminton, MN, Missaoui, WN, Dailey, TA, Dailey, 
HA, Douglas, WS, Wainwright, NJ and Elder, GH (2004). Autosomal recessive erythropoietic 
protoporphyria in the United Kingdom: prevalence and relationship to liver disease. J Med Genet 
41(8): e105. 
Wick, G, Honigsmann, H and Timpl, R (1979). Immunofluorescence demonstration of type IV collagen 
and a noncollagenous glycoprotein in thickened vascular basal membranes in protoporphyria. J 
Invest Dermatol 73(5): 335-338. 
Wiedmann, MW and Caca, K (2004). General principles of photodynamic therapy (PDT) and 






Wiman, A, Floderus, Y and Harper, P (2003a). Novel mutations and phenotypic effect of the splice site 
modulator IVS3-48C in nine Swedish families with erythropoietic protoporphyria. J Hum Genet. 
48(2): 70-76. 
Wiman, A, Harper, P and Floderus, Y (2003b). Nine novel mutations in the protoporphyrinogen oxidase 
gene in Swedish families with variegate porphyria. Clin Genet 64: 122-130. 
With, TK (1968).Quantitative and fractional porphyrin analysis in urine. Clin Biochem 2: 97-104.  
von und zu Fraunberg, M and Kauppinen, R (2000). Diagnosis of variegate porphyria--hard to get? Scand 
J Clin Lab Invest 60(7): 605-610. 
von und zu Fraunberg, M, Tenhunen, R and Kauppinen, R (2001). Expression and characterization of six 
mutations in the protoporphyrinogen oxidase gene among Finnish variegate porphyria patients. 
Mol Med 7: 320-328. 
von und zu Fraunberg, M, Timonen, K, Mustajoki, P and Kauppinen, R (2002). Clinical and biochemical 
characteristics and genotype-phenotype correlation in Finnish variegate porphyria patients. Eur J 
Hum Genet 10: 649-657. 
von und zu Fraunberg, M, Pischik, E, Udd, L and Kauppinen, R (2005). Clinical and biochemical 
characteristics and genotype-phenotype correlation in 143 Finnish and Russians patients with 
acute intermittent porphyria. Medicine 84(1): 35-47. 
Wood, GS and Warnke, R (1981). Suppression of endogenous avidin-binding activity in tissues and its 
relevance to biotin-avidin detection systems. J Histochem Cytochem 29(10): 1196-1204. 
Yamamoto, S, Kitano, Y, Eimoto, T and Horie, Y (1994). Erythropoietic protoporphyria with severe 
cholestasis. Intern Med 33(802-5). 
Zaider, E and Bickers, DR (1998). Clinical laboratory methods for diagnosis of the porphyrias. Clin 
Dermatol 16(2): 277-293. 
Zoller, H, Decristoforo, C and Weiss, G (2002). Erythroid 5-aminolevulinate synthase, ferrochelatase and 
            DMT1 expression in erythroid progenitors: differential pathways for erythropoietin and iron-        





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix 3: Differential diagnosis of cutaneous porphyrias according to the skin manifestations 
 
Skin manifestation Differential diagnosis Diagnostic method 
Photosensitivity Polymorphous light eruption Clinical signs and history 
Phototesting 
Histopathology (if necessary) 
Solar urticaria Clinical signs and history 
Phototesting 
Lupus erythematosus  
 
Clinical signs and history 
Histopathology, DIF1 
Lupus serology 
Photocontact dermatitis  Clinical signs and history 
Phototesting 
Histopathology (if necessary) 
Oedema Angioedema  Clinical signs and history 
Serum complement analysis (HAE) 
Erythema Erythema solare (Sunburn) Clinical signs and history 
Negative porphyrin biochemistry 
Histopathology (if necessary) 
Burning sensation of the skin  
 Erythema solare (Sunburn) As above  
 Erythromelalgia Clinical signs and history 
Heat provocation 
 Brachioradial pruritus Clinical signs and history 
Blister formation  and skin fragility on the sun-exposed areas 
 Pseudoporphyria Histopathology, DIF  
Negative porphyrin biochemistry 
 Epidermolysis bullosa acquisita 
classic type 
Histopathology, DIF 
Sodium chloride split skin+DIF  
Autoantibodies to collagen VII 
 Epidermolysis bullosa Histopathology, DIF (negative) 
Electron microscopy 
Mutation analysis 
Clinical signs and history 
Family history 
 Bullous amyloidosis Histopathology, DIF (negative) 
Clinical signs and history 
Blister formation  without  skin fragility on the sun-exposed areas 
 Bullous pemphigoid Histopathology, DIF 
Autoantibodies to EBMZ2 antigens 
Clinical signs and history 
 Bullous dermatitis of diabetes Histopathology, DIF (negative) 





Histopathology, DIF (negative) 
Clinical signs and history 
Bullous lupus erythematosus Histopathology, DIF, Lupus serology 
Clinical signs and history 
Hypertrichosis Hirsutismus Endocrinological examination 
Hyperpigmentation Melasma, systemic diseases, 
phototoxic reaction 
Clinical and laboratory examination 
Histopathology (if necessary) 






Appendix 4: Differential diagnosis of cutaneous porphyrias according to the histopathological  
and immunofluorescence  changes 
Histopathological finding Diagnosis  Direct imunofluorescence of the skin 
Subepidermal bulla   
    Noninflammatory PCT, VP IgG IgA, IgM, C3 in the vessel walls 
and variably at EBMZ1 
    Noninflammatory Pseudoporphyria IgG IgA, IgM, C3 in the vessel walls 
and variably at EBMZ 
    Noninflammatory Bullous dermatitis of diabetes Negative 
    Noninflammatory Bullous amyloidosis Negative 
    Noninflammatory Junctional epidermolysis bullosa Negative 
    Noninflammatory or 
    inflammatory 
Epidermolysis bullosa acquisita 
classic or inflammatory type   
Linear IgG C3 at EBMZ 
 
    Eosinophilic infiltrate Bullous pemphigoid Linear IgG C3 at EBMZ 
    Neutrophilic infiltrate Dermatitis herpetiformis Granular IgA at EBMZ 
    Neutrophilic infiltrate Linear IgA disease Linear IgA C3 at EBMZ 
    Lymphocytic infiltrate or 
    noninflammatory 
Bullous lupus erythematosus Subepidermal band of IgG, IgM, C3 
Thickening of the dermal vessel walls  
     PAS-positive                   
    Amorphous deposits         
EPP     IgG IgA,IgM,C3 in the vessel walls 
 
    PAS-positive                       PCT,  VP IgG IgA,IgM,C3 in the vessel walls 
and variably at EBMZ 
    PAS-positive Diabetes Negative 
    PAS-positive Rheumatoid arthritis Negative 
    Congo-positive Amyloidosis Negative 
1EBMZ = Epidermal basement membrane zone    
       
 
